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The aim of this study was to further characterise the clinical response to primary
systemic endocrine therapy in breast cancer and to determine whether it is possible to
identify biological markers of tumour phenotype that can be used to predict subsequent
clinical response to neoadjuvant treatment with letrozole for three months.
137 postmenopausal patients with locally advanced oestrogen receptor (ER) positive
breast cancer were treated with 2.5mg letrozole daily. Tumour samples were taken at
diagnosis, at three months and, in 62 patients, additionally at 10-14 days. Serial clinical
tumour measurements were made over the three month treatment period. Ultrasound
scanning (USS) was shown to be the most accurate method of assessing clinical
response to treatment and the modality that corresponded most closely with pathological
response. Patients with ER rich tumours were shown to be those most likely to derive
maximal benefit from neoadjuvant letrozole.
In this series, 67% of patients showed a clinical response to treatment (> 50% reduction
in tumour volume at three months on USS) and 63 % had their surgery down-staged
from mastectomy to breast conserving surgery. Of the 125 patients who completed the 3
month audit period, with a mean follow up period of 39 months (4-58), 42 patients had
died. Of these, 16 had evidence of recurrent breast cancer at the time of death. 7 local
recurrences have occurred in the series (5%).
75% of tumours displayed evidence of a pathological response (decreased cellularity/
increased fibrosis) at three months. Significant decreases in PgR expression were seen
after both 14 days and three months but this did not correlate with clinical or
pathological tumour response. Baseline proliferation, assessed using Ki67) was similar
in responders and non-responders whether assessed clinically or pathologically.
Treatment was associated with highly significant decreases in Ki67 in all tumour
subgroups (at least P<0.005 by paired Wilcoxon rank test) at 14 days. There was no
significant difference in Ki67 expression at 14 days between subsequent clinical
responders and non-responders. However, when correlating the decrease in proliferation
with pathological response, Ki67 expression at 14 days was significantly higher in
tumours which subsequently failed to show morphological evidence of response.
The percentage reduction in Ki67 over the three month treatment period showed a
significant correlation with cause specific survival (p=0.007). However, it was not
possible to use changes in proliferation to predict response for an individual patient. The
fresh tissue collected in parallel with the formalin fixed tissue in this study is currently
being analysed by microarray and will hopefully suggest possible avenues for other
markers which may prove more helpful in predicting response to neoadjuvant endocrine
treatment on an individual patient basis.
Section 1: Introduction
1.1 Incidence and prevalence of breast cancer
In the western world, breast cancer is the commonest cancer to affect women accounting
for a quarter of all female cancers. Approximately one in nine women in the UK will
develop it during their lifetime
Scotland has one of the highest incidence rates of breast cancer with an annual incidence
of approximately 3,600 new cases per year (110-120 per 100,000 women per year) . It
results in 19% of cancer deaths in women.
Worldwide, breast cancer affects approximately one million new patients annually,
causing substantial morbidity and mortality 3. Prevalence is about five times higher. It is
the third most common cancer worldwide and is responsible for 10% of the global
cancer burden 4. It principally affects women although approximately 1% of cases occur
in men 5.
In Scotland, the incidence of breast cancer has risen by 46% between 1981 and 2000
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Figure 1: Trends in incidence of breast cancer in Scotland: Age-standardised incidence
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Figure 2: Trends in mortality from breast cancer in Scotland: Age-standardised incidence rates
per 100 000 person-years at risk (European standard population): period 1979-2002
Mortality rates peaked in the mid 1980s and have been in steady decline since; standing
at 30 per 100,000 women in 2002
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The increase in breast cancer is thought to be due to a number of factors including
greater longevity (one in three women over the age of 75 will develop breast cancer),
women delaying childbearing until later in life and greater use of hormone replacement
therapy (HRT). It may also be in part due to an increase in detection rates following the
introduction of the National Screening Programme in the UK in 1988.
3
1.2 Aetiology
The causes of breast cancer are not fully understood. Breast cancer is unusual in women
under 25 and then incidence doubles every 10 years until the menopause after which the
rate of increase slows dramatically. In the UK, the average age at diagnosis is 58 and
one third of all breast cancer occurs in women over 75 6.
There is a marked geographical variation in the incidence of breast cancer between
countries. Age-adjusted incidence and mortality varies by a factor of up to five between
different regions. Western countries have a much higher incidence than far eastern
countries although the scale of this difference is decreasing. Immigrants from countries
which have a low incidence of breast cancer to countries with a higher incidence
increase their own incidence to almost that of their adopted country within three
generations. This suggests that environmental factors may be more important
aetiological factors than genetic ones.
Breast cancer is more common in women of higher socio-economic group 7 and this may
be partly due to better nutrition in early life.
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1.2.1 Genetic predisposition
5-10% of breast cancers occur in women with a genetic predisposition 8. This is most
commonly inherited as autosomal dominant susceptibility genes. Two of these, BRCA1
and BRCA2, are located on the long arms of chromosomes 17 and 13 respectively.
Together these genes account for a substantial proportion of high risk families. These
can be transmitted through either maternal or paternal lines. Women with a BRCA1/2
mutation have a 65-85% cumulative lifetime risk of developing invasive breast cancer 8.
The main characteristics of inherited breast cancer are (i) early age of onset, (ii) two or
more affected first degree relatives (especially if premenopausal at time of onset) and
(iii) bilateral or multiple primaries in the same patient. In the UK., women considered to
be at risk are often referred to a genetics service. Here they can discuss individual risk
factors and undergo BRCA1 or BRCA2 testing if this is considered appropriate. Since
both genes are very large and mutations can occur at any point, screening for a particular
mutation can be difficult and time consuming.
There are certain inherited syndromes (eg. Li Fraumeni), which confer a high risk of
developing breast cancer. There are also some families which have high rates of other
cancers such as ovarian, prostatic or colorectal carcinoma in addition to breast cancer.
These are all likely to be due to inherited mutations. There are also likely to be other as
yet unidentified breast cancer susceptibility genes which increase the risk of developing
5
breast cancer to a lesser degree than BRCA1 and 2. These are more difficult to identify
but are likely to be much commoner and may account for a significant proportion of
breast cancer cases in the community.
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1.2.2 Hormonal risk factors
Increased risk of breast cancer is also associated with increased length of exposure to
hormonal menstrual cycling. Women who have an oophrectomy before the age of 35
reduce their risk of breast cancer by more than 40% when compared to women who have
a normal menopause 9. A woman who has a natural menopause after the age of 55 has
double the risk of breast cancer compared with a woman who has her menopause before
45 9.
Nulliparity increases the risk of breast cancer as does increasing age at first pregnancy.
A young age at the birth of a second child further reduces risk. Interestingly, women
who have their first child when over the age of 35 have a higher risk than those who
have no children at all 9. Breastfeeding is thought to slightly reduce the risk of breast
cancer 10.
Long term use of hormone replacement therapy (HRT) and the oral contraceptive pill
(OCP) (>10 years) are also thought to be associated with an increased risk of breast
cancer. The risk with the OCP ( 1.24 relative risk) seems to disappear within 10 years of
stopping treatment 11.
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1.2.3 Effect of hormone replacement therapy
Over the past few years, there has been much controversy over the impact ofHRT on the
incidence of breast cancer and the risk of death from breast cancer. Currently, a
significant proportion of women in their 50s and 60s are using HRT. Theoretically,
increasing exposure to oestrogen in this way should increase the incidence of breast
cancer but several early studies did not support this. However, these studies involved
retrospective analysis, they had too small numbers, only had baseline information about
HRT and involved many preparations that are no longer in current use.
The use of oestrogen alone or combined oestrogen and progestogen preparations in
perimenopausal women has been shown to increase breast density. This results in breast
screening being less sensitive and specific l2. As a result, the detection of breast cancer
can be delayed.
Recent large prospective studies have reported increased breast cancer rates, particularly
for preparations containing a combination of oestrogen and progestogen. The Million
Women Cohort Study 13 enrolled 1084110 women aged 50-64 who attended for breast
screening between 1996 and 2001. Half of these women had taken HRT at some time.
There was an average follow up of 2.6 years for incidence and 4.1 years for mortality.
Current users of HRT were found to be 1.66 times more likely to develop breast cancer
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than those who had never used HRT. The risk was doubled with oestrogen and
progestogen containing preparations 13.
It has also been shown that the longer HRT is used, the greater the risk. It remains
unclear whether breast cancer mortality is higher in women who have used HRT than in
those who have not. The Million Women study reported a 1.22 relative increase in risk
of death from breast cancer in 'current users' compared with 'never users' 13. However,
longer follow up is required to confirm the findings.
The issue ofHRT use in breast cancer survivors also remains unclear. Initial small scale
studies were reassuring about its safety but the HABITS study in Sweden was
terminated early because of a significant increase in breast cancer events in women
randomised to receive HRT.
Safer alternatives to HRT such as tibolone have been suggested. Tibolone is a synthetic
steroid which has been shown to have weak oestrogenic, androgenic and progestogenic
activity. It has been shown to relieve menopausal symptoms to a similar degree as
combined HRT but does not appear to have the same adverse effects on the
endometrium and has beneficial effects in protecting against osteoporosis. It does not
appear to increase breast density to the same extent as HRT although its effects on the
breast have not been fully investigated. However, the Million Women Study showed an
increased risk of breast cancer of 1.44 with tibolone although there was no increased risk
of endometrial cancer.
9
The full effect of the widespread use of HRT over the past few decades remains to be
seen. It also remains a challenge to treat menopausal symptoms while limiting the risks
associated with increased exposure to hormonal therapy.
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1.2.4 Other risk factors
Other risk factors include postmenopausal obesity, proliferative conditions such as
atypical ductal hyperplasia and previous breast irradiation9. Dietary factors may be
important in the substantial difference in incidence between different geographical areas.
It has been suggested that a diet rich in saturated fat may increase risk especially if
consumed when young. Olive oil may have a protective effect 14. Smoking has not been
shown to increase risk but alcohol consumption of greater than three units per day does
appear to increase risk '5.
ll
1.3 The role of oestrogen in the normal breast
Histologically the breast is a mammary gland which comprises a rudimentary branching
duct system within a fat pad. After puberty there are cyclical increases in the ductal
branching to fill the fat pad. During pregnancy the branches develop further and end
buds develop which produce milk. After weaning, apoptosis causes mammary gland
regression to a pre pregnancy state. The ductal structure consists of a basement
membrane, myoepithelial cells and a continuous layer of epithelial cells which produce
milk and secrete it into the lumen. There are fibroblasts surrounding the cell layers.
The breast requires oestrogen in order to develop normally at puberty. The reduction in
circulating oestrogen at menopause results in breast involution and replacement of
epithelial tissue with fat. Between these times the breast undergoes cyclical growth and
involution in response to the menstrual cycle and to pregnancy and lactation.
12
1.3.1 The oestrogen receptor
The effects of oestrogen on the breast are mediated by the oestrogen receptor (ER).
These receptors are present in the epithelial cells of the terminal duct lobular unit which
is where the majority of breast cancers originate. ERs are present on the epithelial cells
of normal breasts. However, in the majority of breast cancers ERs are found at levels
greater than in normal breast tissue. In the resting breast between 15 and 25% of
epithelial cells are ER positive. The level of ER expression varies throughout the
menstrual cycle with lowest levels during the luteal phase (corresponding to highest
levels of circulating oestrogen). This corresponds with the maximal proliferation of
epithelial cells in the breast. What triggers ER positive cells to proliferate in response to
oestrogen remains unclear.
The majority of oestrogen in premenopausal women is produced by the ovaries. In
postmenopausal women, the ovaries cease to produce oestrogen. The majority of
oestrogen in plasma is converted from androgens (eg androstenedione and
dehydroepiandrosterone secreted from the adrenal glands) by the enzyme aromatase in
peripheral tissues such as fat, liver and muscle. In postmenopausal breast cancer, the
intra-tumoural concentrations of 17B-oestradiol (oestrogen's main circulating form) are
more than 20 times higher than in plasma I6. This is likely to result from breast tumours
having either greater levels of uptake or high levels of synthesis and so high levels of
aromatase, the enzyme which synthesizes oestrogens from adrenal steroids.
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There is considerable evidence that the risk of breast cancer increases with prolonged
exposure to oestrogens. The exact mechanism for this remains unclear. One possibility
is that the proliferative effect of oestrogens on the breast promotes malignant cell
proliferation and breast cancer progression. Approximately two thirds of breast cancers
are ER positive, compared with 15-25% of normal breast epithelial cells. Additionally,
ER expression is higher in benign breast epithelial tissue in women with breast cancer
than in women who do not have breast cancer. This suggests that ER expression may
have a role in early events that lead to the development of breast cancer.
The highest ER values are found in postmenopausal women with well differentiated
tumours. The expression of ER is inversely correlated with proliferation rates in breast
cancers. This is in keeping with the finding that ER and Progesterone receptor (PgR) are
more likely to be expressed by well differentiated tumours which have lower degrees of
proliferation and a better prognosis. The value of ER alone as a prognostic factor is
weak and gradually decreases with time.
Interestingly, it has been suggested that ER positive cells may promote proliferation of
surrounding ER negative cells rather than proliferating themselves 1 .
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1.4 Management of breast cancer
1.4.1 Diagnosis
In the UK, women with a breast lump usually first present to a general practitioner who
refers them to a breast clinic which is usually run by a general surgeon with a special
interest in breast surgery. Women who are treated by specialists, who see large numbers
of patients with breast cancer and who work as part of a multidisciplinary team, have
better clinical outcomes 17. Currently, patients who present to a breast clinic with a
breast lump have a detailed history taken and are investigated using triple assessment.
This involves clinical examination, imaging and cytohistological assessment.
Imaging routinely involves mammography for all women over 35 years of age and often
an ultrasound (US) scan of any palpable lump for women under 35. Pathological
assessment includes fine needle aspiration (FNA) of any breast lump and results are
usually available within one hour. This can be done freehand on any palpable lump or
under ultrasound or mammographic visualisation if the lump is not palpable. Increasing
use is being made of 14 gauge core biopsy either in addition to or as replacement for
FNA. This gives additional information preoperatively, including the presence of
invasion and oestrogen receptor (ER) status.
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After a woman has been diagnosed with breast cancer she will typically have routine
staging investigations performed. This involves blood tests (full blood count, urea &
electrolytes, and liver function tests) and chest x-ray (CXR) for women with early stage
disease. It may also include liver ultrasound and bone scan for women with more
advanced disease.
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1.4.2 Use of core biopsy
Fine needle aspiration cytology has been the first line pathological diagnostic test in
assessing breast lumps for many years. It has high sensitivity and specificity 18.
Increasingly, core biopsy is being performed in addition to FNA or in preference to it.
Core biopsy has been shown to increase the rate of diagnosis of both invasive and pre
invasive breast cancers. Tissue from core biopsies is extremely useful in treating
advanced breast cancer as it can be used to assess prognostic markers such as ER which
may influence the choice of primary endocrine or primary chemotherapy treatment. It is
also useful for research purposes as it can be used as a baseline for assessments prior to
starting any systemic therapy. Cores can also be obtained during treatment at different
time intervals to assess pathological response and compared with final tumour excision
specimens. Core biopsy specimens do have some potential drawbacks because of their
relatively small size. Known tumour heterogeneity may lead to differences in results
that are due to sampling technique rather than as a result of treatment. However there is
generally good concordance between core biopsies and tumour sections in relation to
several pathological variables such as oestrogen receptor 19.
17
1.4.3 Treatment of breast cancer
Staging
Breast cancer is currently staged using the TNM (primary stage, regional nodes,
metastasis) classification (Table 1):
Tis In situ disease only
T1 <2cm
T2 >2 - 5cm
T3 >5cm
T4a Chest wall involved
T4b Skin involved
T4c Both skin and chest wall involved
T4d Inflammatory cancer
NO no regional node metastasis
N1 mobile ipsilateral nodes
N2 fixed ipsilateral nodes
N3 internal mammary nodes involved
MO no evidence of metastasis
Ml distant metastasis
Table 1: Classification of breast cancer using TNM staging
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The treatment of breast cancer varies according to the stage at which it presents. If
untreated, approximately 20% of patients will be alive five years after diagnosis and 5%
will be alive after 10 years. Patients with early stage breast cancer who are treated
appropriately now have over an 80% probability of being alive five years later.
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1.4.3.1 Early breast cancer
Women with early breast cancer Tl-3, NO-1, MO are those considered to have operable
disease. Their primary treatment therefore consists of surgery. The aim is to cure by
excising loco-regional disease and treat potential micro metastases. In addition to
surgery, adjuvant radiotherapy, chemotherapy and/or endocrine therapy can be used
depending on individual circumstances.
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1.4.3.2 Locally advanced breast cancer
Some patients with locally advanced (usually inoperable) breast cancer but no evidence
of metastasis can be treated with neoadjuvant therapy to down stage their tumour and
allow surgical excision. In this group, after primary treatment they can be treated in the
same way as patients with early breast cancer and given post-operative adjuvant
treatment with the aim of cure. If they have had successful neoadjuvant endocrine
treatment, they can continue on the same drug therapy post operatively with the
advantage of knowing that their tumour is sensitive to the treatment.
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1.4.3.3 Advanced breast cancer
Women with advanced or inoperable breast cancer are treated differently. The main aims
of treatment are to control local disease and maintain quality of life. With the advent of
more effective endocrine agents and chemotherapy it is now also possible to prolong
survival. In this group, it is important to remember the impact of any intervention on
quality of life. The main goal of treatment remains palliation although some patients
with associated comorbidity may not die as a direct result of their breast cancer. These
women can be treated with primary (neoadjuvant) endocrine therapy or chemotherapy.
Another option in this group is to palliate local or metastatic disease using radiotherapy.
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1.4.4 Surgical treatment of the breast and axilla
Surgical treatment of breast cancer consists of excision of the primary breast cancer and
draining regional lymph nodes from the corresponding axilla.
Over the past decade there has been a move away from mastectomy towards breast
conserving surgery. This consists of excision of the tumour with a surrounding 1cm
macroscopic margin of normal tissue.
Several trials have shown similar rates of survival between patients treated with breast
conserving surgery and mastectomy 20. However, breast conserving surgery has a higher
rate of local recurrence than mastectomy unless it is followed by postoperative
radiotherapy 21. Therefore, for women with a single primary tumour less than 4cm in
size that is not locally advanced and does not have extensive nodal involvement or
evidence of metastasis, the treatment of choice is wide local excision followed by
radiotherapy. Breast conservation is not possible or appropriate for all tumours eg.
multifocal breast cancers or those surrounded by large areas of ductal carcinoma in situ
(DCIS). Mastectomy may also give a better result for women with larger tumours in
small breasts.
The role of axillary surgery in breast cancer is both to stage the axilla and to treat any
axillary disease that may be present. There have been some changes in management of
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axillary surgery over the past few years. Previously, most patients with breast cancer
were routinely treated with a level II or III axillary clearance. Since half of symptomatic
breast cancers and 80-90% of screen detected cancers have no nodes involved, a
significant proportion of patients were having unnecessary surgery sometimes resulting
in significant morbidity in terms of lymphoedema and nerve damage 22.
Over the past few years, there has been a move towards axillary sampling (taking 3 or 4
nodes from level I) and sentinel node biopsy rather than clearing the axilla for smaller
tumours. Since size of primary tumour is directly related to likelihood of presence of
axillary metastasis, many centres treat patients with small tumours (<2cm) who are
clinically node negative with axillary sampling. Sentinel node biopsy of the axilla has
now taken over as the method of determining which patients require either an axillary
clearance or post operative radiotherapy to the axilla. This is being introduced gradually
in all patients undergoing breast conserving surgery and in many patients undergoing
mastectomy who are clinically node negative.
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1.4.5 Factors influencing breast cancer prognosis
Breast cancer differs from other epithelial tumours in that it can have an extended
clinical course over up to 30 years. This means that decisions regarding adjuvant
treatment need to be guided by prognosis. The most important factors in influencing
prognosis are tumour size at presentation, degree of involvement of axillary lymph
nodes and tumour grade. The most widely used tool in calculating prognosis and aiding
decision-making in adjuvant therapy in the UK is the Nottingham prognostic index
(NPI).
The NPI was constructed in 1982 for patients with primary, operable breast cancer. The
index was based on a retrospective analysis of nine risk factors in 387 patients. Only
three of the factors (tumour size, stage of disease, and tumour grade) remained
significant on multivariate analysis. The NPI uses lymph-node stage, tumour size and
pathological grade to calculate a score using the formula (0.2 x size of invasive cancer in
cm) + lymph node stage + grade. Lymph node stage is assigned as follows,
1 if no nodes are involved
2 if one to three nodes are involved
3 if four or more nodes are involved.
The NPI has been subsequently validated in several prospective studies.
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The index can be used to define a number of groups of patients clustered according to
their prognosis. Originally the NPI was used to divide women into good, intermediate or
poor prognostic groups. The good prognosis group comprises approximately 30% of
patients and has a survival close to that of age matched controls (83% 15-year survival).
This group benefits little from aggressive adjuvant therapy. In contrast, the poor
prognostic group (17% of patients) has only a 13% 15-year survival and therefore may
well derive benefit from aggressive systemic therapy. Recently the NPI has been refined
and further divided into 6 groups based on 10 year survival (table 2).




Excellent <2.4 96 94
Good 2.41 - 3.4 93 83
Moderate I 3.41 -4.4 82 70
Moderate II 4.41 - 5.4 75 51
Poor 5.41-6.4 53 } 19
Very poor >6.41 39 } 19
Table 2: Nottingham Prognostic Index " '
There has been a dramatic improvement in survival over the last decade. The 10-year
survival data shown in table 2 is from patients with primary operable breast cancer
treated between 1990 and 1996 (Nottingham Tenovus Primary Breast Cancer Series) and
1980-86 25.
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1.4.6 Adjuvant treatment of breast cancer
In the 1970s, it became obvious that locoregional treatment alone for breast cancer was
insufficient to control disease. Patients were dying from metastatic disease, probably
from occult micrometastases that were already present at the time of diagnosis and
subsequent surgery. As a result, the use of adjuvant systemic treatment has become
routine. This consists of either chemotherapy or endocrine therapy or a combination of
both. Interest in the importance of ER status in breast cancer increased as it became
apparent from trials that patients who benefited most from hormone therapy were
patients with ER positive cancers. However, those who benefited most from
chemotherapy were young women with ER negative tumours 26. Chemotherapy does
produce some improvement in survival in postmenopausal women although the
improvement is not as great as in those women who are still menstruating.
Until recently almost all women with ER positive tumours were treated with five years
of adjuvant tamoxifen. As more data has become available from the adjuvant studies
comparing tamoxifen with aromatase inhibitors, increasing numbers of women
especially those with higher risk cancers are being treated with an aromatase inhibitor.
This varies between starting adjuvant treatment with an AI, switching from tamoxifen to
an AI after two or three years or having extended adjuvant therapy with an AI after
completing five years of tamoxifen. Treatment is tailored according to an individual
patients risk profile.
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Radiotherapy is used routinely for all women who have breast conserving surgery and
for selected women identified to be at relatively higher risk of local recurrence after
mastectomy.
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1.4.7 Neoadjuvant treatment of breast cancer
Traditionally, breast cancer treatment has consisted of surgery followed by radiotherapy
and then adjuvant systemic therapy. Fewer women are now treated surgically by
mastectomy and more by breast conserving surgery. To extend the use of breast
conserving surgery, there has been increasing use of both primary (neoadjuvant)
chemotherapy and endocrine therapy to reduce tumour size prior to surgery 27"35.
Until recently, neoadjuvant protocols in breast cancer have most frequently utilised
chemotherapy to downstage the size of the primary tumour and allow more breast
conserving surgery to be performed. Both disease-free survival and overall survival
have been reported to be similar in patients treated with neoadjuvant chemotherapy
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preoperatively and in patients treated with systemic therapy after surgery " ' " although
significantly more patients can be treated without mastectomy following preoperative
chemotherapy. It is of interest that complete response rates with chemotherapy are lower
in patients whose tumours are ER positive compared to patients who are ER negative
36;37
In the past, endocrine agents were used as sole therapy without surgery in elderly
patients whose tumours fortunately tend to be ER positive. Such agents are much better
tolerated than chemotherapy. Later tamoxifen was used to downstage the surgical
procedure which could be performed. This is important in elderly patients who tend to
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have other significant comorbidity and have significant risk factors for surgical
complications.
Tamoxifen was the first widely used neoadjuvant endocrine treatment and was
successful in elderly patients at reducing the size of tumours38. This allowed inoperable
tumours to become operable and tumours which would have required mastectomy to be
removed by wide local excision " ' . However studies which compared tamoxifen
treatment alone with tamoxifen followed by surgery showed that, although most tumours
responded initially, local disease control was poor with endocrine therapy alone 31'33"35.
Further, survival from breast cancer was poorer in the tamoxifen alone group 40. More
recent studies have shown that letrozole is a more effective agent than tamoxifen in this
setting in postmenopausal women 41.
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1.5 Breast cancer in the elderly patient
30% of breast cancer occurs in women aged over 70 and 48% in those aged over 65 42;43.
These figures are likely to increase in line with the growth in the elderly population.
The elderly are excluded from many clinical trials despite the fact that studies have
shown they are willing to participate 44. Elderly patients differ in a number of ways
which might affect the outcome of treatment. They have a shorter life expectancy,
increased co-morbidity and different psychological and functional profiles 45~47. There is
also the possibility that breast cancer in the elderly behaves in a biologically different
way, manifesting itself as a less aggressive disease. These factors mean that it is
increasingly important to include the elderly population with breast cancer in clinical
trials and to investigate the disease in this population.
Survival data in the elderly are notoriously difficult to interpret because of comorbidity.
Many patients with breast cancer die from unrelated conditions. Breast cancer causes
73% of deaths in affected patients aged between 50 and 54 but only 29% in those aged
over 85 48. However, life expectancy is often longer than realized at the extremes of age.
At age 70, the average life expectancy is 15 years but at age 80 it is 8 years 45. It is
therefore particularly important to treat breast cancer appropriately in the elderly
population.
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Cosmetic treatment of breast cancer has often been considered an area more relevant to
younger women than the elderly. In terms of making the choice between breast
conserving surgery and mastectomy, younger women are more likely to be offered
breast conservation 49. However, the only study to have examined patient choice in
women over 70 reported that the majority of women with early breast cancer would
prefer BCS. They were fully prepared to go through a full course of radiotherapy in
order to optimize the cosmetic result and local disease control 50. Only one of 31
patients considered that radiotherapy would be 'too much trouble'. The elderly are also
less likely to want to be involved in making treatment decisions and are happier to allow
doctors to advise them. They are also less likely than younger women to ask questions or
to seek a second opinion 51.
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1.5.1 Biology of breast cancer in the elderly
Breast cancer in the elderly has traditionally been considered to be less biologically
aggressive than in younger women. There is evidence of greater sensitivity to oestrogen
with a higher proportion of tumours being ER positive. There are also small but
significant differences in other markers of aggressive disease eg grade and HER2
expression 51. There are a higher number of more differentiated tumours such as
mucinous, lobular and papillary breast cancer (Table 3). 48>52~54.






37 Poorly differentiated <71 39 >71 24 <0.001
28 Lobular 55-64 8 >65 9.1 <0.001
28 Mucinous 55-64 1 >65 3 <0.001
40 Papillary 35-69 0.2-1 70-85 1.6-2 NS
37 ER positive <71 59 >71 77 <0.001
37 PgR positive <71 51 >71 63 NS
Table 3: Incidence of different histological types of breast cancer according to age
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1.5.2 Response to tamoxifen in elderly patients
In the early 1980s several studies reported the use of tamoxifen as primary endocrine
therapy for breast cancer in the over 70s age group 5>;>9. The initial results were
promising, with significant numbers of patients achieving response or stasis in their
tumour after a year of treatment. After ER status was taken into account, a good
response to treatment could be expected in 79 to 90% of patients whose tumours were
moderately or strongly ER positive 55>56'60>61. Jhis was an attractive option for elderly
patients and for surgeons and many patients were treated in this way. However, with
time it became apparent that the major drawback of treatment was the short duration of
response and disease control (mean response 18-24 months) 55'60. This meant patients
required to change to second line treatment or face surgery or radiotherapy when they
were two years older than when first diagnosed.
Based on long term results (after 12 years of follow up), 38% of women develop
progressive disease after surgery, compared with 81% of women treated with primary
tamoxifen. There is also a significant reduction in survival in the tamoxifen-only group
62. However, there was a small group of long term responders (19% in one study) 63 who
had good local control 12 years after primary tamoxifen treatment. They had been
spared surgery. If it was possible to identify this subgroup there may still be a place for
primary endocrine therapy alone. Out with this small subgroup of patients, primary
endocrine therapy is still best combined with surgery to obtain optimal disease control.
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1.5.3 Surgical treatment in the elderly
Mastectomy carries small but significant morbidity and mortality rates. Morbidity is
approx 19% in those over 65 and does not increase significantly with age 51. The
majority of complications are wound seromas, haematomas and infections which can be
resolved relatively easily. Mortality is 1% in patients over 65 64'65. There are lower rates
of morbidity and mortality with breast conserving surgery than with mastectomy.
Mortality in patients over 70, having had breast conserving surgery, has been reported to
be 0.3%. 51. Elderly patients are more likely to be offered BCS than mastectomy,
probably because it is easier to perform BCS under local anaesthesia 43>48>66>67. Axillary
surgery is more likely to be omitted in the elderly as is adjuvant radiotherapy 3|. Several
studies have reported local recurrence rates varying between 3 and 47% after wide local
•3T.TC./"Q "7 1
excision alone without radiotherapy ' ' " . The mean time from operation to local
recurrence is short therefore necessitating further treatment.
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1.5.4 Axillary surgery in the elderly
Only 10% of elderly patients present with palpable axillary disease but approximately a
third of all axillary clearance specimens are node positive 31. A review of studies in the
elderly where no axillary surgery was performed (1873 patients in total) showed an
axillary recurrence rate of 12.6% after follow up of 3-10 years. However, in only 0.3%
of cases the disease was not able to be controlled by operation or radiotherapy 51.
The risks of axillary clearance are no higher in the elderly population although the
morbidity is higher than when breast surgery alone is performed. This is true of all age
groups 72'73. Younger patients have a worse outcome following axillary surgery in terms
of restriction of daily activities than older people, presumably because they were
generally more active. The use of axillary sampling or sentinel node biopsy allows
elderly patients the advantages of accurate staging without the increased morbidity of
clearance.
There is a concern that women who fail to respond to primary endocrine therapy have
had a delay in effective loco-regional treatment. This is obviously a particularly
important factor for elderly patients as one or two years can make a significant
difference to whether or not they may be considered fit for surgery.
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1.6 Endocrine treatment of breast cancer
The growth of many breast cancers is dependent upon hormones, most notably
oestrogen, and endocrine deprivation is therefore a major treatment modality. It is well
established that oophrectomy or ovarian ablation can result in tumour regression. Over a
century ago, it was first appreciated that approximately one third of patients with
advanced disease responded following oophrectomy. Since then various forms of
surgical endocrine manipulation have been used in the treatment of breast cancer
including hypophysectomy and adrenalectomy. However, these procedures had
significant associated morbidity requiring replacement corticosteroid therapy
administration, and have therefore been replaced by drugs which result in hormone
deprivation.
Lutenising hormone releasing hormone (LHRH) analogues (eg. goserelin) can now be
used to cause a 'medical oophrectomy' in premenopausal women thus avoiding the need
for surgery. However, this is often achieved as a useful "side effect" of cytotoxic
chemotherapy.
Tamoxifen has been the endocrine agent of choice since the 1970s. However, over
recent years there has been increasing use of aromatase inhibitors to treat breast cancer.
It is likely that they will replace tamoxifen as the agents of first choice in
postmenopausal women over the next five years.
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1.7 Tamoxifen use in breast cancer
Tamoxifen was first used in patients with advanced disease. It produced a clinical
response in approximately one third of women treated. Initially it was given to all
patients, regardless of ER status but it gradually became apparent that it was only
effective in those who were ER positive. It is currently used as an adjuvant treatment for
both pre and postmenopausal women with breast cancer.
Tamoxifen is a selective oestrogen receptor modulator and has now been established for
nearly 30 years as standard first line hormonal therapy for ER positive tumours. It is
routinely given both as adjuvant therapy for five years postoperatively in low risk
women and used alone or in combination with other treatments in advanced breast
74
cancer .
Tamoxifen antagonises ER function by binding competitively to the receptor but it also
has partial agonist properties. Its activity in breast cancer appears to be due to its anti-
oestrogenic effects. Extensive clinical studies have confirmed tamoxifen's efficacy in
both early and advanced breast cancer 75.
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1.7.1 Use of tamoxifen in the adjuvant setting
As the concept of early micrometastasis in breast cancer became established a need was
identified to treat women with systemic adjuvant therapy after primary locoregional
therapies. The aim of systemic adjuvant therapy was to eradicate or control these
micrometastases without giving the patient further significant adverse events.
Tamoxifen has been shown to decrease both recurrence rates and mortality when
compared with no adjuvant treatment 74"76. In addition, it reduces the rate of contralateral
breast cancer development when compared with placebos. As predicted, it is most
effective in ER positive tumours.
There has been much discussion about the optimal duration of adjuvant tamoxifen
treatment74. However, using tamoxifen for more than five years has not been shown to
provide any additional benefit. In fact, outcomes may be worse because tamoxifen is
known to have adverse side effects eg two-three times increased risk of endometrial
cancer and increased thromboembolic events. Therefore, five years is the current
standard adjuvant period for women with low risk breast cancer being treated with
tamoxifen alone. As aromatase inhibitors are being increasingly used in the adjuvant
setting, tamoxifen alone is currently reserved only for women with a very low risk of
recurrence.
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1.7.2 Use of tamoxifen in the neoadjuvant setting
Tamoxifen was first used for the treatment of advanced disease. An early study of 1200
patients in this setting showed a 32% response rate to tamoxifen 11. This rose to 50%
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when only ER positive patients were considered . Additionally, there was increased
survival in the group of patients that responded. Tamoxifen has also been studied
widely in the neoadjuvant setting. It is relatively well tolerated by most patients and does
not have the significant associated morbidity of neoadjuvant chemotherapy. However,
as previously described, when used alone it has been shown to have low rates of long
term local disease control and is best used in combination with surgery. There has been
growing interest in the past few years of the use of aromatase inhibitors in this setting.
Following the publication of the P024 study which showed letrozole to be more
effective in the neoadjuvant setting than tamoxifen, letrozole has become the agent of
first choice in this setting 41.
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1.8 Use of aromatase inhibitors in breast cancer
Aromatase inhibitors (AIs) work by blocking oestrogen production via inhibition of the
aromatase enzyme 79. Aromatase is a cytochrome P-450 dependent enzyme that converts
androgen substrates to oestrogens. In postmenopausal women, the major sites of
aromatase are in peripheral tissues including adipose tissue, muscle, skin and both
benign and malignant breast tissue. Third generation AIs are able to reduce circulating
plasma oestrogen levels to below detectable limits in post menopausal women 80,81. Over
the past decade, there has been increasing use of aromatase inhibitors in the treatment of
ER positive breast cancer in postmenopausal women.
Aminoglutethimide was the first AI used clinically. It had similar efficacy to tamoxifen
but adverse effects limited its clinical use. Second generation inhibitors were developed
which were less toxic but it was not until third generation AIs appeared that their clinical
use expanded. These third generation AIs are extremely potent inhibitors of the
aromatase enzyme (inhibiting oestrogen synthesis by 97-99% compared with 85-90%
for second generation compounds82). There are also data comparing these newer agents
and suggesting that letrozole is a more complete inhibitor of oestrogen synthesis than
anastrozole 81'83AIs in current use result in near maximal oestrogen suppression 84'85, but
unlike the earlier aromatase inhibitor aminoglutethimide, they are selective for the
aromatase enzyme and do not interfere with production of other steroid hormones such
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as adrenal corticosteroids . Consequently, they do not need to be given with
corticosteroid replacement, as was the case with aminoglutethimide.
There are two different groups of AIs in current use. The first group includes the type I
inhibitors or inactivators such as exemestane. These are generally androgen analogues
which are steroidal and interact directly at the substrate molecule-binding site. They
bind irreversibly hence the term "inactivator". The second group, known as type II
aromatase inhibitors, are non-steroidal and include anastrozole and letrozole (Figure 3).
They inhibit aromatase by binding reversibly to the adjacent heme site of the enzyme.
This blocks the access of androgens to the substrate molecule binding site, so preventing
oestrogen production. The different mechanisms of action of inactivators and inhibitors
may have implications for the ability of breast cancers to develop resistance to these two
types of aromatase inhibitor. There is some clinical data to suggest that tumours, which
are no longer responding to type II inhibitors such as letrozole or anastrozole, can still
• 86
respond to the type I inhibitor exemestane .
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Structure of anti Aromatase Agents
Androgen Substrate Steroidal Inactivators
Figure 3: Structure ofAromatase inhibitors
Since the mid 1990s, these orally active, potent, selective third-generation aromatase
inhibitors have been used in the treatment of metastatic breast cancer in postmenopausal
women with oestrogen receptor positive tumours. Randomised clinical trials have
established their superiority over megestrol acetate in the second line setting which was
formerly the drug most commonly used after tamoxifen failure 87-89. More recent studies
suggest that aromatase inhibitors are superior to tamoxifen when given as first line
therapy in advanced breast cancer 90-92.
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1.8.1 Aromatase inhibitors in the adjuvant setting
Tamoxifen, given as adjuvant hormonal therapy for breast cancer, dramatically reduces
the risk of relapse after surgery in early breast cancer. Five years of treatment with
tamoxifen reduces the risk of recurrence by 47% and the risk of death by 26% in ER
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positive patients . AIs have the potential to be even more effective in this setting and
recent reports of large trials indicate a better outcome for women given AIs compared
with tamoxifen in the adjuvant setting 94'95.
The ATAC (Arimidex, Tamoxifen Alone or in Combination) trial was the first large
randomised controlled trial of an adjuvant AI for which results have been published. It
compared the aromatase inhibitor anastrozole with tamoxifen. Between July 1996 and
March 2000, 9366 postmenopausal women with invasive breast cancer from 381 centres
in 21 countries were recruited. After completing primary therapy (surgery +/-
radiotherapy +/- chemotherapy) women were randomised to receive anastrozole plus
placebo, tamoxifen plus placebo or anastrozole and tamoxifen together for five years as
adjuvant therapy. Patients in each of the groups had similar demographics and tumour
characteristics and had similar primary treatment of their cancer. In each group,
approximately 83% of tumours were oestrogen receptor positive, 7% were oestrogen
receptor negative and 10% were unknown. Updated results were published in 2004 after
a median follow up of 68 months 96.
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Anastrozole was superior to tamoxifen in terms of disease free survival in both the
overall study population (hazard ratio 0.87 [95% CI 0.78-0.97], p=0.01) and the
oestrogen receptor positive subgroup. Anastrozole was also superior to tamoxifen in
terms of time to recurrence (0.79[0.70-0.90], p=0.0005) and time to distant recurrence
(0.86 [0.74-0.99], p=0.04). There were also significantly fewer new contralateral
primary tumours in the anastrozole treated group (42% reduction [95% CI 12-62] p=0.01
for all patients; 53% for hormone receptor positive patients [95% CI 25-71 p=0.001).
Interestingly the combined arm did not show any significant improvement over
tamoxifen alone.
The breast international group (BIG) 1-98 study compared not only letrozole alone with
tamoxifen as initial adjuvant endocrine therapy but also sequential treatment with the
two agents in either order. The study involved 8010 postmenopausal women with
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hormone receptor positive breast cancer . Only data from the direct comparison
between letrozole and tamoxifen is currently available. After a median follow up of 25.8
months, 351 events had occurred in the letrozole group compared with 428 in the
tamoxifen group, with five year survival estimates of 84% and 81.4% respectively.
Letrozole significantly reduced the risk of an event ending a period of disease free
survival when compared with tamoxifen (hazard ratio 0.81; 95% CI 0.7-0.93; p=0.003).
This was particularly the case when looking at distant recurrence (hazard ratio 0.73; p =
0.001) which is what is likely to impact most on survival.
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1.8.2 Extended adjuvant therapy
Because of the lack of cross resistance between tamoxifen and AIs and their different
mechanisms of action there has been interest in the extended use of adjuvant endocrine
therapy with AIs after completion of five years of adjuvant tamoxifen.
The double-blind, placebo-controlled MA 17 trial was designed to evaluate whether
postmenopausal women with hormone receptor-positive early breast cancer, who had
completed five years of adjuvant treatment with tamoxifen could benefit from receiving
an additional five years of treatment with letrozole 97 . 5 1 87 patients were enrolled with a
median follow-up of 2.4 years. At the first analysis, there was a significant difference in
disease free survival (DFS) (P <0.001), with 75 recurrences or new primary contralateral
breast cancers in the letrozole group compared with 132 in the placebo group. The
estimated four year DFS rates were significantly higher for letrozole (93% and 87% for
letrozole and placebo, respectively; P <0.001). On the basis of these results, the data and
safety monitoring committee recommended that the trial should be terminated early and
the results of this interim analysis be published. Updated results were presented at ASCO
2004, indicating that letrozole was associated with a 43% reduction in risk, producing an
absolute improvement in three year DFS of 3% and 7% in patientswith node-negative
and node-positive disease respectively.
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As a result of the early discontinuation of the trial, the study did not achieve its main aim
of determining DFS and overall survival in women switching from tamoxifen to
letrozole or placebo for five years. Thus the optimal duration of letrozole therapy in this
context remains undefined. Several studies are ongoing in an attempt to determine the
optimum duration of extended adjuvant treatment. Some recent preliminary data
suggests that at least 10 years adjuvant treatment should be used for node positive
patients and that even patients who have had a gap since stopping tamoxifen could
benefit from starting on letrozole.
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1.8.3 Sequencing adjuvant therapy
A benefit has been seen in switching from tamoxifen to an AI after two to three years for
both anastrozole and exemestane. The intergroup exemestane study (IES) randomised
patients who had been on tamoxifen for two or three years. They switched to
exemestane or continued with tamoxifen for up to five years 95. Switching to
exemestane improved relapse free survival and metastasis free survival. Combined
analysis of the ARNO and ABCSG trials, which compared anastrozole with tamoxifen
with a similar trial design to IES, showed similar beneficial outcomes in event free
survival after switching to anastrozole 98. The rationale behind such a treatment strategy
is that initial treatment with tamoxifen may 'sensitise' micrometastatic disease to
aromatase inhibition. There are several ongoing trials which hope to address the optimal
time to switch and the optimal sequence of drugs to choose.
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1.8.4 Summary of optimal adjuvant Al use
In summary, in two Phase III trials comparing an AI with tamoxifen for the adjuvant
treatment of breast cancer in postmenopausal women, disease-free survival was
significantly improved with anastrozole and letrozole compared with tamoxifen as initial
adjuvant treatment (P = 0.01 and P = 0.003, respectively) 93'94. A switch to either
anastrozole or exemestane after two to three years of adjuvant tamoxifen therapy was
more effective in reducing the risk of recurrence than continuing with tamoxifen therapy
(P = 0.006, P < 0.002, and P < 0.001, respectively) 95'98. In another Phase III trial,
letrozole was found to improve disease-free survival in the extended adjuvant setting (P
Q7 •
<0.001) and was the only AI consistently more effective than tamoxifen in the
neoadjuvant setting 41.
The use of adjuvant tamoxifen and AIs is complex at present. Evidence from recent
studies and numerous ongoing studies which aim to clarify the optimal choice of drug in
each setting have not been entirely conclusive and further results are awaited before a
clear treatment strategy emerges. Their use has to date been based on available evidence
from trials and each individual drug's licensed indications. At present, women
considered to be at low risk of recurrence are offered five years of adjuvant tamoxifen.
Women with contraindications to taking tamoxifen and those considered to be at high
risk of early relapse on tamoxifen alone are offered an upfront AI.
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A retrospective analysis of the Edinburgh Breast Unit database looking at risk factors for
relapse in women who took five years of adjuvant tamoxifen between 1981 and 1998
was performed. 670 women were identified who had breast conserving surgery, of
whom 121 had relapsed to date Risk factors for relapse in the first 2.5 years were ER
poor tumours, Grade 3 tumours and 4+ positive nodes. These are the patients who the
authors felt should be considered for an up front AI. The only individuals who did not
have a significant relapse rate within the first five years were those with Grade 1
tumours who could be considered for tamoxifen alone. They concluded that all other
patients should be considered for switching to an AI after two to three years of treatment
with tamoxifen as there were no particular features identified which predicted for mid-
to late relapse. Beyond five years only tumour grade and number of lymph nodes
involved were predictors for recurrence.
Until a clearer picture emerges about the optimal place for aromatase inhibitors and
tamoxifen in the adjuvant setting, it is likely that different units will have different
policies about who to treat with which agents and in which sequence. This will probably
be tailored according to the patient's individual risk profile for recurrence. Cost of
treatment and side effects will also need to be taken into account and more data is
constantly emerging regarding these factors.
In a patient-preference study, those receiving letrozole reported fewer adverse events
than those receiving anastrozole (43% vs 65%; P < 0.003), and more patients preferred
letrozole to anastrozole (68% vs 32%; P < 0.01) 10°.
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1.8.5 Side effects of Aromatase inhibitors
Previous studies, comparing aromatase inhibitors with tamoxifen, have shown a similar
or an improved side effect profile for the AIs. The ATAC study showed anastrozole
treated patients had a lower incidence of thromboembolic events, vaginal bleeding and
endometrial carcinoma than those treated with tamoxifen 94>101. However, since
aromatase inhibitors lower oestrogen levels so potently, women in the ATAC study had
problems with a higher rate of bone fractures since oestrogens are important for bone
metabolism. The AIs may turn out to have an adverse effect on lipid metabolism as well
and there have been concerns about potentially increased cardiovascular morbidity and
mortality. However, findings from studies to date have not been consistent with regard
to hypercholesterolaemia and the reported differences in cardiac events between
tamoxifen and AIs are likely to be due to the protective effect that tamoxifen has on lipid
profile rather than an adverse effect from the AIs.
There is concern about the osteoporotic effects of AIs as the concentration of oestradiol
becomes virtually undetectable in patients on AIs. It is much lower than in normal
postmenopausal women and that normally required to maintain good bone health.
However, when comparing the increased fracture rates seen in the adjuvant AI trials it is
evident that the fracture rates with AIs are only marginally worse than those seen with
placebo and that rates seen with tamoxifen treated patients are similar to those seen in
postmenopausal women on HRT. Therefore, it is likely that the bone changes seen in
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the AI trials are probably due to the absence of, or switching from, tamoxifen rather than
simply due to the AI. It is also likely that bisphosphonates can be used to treat
effectively any significant adverse effect on bone. For this reason, patients embarking
on treatment with an AI should have a baseline DEXA scan to assess their bone mineral
density and to guide any potential requirement for treatment with bisphosphonates.
AIs may also have a role in breast cancer prevention l02. In settings in which apparently
well women are taking AIs, side effects, morbidity and tolerability become as important
as the anti-tumour properties of the drugs.
In advanced breast cancer, side effects of aromatase inhibitors have resulted in treatment
being stopped in less than 4% of women103.
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1.8.6 The use of aromatase inhibitors in the neoadjuvant setting
With the recent expansion of the use of aromatase inhibitors in postmenopausal breast
cancer patients the scope for using them in the neoadjuvant setting has increased.
Initial small scale pilot studies in Edinburgh compared the use of all three currently
available aromatase inhibitors with tamoxifen in the neoadjuvant setting l01>104>105_ These
studies were non-randomised or randomised to different doses of an aromatase inhibitor.
Patients selected were postmenopausal and had large operable or locally advanced ER
positive breast cancer.
In the first study, 24 postmenopausal patients were treated for three months with
letrozole prior to surgery. A clinical response rate of 92% was seen in this group 101. 15
of these patients who required mastectomy preoperatively were able to have breast
conserving surgery after neoadjuvant treatment. A second group of 24 patients were
treated with three months of anastrozole prior to surgery l04. On ultrasound scanning,
there was a 75.5% response to treatment after three months. Of the 17 patients who
initially required mastectomy, 15 were able to have breast conserving surgery at the end
of the three month period. A third group of 12 patients were treated with three months of
neoadjuvant exemestane 105. There was a >80% median reduction in tumour volume on
clinical examination, ultrasound scan and mammography in this group. Out of 10
patients initially requiring mastectomy, eight were ultimately able to have breast
conserving surgery.
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All three aromatase inhibitors were shown to have a superior response rate to that seen
with tamoxifen leading to increased tumour shrinkage and more patients being down
staged to have breast conserving surgery. Additionally, in these small studies, the
aromatase inhibitors were extremely well tolerated. Indeed, several studies have shown
that patients taking aromatase inhibitors have similar or lower incidence of side effects
than tamoxifen with fewer patients having to stop treatment because of adverse effects
87-89,94,106-m After such promising initial results from these pilot studies of neoadjuvant
treatment with aromatase inhibitors, larger Phase III randomised studies were
performed.
The P024 study was a large randomised double blind multicentre study, comparing
neoadjuvant letrozole with tamoxifen. In this study, 337 postmenopausal women with
ER and/or PgR positive primary untreated breast cancer were randomised to receive
20mg tamoxifen or 2.5mg letrozole daily for four months 41. The primary tumours were
large at diagnosis (> T1) and were either inoperable (14%) or not suitable for breast
conserving surgery. Baseline demographics and tumour characteristics were similar in
the two groups.
Efficacy endpoint Letrozole Tamoxifen P value
(n= 154) (n= 170)
Clinical response 55% 36% <0.001
Ultrasound response 35% 25% 0.042
Mammographic response 34% 16% <0.001
Breast conserving surgery 45% 35% 0.022
Table 4: Results of the P024 trial comparing neoadjuvant tamoxifen and letrozole.
Percentages refer to % of patients showing response or having BCS.
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The results showed letrozole was significantly superior to tamoxifen in all three
measurable endpoints, namely clinical response measured by palpation, ultrasound
response and mammographic response (Table 4). There was also a significant difference
in the number of patients who were able to be treated by breast conserving surgery (45%
in the letrozole group vs 35% in the tamoxifen group, p= 0.022) after neoadjuvant
therapy (Table 4).
The IMPACT trial (Immediate preoperative anastrozole, tamoxifen or combined with
tamoxifen) compared 12 weeks of neoadjuvant treatment with anastrozole, tamoxifen or
a combination of the two drugs in 330 post-menopausal women 113. Biopsies were taken
prior to starting treatment and after two and 12 weeks. Response rates as assessed by
clinical examination were no different between the groups. The rate of breast
conserving surgery was 44% for anastrozole compared with 31% for tamoxifen and 24%
for the combined drugs. These results were not as impressive as the P024 results for
letrozole although there are several reasons why this might be the case. Firstly, the third
arm in the IMPACT study resulted in fewer patients in each arm giving the study less
power. The minimum tumour size for entry into IMPACT was smaller than for P024 so
many patients enrolled in IMPACT may have had tumours which were suitable for BCS
before starting neoadjuvant therapy. The required degree of oestrogen receptor
expression was also lower in IMPACT. The treatment period in IMPACT was also
shorter being three months compared to four in P024. Another study, PROACT, also
compared anastrozole and tamoxifen in the neoadjuvant setting. Importantly in this
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study, patients could be given neoadjuvant chemotherapy in addition to their endocrine
therapy during the three month treatment period 114. 451 patients were randomised and
objective response rates were higher with anastrozole than tamoxifen (37% vs 24%,
p=0.03). In addition, significantly more patients were able to undergo breast conserving
surgery in the anastrozole treated group (43% vs 31%, p=0.04).
One small study has compared neoadjuvant endocrine therapy using anastrozole with
neoadjuvant chemotherapy using a regimen of doxorubicin and paclitaxel over a period
of three months in 121 postmenopausal hormone receptor positive women 115. This
study showed response rates of 76% for chemotherapy and 90% for endocrine therapy
with more breast conserving surgery being performed in the endocrine treated group
(37% vs 21%). The same group presented a study comparing neoadjuvant exemestane
with tamoxifen involving 151 postmenopausal women who were randomised to one or
other drug for 3 months prior to surgery 116. Exemestane was seen to perform better in
terms of clinical response rate (76% vs 40%, p=0.05) and breast conserving surgery rate
(37% vs 20%, p=0.05).
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1.9 Optimal duration of neoadjuvant endocrine therapy
Standard practice with neoadjuvant chemotherapy has been to administer between three
and six cycles prior to surgery. This approach provides enough time to distinguish
between responders and non-responders and to achieve optimal tumour shrinkage
preoperatively 117. The optimal period of neoadjuvant endocrine therapy has never been
investigated in detail.
One study in the Edinburgh Breast Unit gave neoadjuvant tamoxifen to 100 elderly
patients (>70 years) with ER rich breast cancer (>20 fmol/mg cytosol protein) "8. After
three months, 72 patients showed tumour response (a greater than 25% reduction in
tumour volume on ultrasound scan and only one patient had progressive disease. The
remaining 27 patients continued on tamoxifen for a further three months. During this
time, 18 patients continued with static disease, four responded but five patients had
progressive disease. From these data, it can be concluded that if patients are not
responding to an endocrine agent by three months then they are unlikely to respond if
the drug is continued for longer. There is also concern that, if they continue on hormonal
treatment alone, their disease may progress.
It would appear that three months is sufficient to demonstrate whether or not a tumour is
responsive. However, maximal response may take considerably longer than three
months so the optimal period of treatment depends on initial tumour size and the
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purpose of the neoadjuvant therapy. If the purpose is to downstage the tumour to allow
breast conserving surgery to be performed, this can be achieved in the majority of
patients in three to four months.
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1.10 Predicting response to endocrine treatment
The main purpose of all endocrine therapies is to improve survival. However, using
survival as an end point takes many years because of the natural time course for breast
cancer. Furthermore, survival is influenced by many confounding variables over time. It
would be very useful to be able to accurately predict on an individual basis which
tumours are likely to benefit from endocrine treatment so that a patient's treatment
schedule could be individually tailored. One objective method of assessing tumour
response to endocrine therapy is to leave the tumour in situ during systemic treatment.
In this way, it would be possible to assess response to treatment and during treatment to
obtain serial tumour samples to investigate the effect of the drug on different biological
markers.
None of the classical clinical prognostic factors (eg grade, tumour size, lymph node
status) predict sensitivity to endocrine therapy. ER is known to be the most important
factor in determining response to endocrine treatment but it is not the only one, and not
all patients who express ER, even when expression levels are high, respond to endocrine
therapy.
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1.10.1 Oestrogen and progesterone receptors and response
to endocrine treatment
The initial step in the action of oestrogen is for it to bind to its receptor. Therefore, the
presence or absence of oestrogen receptors in a tumour is an important indicator of
which tumours will be endocrine sensitive. However, not all ER positive tumours
respond to treatment. Although there is anecdotal data that some ER negative tumours
appear to respond, this is probably related to ER positive tumours being classified as ER
negative because of failures in the ER assessment technique.
60 - 75% of breast cancers are ER positive. A patient is more likely to have a tumour
which is ER positive if it is low grade, if they are older and if they have become
postmenopausal. Over recent years, there has been an increase in the percentage of
tumours which are classified as ER positive. This could be due to an ageing population
or alternatively, and more likely, to more sensitive hormone receptor assays.
It has been established clearly that response to neoadjuvant tamoxifen and aromatase
inhibitors is related to ER status. However, even selecting an ER positive subgroup,
only approximately 70% of patients respond to neoadjuvant tamoxifen 54-119.
Progesterone receptor (PgR) synthesis is oestrogen regulated and the level of PgR
expression is theoretically an indicator of an intact oestrogen response mechanism and
the functional integrity of the ER. PgR is synthesised by tumour cells that are stimulated
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by oestrogens through an interaction with ER. This means that in theory PgR should be a
better indicator of hormonal sensitivity than ER because, in some patients ER may be
present but not functional. PgR can be detected in approximately two thirds of ER
positive tumours. The incidence of PgR positivity also increases as the ER
concentration increases.
Addition of PgR assessment increases accuracy in predicting response. Tumours that are
both ER and PgR positive have higher response rates of between 66 and 83% than
tumours that express only a single hormone receptor119. There is some evidence that
small numbers of tumours, recorded as ER negative but PgR positive, respond to
endocrine treatment. This is likely to be due to methodological problems with ER
analysis resulting in occasional false negatives or a variant ER which is not detectable
by the monoclonal antibodies used to detect ER. However, the ER that is present still
stimulates PgR production.
During endocrine treatment, decreases in PgR expression within a tumour may be
considered indicative of the anti-oestrogenic effect of treatment. Tamoxifen, a partial
oestrogen agonist, has been shown to have dual dose-dependent oestrogenic and anti-
oestrogenic properties. This is apparent in its induction of the progesterone receptor.
With low doses, tamoxifen is potently oestrogenic and rapidly induces PgR over a 24-48
hour period. Indeed after four to six days the increase is four to ten fold. However, at
high doses of tamoxifen, the induction of PgR is suppressed120. In the clinical setting it
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has been shown that neoadjuvant tamoxifen treatment increases PgR expression . In
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contrast, treatment with aromatase inhibitors decreases PgR expression over as short a
period as 10-14 days.
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1.10.2 Proliferation markers
After oestrogen binds to its receptor, it exerts action at a cellular level by stimulating
proliferation. It may therefore be possible to accurately determine sensitivity to
endocrine treatment by measuring changes in proliferation after a period of endocrine
treatment. One proliferation marker which has been widely studied in breast cancer is
Ki67.
Ki67 is a nuclear antigen that is expressed by cells in Gl, S, G2 and M of the cell cycle
but not during GO 122. Immunohistochemical staining for MIB1 (the monoclonal
antibody to the Ki67 nuclear antigen) is therefore clinically useful as a marker of tumour
proliferation. It is most frequently expressed in poorly differentiated tumours which
have high rates of mitotic activity. High levels of proliferation are associated with early
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recurrence of breast cancer after mastectomy . However, the amount of staining seen
1 7^
is independent of tumour size, lymph node status and ER expression
Ki67 levels in normal breast tissue have been shown to be unaffected by neoadjuvant
endocrine therapy with letrozole 124. In this study, 32 women without active breast
disease were recruited to a study where they were given three months of treatment with
letrozole (2.5 mg/day) Core-cut biopsies from the breast were collected before and at the
end of treatment. There was no significant change in the proliferation marker Ki67 or
oestrogen receptor in breast epithelial cells with treatment.
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Proliferation when assessed using Ki67 has been shown to decrease by 79% in patients
after treatment with tamoxifen for as short a period as 10-14 days 125. This was shown to
correlate with subsequent clinical response in that one small study. In this study all
patients who responded to tamoxifen showed a decrease in Ki67 at 14 days. In those
who did not respond, any changes were small, with a median value close to zero.
However, by eight weeks, the observed reductions in Ki67 no longer correlated with
response. Other studies have failed to show that a drop in proliferation correlates with
clinical response.
Proliferation has also been shown to drop early during treatment with aromatase
inhibitors. Studies continue to investigate the effects of AIs on biological markers early
in neoadjuvant treatment to see if reduced proliferation does correlate with subsequent
clinical response.
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1.10.3 Epidermal growth factor receptor (EGFR) and HER2
(Erb B2)
The ErbB family of cellular type I receptor tyrosine kinases (TKs) plays a central role in
normal cell proliferation, survival, and differentiation in a variety of tissues. Ligand
binding to the epidermal growth factor receptor (EGFR, ErbB-l) results in receptor
activation. ErbB-2 (HER-2) activation results in activation of signalling pathways
involved in cell proliferation, survival, and transformation. Over expression of the
EGFR or ErbB-2 receptors results in cell transformation and is associated with poor
clinical outcome in a number of malignancies 126>127. The HER2 gene is amplified and
over expressed in 25-30% of breast cancers. It is more likely to be over expressed in ER
negative tumours than ER positive tumours where approximately 10% of tumours have
an amplified F1ER2 gene. The potential roles of the EGFR and ErbB-2 receptors in
tumour cell proliferation and survival have led to the development of monoclonal
antibodies that inhibit the receptors. This includes the well publicised trastuzumab
(Herceptin®) which is a monoclonal antibody to the ErbB-2 receptor.
EGFR is present in almost half of all clinical breast tumours. In breast cancer tissue,
excess EGFR expression is associated with increased tumour proliferation, and a poor
prognosis. There is an inverse relationship between ER and EGFR expression with over
expression of EGFR determining a highly malignant potential. It is thought that EGFR
expression may represent the progression of a cell towards oestrogen independence and
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high levels of expression have been shown in tumours relapsing on tamoxifen.
Expression of EGFR prior to treatment in locally advanced and metastatic breast cancer
has been shown to predict tumours which are less likely to respond to primary therapy
with anti-oestrogens.
In experimental models, human epidermal growth factor receptor-2 (HER-2)
amplification has been shown to correlate with oestrogen independence and tamoxifen
resistance in ER positive human breast cancer cells. Some reports suggest an association
between HER-2 positivity and hormone independence in breast cancer patients.
There has been little published work on the relationship between aromatase inhibitors
and Erb B-l and Erb B-2 over expression. Small non-randomised studies in Edinburgh
showed that the response rate to neoadjuvant anastrozole was similar in both erb B1/B2
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positive patients and negative patients . However, differences in response between
letrozole and tamoxifen in the P024 study were largest in the subgroup of tumours that
was ER and or PgR positive and were also positive for Erb B-l and/or Erb B-2 (88% for
letrozole vs 21% for tamoxifen) 129. It has been hypothesised that these patients are
resistant to tamoxifen but respond to aromatase inhibitors. This could explain why
aromatase inhibitors appear to have improved efficacy in direct comparison with
tamoxifen. Assessment of HER2 status for prognosis and treatment of breast cancer
patients can be performed by immunohistochemistry and/or fluorescence in situ
hybridization (FISH).
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1.11 Neoadjuvant endocrine therapy study models
There have been two main study models described to investigate the effects of endocrine
agents on breast cancer in vivo.
The preoperative model involves giving patients preoperative endocrine therapy in the
14-21 days between diagnosis and surgery (Figure 4). Tissue is taken at the time of
diagnosis and further tissue is obtained from the same tumour during definitive surgery.
Studies have shown that without any intervening treatment the tumour remains stable
with no changes in hormone receptor expression or proliferation. This allows
comparison of tumour tissue before and after exposure to agents such as different
endocrine therapies, with the certainty that changes are as a consequence of the drug
therapy. A limitation of this model is that information on clinical response is not
available to correlate with the biological changes which occur as a result of the drug
treatment. Figure 4 summarises the preoperative model where patients have an initial
diagnostic biopsy and then 14-21 days later undergo surgery. Patients are given drug
treatment between these two time points and changes in the tumour can be correlated




Figure 4: Preoperative model of neoadjuvant endocrine therapy
The other model system involves treating patients with neoadjuvant endocrine therapy
for between three and four months (Figure 5). Tissue can be collected at different time
points during the study period. Clinical response is assessed by both clinical examination
and imaging over the treatment period. This model has the advantage that clinical
response can be correlated with pathological and biochemical changes in individual







Figure 5: Three month model of neoadjuvant endocrine therapy
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1.12 Assessing clinical tumour response to neoadjuvant
therapy
It is important to be able to assess accurately the degree of response to neoadjuvant
treatment in order to be able to assess its effectiveness. The natural course of breast
cancer untreated is to grow in size, but the rate of growth is variable with a median
doubling time of approximately 60 days. It is however rare for a tumour to regress
spontaneously and therefore sustained reduction in tumour size is likely to be as a result
of therapy. It remains a challenge to accurately measure tumour size over time.
Potential methods of serial assessment are performing clinical examination and calliper
measurements, mammographic measurements or ultrasound measurements. Previous
studies have shown that ultrasound response is the modality which corresponds most
130
closely with pathological response
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1.12.1 Clinical measurements
Clinical measurements by calliper are notoriously inaccurate, being prone to large
degrees of inter-observer variability and influenced by factors such as tissue oedema and
• i • 131132 •
patient obesity ' . The method used is indirect with the tumour being measured
through the skin by palpation and using callipers. The measurement can also be
influenced by the depth of the tumour within the breast tissue. It has been demonstrated
that two observers may produce significantly different measurements for the same
inoperable breast cancer. 13 . However, it has been shown that if the same observer
remained consistent in their method, changes in lesion size were very similar over time.
Only those lesions which were discrete and easy to measure gave reproducible results in
this study and observers had to remain blind to their previous measurements. The false
positive rate of this method is also reduced if two or more successive measurements
show a consistent change. Therefore, the optimal method of assessing response by
clinical measurement alone is for one observer to make repeated serial measurements
over a period of time.
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1.12.2 Mammographic measurements
Mammography can be used as an objective method of assessing response of breast
cancers to treatment but it is also not without concerns. Frequent repetition of
mammography is not advisable because of the dose of radiation involved. In some
elderly women, who often have additional comorbidity, it can be technically difficult to
obtain mammograms because of immobility. Additionally, in certain types of tumour
such as lobular carcinoma, the margins are indistinct thus making measurement and
comparisons between mammograms difficult and sometimes inaccurate.
Comparisons have been made between assessing clinical and mammographic response
to systemic therapy. In one study, physical examination overestimated the overall
response rate in 22.9% of cases while the converse was true in 8.6% of cases 134.
However, both clinical examination and mammography have the problem of only being
able to assess the tumour in two dimensions.
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1.12.3 Ultrasound measurements
It has been shown that ultrasound scanning correlates most closely with pathological
size when compared with clinical examination and mammography 133. The same study
showed that inter- and intra-observer variation was less than 10%. Ultrasound has the
advantage of being able to assess tumours in three dimensions thus allowing depth to be
added to the volume calculation.
Breast ultrasound is simple to perform and cheap. It can be performed repeatedly as it
does not involve any radiation dose and a printed permanent record of the measurements
can easily be obtained. For these reasons, ultrasound scanning has become the method




Neoadjuvant endocrine therapy is being used increasingly as primary treatment in very
elderly or infirm patients in order to avoid the need for surgery. It is also being used to
downstage tumours, since it allows inoperable tumours to become operable and allows
tumours which would have required mastectomy to be suitable for breast conserving
surgery. However, concern has been expressed that women who fail to respond to
neoadjuvant treatment have a delay in effective loco-regional treatment which may have
an impact on their survival.
The ability to predict which patients respond to treatment would have the benefit of
allowing selection of those likely to respond to neoadjuvant treatment. Others not likely
to respond would change to more effective local or systemic treatment. Studying patients
with their primary tumour left in situ during systemic drug treatment allows clinicians to
make an accurate estimation of response to therapy. In parallel, access to serial cores of
the same tumours during treatment allows measurement of biological factors that may
predict for response to treatment. Additionally, this knowledge should aid
understanding of the mechanisms of action of, and help explain resistance to, these
treatments. Taking serial fresh frozen tumour samples allows expression of genes to be
assessed using microarray work in order to look at gene expression in parallel with
clinical response.
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This thesis therefore aims to characterise the response of primary breast cancers to
neoadjuvant endocrine treatment with letrozole and to compare the biological changes in
tumour phenotype over the initial 14 days of treatment and after 3 months. The
objectives were:
• to further characterise the clinical response to primary systemic endocrine
therapy in breast cancer in the setting of a clinical trial;
• to determine whether it is possible to identify biological markers of
tumour phenotype that can be used to predict subsequent clinical
response to neoadjuvant treatment with 2.5mg letrozole for three months;
• to determine the effects of treatment on biological markers after 10-14
days and after three months and investigate whether these changes
correlated with clinical responses seen over that period; and
• to identify potential markers of resistance to endocrine therapy.
In order to address these aims, the letrozole audit was carried out as a three month
neoadjuvant study which treated 137 postmenopausal patients with locally advanced
breast cancer with 2.5mg letrozole daily. Samples of tumour were taken both at
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diagnosis and after 12 weeks and, in 72 patients, additionally at 10-14 days. Serial
clinical tumour measurements were made at diagnosis and after six and 12 weeks using
clinical examination and ultrasound scan. Mammography was performed, both at
original diagnosis and after three months.
Firstly the clinical response of tumours to treatment with letrozole over three months
will be discussed. Then the effects of treatment on biological responses to therapy will
be reviewed. In conclusion, there will be a discussion about the significant findings and
the prospects for further research.
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Section 2: Materials and Methods
2.1 Ethical approval
Prior to commencement, this research was approved in advance by the Lothian Research
and Ethics Committee and the NHS Trust Research and Development Department. All
studies were discussed in advance at the local breast cancer multidisciplinary meeting
and all patients who were suitable to be approached regarding taking part in this study
were discussed by the whole multidisciplinary team in advance. This involved
discussion between pathologists, medical and clinical oncologists, surgeons,
radiologists, breast care nurses and research staff.
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2.2 Patient populations
All patients were recruited from the new patient clinics at the Edinburgh Breast Unit
based in the Western General Hospital in Edinburgh. Patients were given an
information booklet about the study (Appendix 1) in addition to discussing it with
medical and nursing staff before deciding about whether or not they wanted to
participate.
Patients were given the option of agreeing to allow extra samples to be taken at the time
of diagnostic core biopsy and stored for research purposes. They completed a consent
form which had been approved for this purpose by the local ethics committee (Appendix
2). Additional core biopsies at 10-14 days were optional and if patients were happy to
allow these to be taken they completed a standard hospital consent form for this purpose.
Core biopsies were performed in the outpatient clinic under local anaesthesia and were
well tolerated. The biopsies were routinely assessed in the pathology department for ER
status using immunohistochemistry. The patient's ER status was used to select those
suitable for neoadjuvant endocrine trials. Patients with a tumour that was ER rich
(defined as an Allred score of 6-8) were most likely to benefit from endocrine therapy.
When patients returned to the clinic to get the result of their core biopsy neoadjuvant
protocols were discussed with them, if considered appropriate, as part of their treatment
plan. All aspects of the patient's management, including potential trial involvement,
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were discussed by the local multidisciplinary team. This ensured that only appropriate
patients were selected and that there was unanimous agreement that the patient was
suitable for the proposed treatment. A copy of the multidisciplinary team's decision was
recorded in the patient's case notes. Patients who agreed to take part in a trial signed the
appropriate consent form for that trial.
Clinical follow up during the study period was performed by, or organised by, the author




Theoretically, any post-menopausal woman with locally advanced breast cancer being
considered for surgery as primary treatment could be enrolled to receive preoperative
endocrine therapy, regardless of clinical stage, providing that their tumour was oestrogen
receptor positive. In practice, this meant that patients with distant metastatic disease
were excluded because surgery was not usually part of their primary treatment. Patients
with severe renal or hepatic impairment were also excluded, as were patients who were
considered to be at risk of transmitting HIV or Hepatitis B or C. Anyone unable to give
informed consent was automatically excluded.
Patients considered eligible for the neoadjuvant study model formed a specific group.
The majority had large operable or inoperable advanced tumours. These would
potentially derive benefit from tumour shrinkage and tumour downstaging, following
successful primary endocrine therapy. These patients were predominantly elderly with a
tumour larger than 3cm clinically (2cm on imaging) which was oestrogen receptor
positive on core biopsy. The majority of patients involved in the study had surgery at the
end of the treatment period but some, who were considered unfit or who declined to
have surgery, continued on primary endocrine therapy if their tumour showed evidence
of clinical response. Some younger post-menopausal patients with large primary
tumours were enrolled onto the three month neoadjuvant study because it was felt that
they might benefit from having their proposed surgery downscaled from mastectomy to
breast conserving surgery.
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2.4 Methods of assessing tumour response
Patients enrolled on the three month neoadjuvant therapy trial had their tumour response
assessed using the following methods.
2.4.1 Clinical examination
Examination was carried out using bidimensional caliper measurement, either by the
author or Mr Dixon, consultant breast surgeon. The size of the primary tumour was
determined by measuring two different tumour diameters at 90° apart. Tumour size was
then determined by multiplying the longest diameter by the greatest perpendicular
diameter (bidimensional measurements). Tumour volume was assessed using the
formula;
V = D3 x 7i where V is the volume and D is the mean diameter
6
Assessment was also made of any change in the appearance of the local tumour eg
tumour ulcerating or re-epithelialising (Figure 6).
Figure 6: Ulcerating tumour before and after treatment with letrozole for three months
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2.4.2 Ultrasound measurements of tumours
A Honda convex scanner model HS-2000 with a linear array probe was used to perform
all the ultrasound scan measurements. All scans and measurements were performed by
one of the same two investigators (the author and Mr Dixon). The probe was held
perpendicular to the skin surface and moved over the tumour until a maximum diameter
was visualised. The tumour was then visualised in two different planes, and in each
view, bidimensional measurements were made across the widest part of the tumour
(Figure 7). The response to treatment was also assessed on the basis of tumour volume
changes which were calculated using the formula for the volume of an ellipsoid 135. This
uses two different diameters measured at 90° intervals and, additionally, the thickness of
the primary breast lesion (tridimensional measurements).
V = D2 x d x 7t where V is the volume, D is the mean of diameters parallel to
6 the skin surface, and d is the mean thickness as measured
by the ultrasound machine's electronic calipers
Figure 7: Measurements being taken of tumour on ultrasound scan
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During training in this technique, the same tumours were scanned and measured blindly
by the author and Mr Dixon (JMD), consultant breast surgeon. There was less than a
10% inter-observer error similar to that previously reported by Forouhi 135.
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2.4.3 Mammographic measurement of tumours
Two-view mammography (oblique and craniocaudal views) was performed at the start
and end of the study period (Figure 8). The largest tumour diameter and the diameter at
90° to the axis were measured. The mean mammographic diameter and tumour volume
were calculated using the following formula;
3 • •V = D x 7i where V is the volume and D is the mean diameter
6
Bidimensional assessment and percentage change in volume were used to assess
response to therapy, comparing tumour area at the start of treatment with that after
three months.
Figure 8: Mammographic appearance of tumour before and after letrozole
treatment, showing a marked reduction in tumour size and density
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2.4.4 Pathological assessment
Pathological response was assessed in those patients who had surgery at the end of their
period of neoadjuvant treatment. Bidimensional tumour size was measured by the
pathologist on the excised specimen. Both macroscopic and microscopic measurements
were carried out to determine the extent of the invasive tumour. Determining
pathological size accurately allowed direct comparisons to be made with final tumour
size as assessed by clinical examination with calipers and mammography and ultrasound
scan. Axillary lymph nodes were also examined histologically for the presence of
metastatic tumour.
Histopathological features of the tumours after three months treatment were compared
with the diagnostic and 10-14 day core biopsy specimens using Haematoxylin and Eosin
(H&E) stained sections. Tumour morphology was judged by comparing changes in
cellularity and fibrosis. The grading was also scored by looking at tubule formation,
nuclear pleomorphism and the frequency of mitosis. This allowed an overall tumour
grade to be calculated (Appendix 3). This method is described in more detail by Elston
and Ellis 136.
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2.4.5 Evaluating tumour response
Modified World Health Organisation (WHO) criteria were used to evaluate tumour
response as follows:
Complete response (CR): no measurable tumour
Partial Response (PR): reduction in tumour bidimensional area >50% from pre-
treatment size.
Minor response (MR): reduction in tumour bidimensional area >25% and <50%
from pre-treatment size.
No change (NC): <25% decrease or <25% increase in tumour area from pre-
treatment size.
Progressive disease (PD): 25% or more increase in tumour area from pre-treatment
size.
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2.4.6 Assessment of side effects
At each visit to the clinic, all neoadjuvant patients were asked about any side effects of
treatment. Patients were asked to contact study personnel in addition to their GP if they




The progress of all patients was followed up to obtain information on disease free
survival, distant disease free survival and overall survival. Survival data were calculated
in May 2006 but follow up of these patients is still ongoing. Recurrences of tumour in
the chest wall, ipsilateral breast or axillary nodes were classified as local recurrences.
Any other recurrences were classified as distant recurrences. Survival was classified as
survival with or without evidence of recurrent disease. The follow up period was
calculated from the date of beginning drug treatment to May 2006, the date on which
data was analysed.
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2.4.8 Definitive locoregional surgery
At the time of starting treatment, the type of surgery that would have been required to
remove the tumour was determined by Mr Dixon who operated on all study patients who
had surgery. Whether the patient required to have a mastectomy, or a wide local
excision was noted in addition to an axillary node clearance or sample. On completion of
systemic therapy, the majority of neoadjuvant patients had surgery to remover their
tumour. The type of surgery actually performed was recorded and compared with the
surgery that would have been required prior to neoadjuvant treatment. The facilitation
of local conservative treatment is an important outcome in neoadjuvant therapy,
especially in breast cancer where there is significant psychological morbidity associated
with mastectomy. However, it remains to be confirmed whether this will have any long
term impact on breast cancer recurrence and survival.
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2.5 Sampling techniques
In both studies several techniques were used to collect and process tissue samples.
2.5.1 Core biopsy
An area of skin overlying the tumour was prepared with betadine solution. 20ml of 1%
lignocaine with a 1:200000 adrenaline solution was then infiltrated under the tumour.
The local anaesthetic and adrenaline was left to become effective for at least 10 minutes.
A 15 bladed scalpel was used to make a small incision in the skin over the palpable
tumour. A Bard Max Core Disposable Biopsy Instrument with a 14G needle was used
to take serial biopsies through the same skin incision. Some of the biopsies were placed
in formalin to allow later histological examination and others were placed in round
bottomed cryogenic vials and immediately fresh-frozen in liquid nitrogen. At least four
cores were taken for diagnostic purposes and wherever possible a further four were
fresh-frozen in liquid nitrogen for later research. After biopsy, direct pressure was
applied over the site to reduce bleeding, and a dressing was then applied. Patients were
advised to leave this in place for 24 hours. The availability of mammatome biopsies
allowed larger samples of tissue to be taken under ultrasound guidance from some larger
tumours (see figure 9). This device used an 11 or 8 gauge core needle (see figure 10)
and vacuum suction assistance to remove larger pieces of tissue than a conventional core
gun.
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Figure 9: Mammatome biopsy being performed
Figure 10: Comparison of the size of core biopsies (left) with mammatome biopsies
- rows are 18 gauge core biopsy and 11 gauge mammatome biopsies
91
It was important that the fresh samples were frozen in liquid nitrogen as quickly as
possible (within a few minutes of being taken) to allow future analyses. This required a
container of liquid nitrogen to be available adjacent to the clinic where the samples were
taken.
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2.5.2 Tissue collection from theatre specimens
Further tissue samples were taken at the time of surgery and both fresh-frozen and
formalin-fixed tissues were obtained. In order to do this, either a pathologist was
available to take a piece of fresh tissue from the excised specimen or one of the surgeons
took core biopsies from the sample or excised a small part of the tumour as soon as
possible after the specimen was removed. The sample was then fixed in formalin and
paraffin sections were obtained after routine processing.
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2.5.3 Storage of fresh-frozen specimens
Fresh-frozen samples were stored in liquid nitrogen in 2ml round-bottomed cryogenic
vials. Relevant identification details were marked clearly using a suitable cryogenic
pen. Patient's details were encoded to anonomise samples. Details of all samples
collected, together with the date the biopsy was performed and details of the study the
patient was enrolled in, were recorded in a detailed log to allow accurate sample
identification at a later date. Immediately after samples were taken and placed into the
cryogenic vials, they were put into liquid nitrogen prior to being transferred to the tissue
bank. If samples taken from wide local excision or mastectomy specimens could not be
taken immediately, specimens were placed on ice whilst awaiting specimen radiology or
sampling by a pathologist.
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2.5.4 Processing of paraffin embedded specimens
As soon as possible after being taken in clinic or theatre, formalin-fixed tissue samples
were placed directly into 4% buffered formalin. They were then taken to the pathology
department for processing and paraffin embedding.
2.5.5 Preparation of blocks
(Specimen Automated Processing Protocol)
Tissue samples were fixed in 4% buffered formalin for 24 hours before processing. The
tissue was then placed in a cassette and processed on a Vacuum Infiltrated Processor
(VIP, Tissue Tech VIP, E300 series, Miles Inc) overnight. Treated tissue was then
placed in a mould and covered in paraffin wax. The detailed protocol is described later
(see appendix 4).
2.5.6 Cutting paraffin sections
Paraffin blocks were first cooled on ice. Using a microtome, 4pm thick sections were
cut from the blocks. Sections were floated on a water-bath before being placed on
Superfrost glass slides. The sections were fixed to the slides by incubation at 37 C
overnight.
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2.5.7 Analysis of tissue samples
Fixed tissue blocks can be used for a wide range of analyses. The preliminary staining
that was performed on study tissue samples included oestrogen receptor (ER),
progesterone receptor (PgR) and a marker of proliferation (Ki67). EGFR and erbB2
were also assessed on the majority of samples.
Fresh tissue was collected from patients since the end-points involved enzyme activity
or the analysis of genetic material by reverse transcription using the polymerase chain
reaction (RT-PCR) or microarray. The morphology of core biopsies on frozen section
was assessed before the material was analysed. This ensured that sufficient malignant
tissue was present within the biopsy for analysis. Mammatome biopsies were
particularly useful for this purpose as more tissue was available. Frozen sections were
kept of each sample submitted for gene array analysis to ensure that there was adequate
tumour in the cores before they underwent this costly investigation. Tissue morphology
was often slightly damaged when they were stored in liquid nitrogen. In some samples,
it was necessary to microdissect specimens to ensure the sample contained enough
malignant tissue.
Work is ongoing involving the fresh tissue samples from patients in the studies
described but the results are outwith the scope of this thesis.
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2.6 Staining techniques for paraffin sections
All paraffin sections were first H&E stained to ensure that there was sufficient invasive




Similar immunohistochemical methods were used to detect a variety of biological
markers. Tissue from the same patient at different time points was stained during the
same run to minimise potential inter-run variation. 4pm sections were cut from paraffin
embedded tumour blocks. The sections were dewaxed and placed in 3% H2O2 to block
endogenous peroxidase activity. The sections were placed in antigen retrieval buffer
(citrate or EDTA) in a pressure cooker and microwaved for six minutes (at full power in
a domestic 800 watt microwave oven). They were then rinsed in distilled water and tris
buffered saline (TBS). Protein block (DAKO: X0909) was added to each section to stop
endogenous peroxidase activity. Sections were rinsed with TBS and the primary
antibody was added for the desired time. Sections were again washed with TBS before
En-Vision chemmate solution (DAKO kit:K5007) was added. After washes in TBS,
DAB Chromogen solution (DAKO kit: K5007) was added to visualise the staining. After
washing in distilled water, copper sulphate was applied to enhance the staining. Sections
were finally counterstained with haematoxylin before being taken up through graded
alcohols to absolute alcohol. The slides were mounted from xylene then coverslipped.
Positively stained structures appeared brown when viewed under direct light microscopy
(Figure 11). Full details of the immunohistochemical technique are given later (See
appendix 6).
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2.6.3 Oestrogen and progesterone receptors
Oestrogen and progesterone receptor status was assessed by immunohistochemistry,
using the envision technique after microwave antigen retrieval using 6F11 (Dako) for
ER-a and PgR636 (Novacastra) for PgR. The method is described later (See appendix
6). Positive control slides were used with each rack of slides in each run.
1T7 •
They were Allred scored as described below. This adds the scores of proportion and
intensity of staining according to the following criteria.
Proportion of cells stained Score
0 0
< 1% 1
1 - 10% 2
11 - 33% 3
34 - 66% 4
> 66% 5





The Allred score is calculated by adding the proportion score to the intensity score (P +
I). It therefore ranges from 0 to 8 although there can be no Allred score 1.
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2.6.4 Allred scoring
The Allred score for ER has been shown to correlate with the response to endocrine
treatment in breast cancer l37. This method is easy to leam and highly reproducible137.
With minimal training, the pathologists involved in the study by Harvey et al were in
agreement in discriminating positive from negative tumours in 99% of cases. Allred
scoring has become the standard scoring of ER and PgR in the majority of pathology
laboratories. Harvey et al showed that the optimal cut off point was an ER score greater
than 2. This means that even patients scoring 3, which corresponds with as few as 1-10%
of weakly staining positive cells, had a significantly improved outcome with endocrine
therapy compared with those who had lower scores,
a) b)
7igure 11: Immunohistochemical staining for PgR a) pre-treatment and b) 14 days
after treatment with letrozole
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2.6.5 Training in Allred scoring of immunohistochemically
(IHC) stained slides
Professor T J Anderson (TJA), consultant pathologist and Professor W R Miller (WRM),
consultant in experimental oncology at the Western General Hospital in Edinburgh
trained the author and other investigators to assess and Allred score ER and PgR in
primary breast cancers by IHC on formalin-fixed paraffin-embedded tissue sections.
Initially, 100 slides were scored independently by the author and TJA or WRM. Results
were in complete agreement in 67% of cases and varied by only one IHC score in the
remaining 33% of cases. This showed a high rate of concordance (weighted kappa 0.96
for proportion and 0.56 for intensity, see tables 4 and 5 and appendix 7).
Proportion Scorer 2
Scorer 1 1 2 3 4 5
1 2 1 0 0 0
2 0 0 0 0 0
3 0 0 1 0 0
4 0 0 0 2 0
5 0 0 0 0 44
Table 4: Inter-observer variation in proportion of staining cells as component ofAllred
scoring ER/PgR stained slides. Kappa = 0.91 (95% CI [0.74, 1.00]). Weighted kappa =
0.96 (95% CI [0.90, 1.00])
Intensity Scorer 2
Scorer 1 1 2 3
1 1 1 0
2 2 18 3
3 0 7 18
Table 5: Inter-o ^server variation in intensity of ce staining as component ofAllred
scoring ER/PgR stained slides. Kappa
0.56 (95% CI [0.36, 0.76])
0.53 (95% CI [0.31, 0.74]). Weighted kappa =
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To further reduce the likelihood of potential inter-observer variation, two investigators
scored every study slide. If results varied, the slide was re-examined jointly by both
investigators and a decision was made on the final agreed Allred score. This was only
required in a minority of cases.
The same slides were also scored at different time points by the same investigators.
Again concordance was high (weighted kappa 0.88 for proportion of staining cells and
0.91 for intensity of staining) with investigators always being at least within one Allred
score of their previous score (see tables 6 and 7 and appendix 8).
Proportion Scorer 2
Scorer 1 1 2 3 4 5
1 0 0 0 0 0
2 0 0 0 0 0
3 0 1 0 2 0
4 0 0 0 2 0
5 0 0 0 0 17
Table 6: Intra-observer variation in proportion of staining cells as component ofAllred
scoring ER/PgR stained slides. Kappa = 0.81 (95% CI [0.52, 1.00]). Weighted kappa =










ibserver variation in intensity of ce
scoring ER/PgR stained slides. Kappa = 0.90 (95% CI [0.70
0.91 (95% CI [0.72, 1.00])
staining as component ofAllred
.00]). Weighted kappa :
102
2.6.6 Cell proliferation- Mib1 staining
Ki67 antigen expression was assayed by measuring the binding of a mouse monoclonal
antibody, Mibl (Dako), to the Ki67 nuclear antigen using EnVision
immunohistochemistry as described later (See appendix 9). The slides were scored using
the technique described on page 103 and appendix 6.
Figure 12 a) at baseline Figure 12b) after 14 days of drug treatment
Figure 12: Assessing proliferation using immunohistochemistry to detect the Ki67
antibody. The brown staining cells are those proliferating. It can be clearly seen that
there are far fewer proliferating cells after 14 days of drug treatment than before.
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Sections of appendix were used as the positive control slides with every run (see Figure
13).
-
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Figure 13: Control slide (appendix) for assessing proliferation using Mib
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2.6.7 Scoring proliferation
Several methods have been described to score proliferation using Ki67 staining. Three
different methods were assessed in this study in order to identify which one which was
the most accurate and reproducible.
In the first method, the percentage of positively staining cells in several fields was
assessed by a consultant pathologist (TJA). An estimate of the proportion of cells
staining across the slide was then made. In the second method, a graticule incorporating
a single line bisecting the field was used. At x40 magnification, the number of
negatively staining nuclei being transected by the line was counted (n). The formula for
area was used to estimate the cell count (A=7ir2) where n was equal to the diameter of the
microscope field, n/2 =r and A equals the estimated total cell count. The positive cells
in the field were also counted. This was repeated in 10 fields. The technique is
described in detail by Simpson et al lj8.
In the third method, sections were examined under a light microscope using x40
objective and a 10x10 eye piece incorporating a graticule. 10 of the 100 squares were
marked randomly and the negative cells in these squares were counted. This number was
multiplied by 10 to estimate the total number of negative cells in the field. Then all the
positive cells in the field were counted. New fields were counted until the total cell
count exceeded 1000 cells. Ki67 positive nuclear staining cells were then calculated as a
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percentage of the total cells. This method has also been previously described I39and is
now widely used for the assessment of Ki67 using Mib antibody.











A B C A B C A B C
6 15 11.82 7.51 1 1.28 0.45 1 0.1 0
7 25 19.76 12.16 1 2.39 1.84 1 0.39 0.64
8 30 35.09 24.09 10 9.76 3.79 5 15.54 4.02
10 5 5.02 9.83 1 1.7 2.4 1 0.46 0.08
12 15 4.62 8.15 1 3.49 1.64 1 9.46 5.25
15 25 19.2 21.8 1 0.6 1.3 1 0 0
17 5 4.6 6.34 1 1.81 3.91 5 0.06 0.25
18 40 33.69 19.74 1 1.38 5.71 5 10.21 15.86
23 15 16.2 4.98 35 7.03 4.55 10 7.51 1.18
24 25 15.13 10.8 5 2.81 1.75 1 1.04 2.29
25 15 19.08 14.48 5 2.4 7.26 1 0.07 5.32
26 25 23.72 19.73 10 6.18 1.47 1 8.11 0.93
27 25 32.21 22.06 1 2.23 7.74 1 0.8 3.21
34 30 27 17.57 10 10.49 8.93 5 3.1 0.8
38 20 22.49 15.78 5 17.48 4.33 10 28.54 8.19
43 10 29.5 10.08 5 7.4 3.59 1 11.5 1.98
44 30 108 16.5 5 10.2 2.89 1 6.4 2.31
50 35 34.2 19.76 10 15.8 3.49 25 18.29 15.79
51 40 34.1 15.53 1 31.8 13.4 20 40.4 16.8
53 5 8.9 17.85 1 8.6 2.84 1 8.3 0.68
57 30 24 1.64 15 17.2 24.78 25 25.9 15.54
58 25 23.4 22.32 5 15 2.67 0 0 0.84
Table 8: Assessing different scoring methods to assess proliferation
Method A = estimated proportion of cells staining (no direct counting of cells).
Method B = scoring technique as described by Simpson et al.
Method C = scoring technique as described by Johnston et al.
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To assess which method was most accurate and reproducible, they were repeated by two
investigators blinded to each others results. The third method described above proved to
be the most accurate and reproducible and was therefore the method of counting cells
used in these studies.
Proliferation in these studies was assessed by the author and one of the other
investigators, Miss Sharon White. Professor T J Anderson, consultant pathologist re¬
examined a selection of cases from the study and concordance with scoring was high
both between observers (Pearson's correlation r = 0.97, p<0.001) and with one
investigator repeating scoring of the same slides at a different time (Pearson's
correlation r = 0.95, see appendices 9 and 10 and figures 14 and 15).
Ki67 inter-observer variation
Count 1





Figure 15: Intra-scorer correlation in scoring same slides. Pearson's correlation r = 0.95
(confidence intervals 0.88-0.98, p = <0.0001)
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2.6.8 HER 2 (ErbB2) staining
To determine the HER2 status of tumours, HercepTest Immunohistochemistry was
performed in an accredited laboratory. This was performed by the author in the
Department of Academic Biochemistry in the Royal Marsden Hospital, London under
the supervision of Professor M Dowsett. Control slides were used with every run. They
were supplied with the HercepTest kit (see figure 16).
Figure 16: a) 3+ positive b) 1+ negative c) 0 negative
HercepTest control slides, see table 9
Paraffin embedded sections were dewaxed in xylene, then taken down through gradient
alcohols (100% x3 then 90%, 80%, 70%) to distilled water. The slides were placed in
antigen retrieval solution, then into a water bath heated to 97°C for 45 minutes and
finally allowed to cool to room temperature. They were then washed with TBS.
Sections were incubated in peroxidase blocking reagent for five minutes. They were
then rinsed in distilled water and then in wash buffer.
Sections were then incubated in the primary antibody, rinsed in wash buffer and then
incubated in the visualisation solution. They were again rinsed in buffer before DAB
chromagen was applied to the sections. Following a further rinse in distilled water they
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were counterstained with haematoxylin. Slides were then taken back up through
gradient alcohol solutions to xylene before being cover plated. Full details of the
technique are described later (see appendix 11).
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2.6.9 Scoring of HER2
The intensity of specific membrane staining in the invasive cancer cells was assessed
using the technique described in the training set that accompanies the materials
(HercepTest kit scoring guidelines). The slides were viewed at xlO magnification under
a light microscope. Staining was scored from 0 to 3 + as shown in table 9.
Staining pattern Score Her2 protein over-
expression
assessment
No staining is observed or membrane staining is
observed in less than 10% of the tumour cells
0 Negative
A faint/ barely perceptible membrane staining is detected
in more than 10% of the tumour cells. The cells are only
stained in part of their membrane
1 + Negative
A weak to moderate complete membrane staining is
observed in more than 10% of the tumour cells
2+ Weakly positive
A strong complete membrane staining is observed in
more than 10% of the tumour cells
3+ Positive
Table 9: Cell membrane staining intensity criteria
Only membrane staining intensity and patterns were evaluated using the 0-3+ scale as
illustrated by the HercepTest kit scoring guidelines above. Scores of 0 or 1+ were
considered negative for HER-2 over-expression; scores of 2+ were considered weakly
positive; and scores of 3+ were considered strongly positive. To qualify for 2+ and 3+
scoring, complete membrane staining of more than 10% of tumour cells had to be
observed. Manual scores of 2 + were tested for amplification by fluorescence in situ
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hybridization by staff in the Department of Academic Biochemistry in the Royal
Marsden Hospital. The technique used is described later (see appendix 12).
To aid in the differentiation of 0, 1+, 2+ and 3+ staining, DAKO supplied an "Atlas for
Interpretation of HercepTest™ Staining" and this was used. It shows representative
pictures of the staining intensities (Figure 17).
Figure 17: 3+ positive membrane staining for HER2
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2.7 The Letrozole audit - study design
The audit was planned to investigate the use of letrozole as neoadjuvant therapy for a
consecutive series of patients with large operable or locally advanced breast cancer. This
was introduced as first line neoadjuvant treatment in 2001. Initially, a treatment period
of three months of letrozole 2.5mg daily was planned. Patients were studied
prospectively and data on response rates were collected. The primary endpoint of the
audit was the response rate as measured by ultrasound and the rate of breast conserving
surgery being performed in the group. Additionally, both fresh-frozen and fixed tissue
samples were collected to look at the biological effects of the drugs.
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2.7.1 Study population
137 post-menopausal patients with hormone receptor positive, large operable or locally
advanced breast cancer were enrolled into this audit. All patients were treated in the
Edinburgh Breast Unit at the Western General Hospital in Edinburgh between 14 May
2001 and 05 August 2004.
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2.7.2 Inclusion criteria
• main breast cancer of any stage if loco-regional surgery was felt likely to be
appropriate after a course of neoadjuvant treatment (T1.4, N0-2, Mo-i)
• Tumour oestrogen receptor rich on core biopsy (Allred ER score 5-8). The vast
majority of patients recruited were ER 7 or 8.
• Invasive breast cancer confirmed on core biopsy
• Postmenopausal (defined as one of the following;
1. No spontaneous menses for at least 1 year in women >55 years
2. Postmenopausal oestradiol levels ( <5ng.dL)
3. Bilateral oophrectomy
• Tumour able to be assessed by clinical examination, mammography and
ultrasound scan
• A life expectancy of at least six months
• If large operable tumour, it needed to be >2cm on mammograms and ultrasound
Exclusion Criteria
• Premenopausal status
• Prior treatment with letrozole or tamoxifen
• Use of other investigational drugs within 30 days of starting letrozole
• Oestrogen receptor negative tumours
• Patients unable to give informed consent or unlikely to be compliant with
treatment regimen
.3 Trial protocol
Patients had a core biopsy performed at diagnosis. From larger tumours, extra
cores were taken and stored fresh-frozen in liquid nitrogen to allow gene array
work to be carried out. Patients completed a standard core biopsy consent form
(See appendix 2) which gave permission to store fresh tissue taken at the initial
diagnostic biopsy. This allowed the tissue to be collected for research purposes
without the requirement for additional baseline core biopsies to be performed.
Postmenopausal patients subsequently identified at the staging meeting as having
large operable or locally advanced oestrogen receptor rich cancer were invited to
take part in the audit. They were given a patient information sheet (appendix 1).
The option of neoadjuvant endocrine therapy and the alternatives were discussed
with each patient and their relatives if present. 405 patients were screened and
identified as potentially suitable. The majority of patients who discussed the
option of neoadjuvant endocrine therapy agreed to take part in the audit.
Informed consent was not obtained from patients because letrozole already had a
product licence for this indication (see appendix 13). Information about
participation in the audit was sent to each patient's GP as part of their standard
clinic letter.
4. Baseline tumour measurements were taken at the staging clinic once patients had
agreed to take part in the audit. The diagnostic mammogram that had already
been performed was used as the baseline. Clinical examination and ultrasound
measurements were performed. Details of each patient's past medical history and
current prescribed medication were documented.
5. Patients were initially prescribed three months of letrozole at a dose of 2.5mg
daily.
6. Patients returned to clinic after 10-14 days of treatment. They were asked about
any side effects or problems with the treatment. The visit included an optional
10-14 day core biopsy. It was explained to all patients that this biopsy would not
influence their treatment and that the core biopsy was only being performed for
research purposes. If they agreed to have this biopsy performed, they signed a
consent form.
7. Patients returned again to clinic six weeks after the start of treatment. Again they
were asked about any side effects of treatment. The tumour was measured
clinically using callipers and by ultrasound scan. If there was any evidence that
the tumour was not responding to letrozole and enlarging on treatment, a change
of treatment was instigated as appropriate. If the tumour was responding a
decision was made about surgery. All patients were assessed by a single
consultant surgeon Mr Dixon, who operated on all these patients. He decided
whether the tumour was suitable for excision by breast conserving surgery, by
mastectomy or whether a longer period of drug treatment was required. If
surgery was planned, a date was organised.
8. Patients were seen in the breast clinic the day before their planned surgery.
Repeat clinical examination, ultrasound scan and mammography were
performed. Mr Dixon had a chance to review the patients and their response to
neoadjuvant therapy and to make any final changes to the proposed surgery.
9. During surgery, fresh and fixed tissue from the cancer specimen were removed
for analysis as previously described.
10. All patients who had responded to neoadjuvant letrozole continued on it for five
years post operatively as adjuvant therapy. The audit patients were discussed in
detail at both the pathology meeting and the multidisciplinary meeting following
the surgical procedure. Further treatment was planned according to local
protocols.
11. Patients continue to be followed up for disease recurrence and survival. Follow
up data presented in this thesis was collected in May 2006 after a mean follow up
period of 39 months (4-58).
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2.7.4 Methods of collecting information
A proforma was completed for every patient. It collected data on the following;
date of entry to study, patient age, ER status, stage of tumour at diagnosis, type and date
of surgery, start date of drug, any past medical history and any current medications.
Additionally, it was noted which investigator discussed the trial with the patient and
which types of tissue sample were collected. Copies of any consent forms and
pathology reports from the diagnostic core biopsy and final surgical excision specimen
were filed within these proformas. Data were collected and filed at each clinic visit.
Clinical measurements were recorded. Copies of ultrasound scans with electronic
calliper measurements were filed. Mammographic measurements were also noted.
These data were all collected prospectively which made data interpretation easier at a
later date.
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2.7.5 Laboratories used for tumour measurements
Tumour biological measurements were performed in the Edinburgh Breast Unit
Research Laboratories in the Paderewski Building of the Western General Hospital,
Edinburgh under the direction of Professor W R Miller and in the Royal Marsden
Hospital, London under the direction of Professor M Dowsett. EGFR and HER2
assessment was also performed by Yuo Tao at Duke University, USA under the
direction of Professor Matthew Ellis.
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2.7.6 Letrozole audit summary diagram
New Patient Clinic Potentially suitable patients identified. Core biopsy
performed to confirm diagnosis, oestrogen receptor status
and to obtain fresh tissue.
Day 0 Staging Meeting: Patient identified and audit discussed.
Baseline clinical, mammographic and ultrasound scan
measurements performed. Patients prescribed letrozole
2.5mg daily for three months (last dose to be taken on the
day of surgery).
Day 10-14 Return to clinic. Any side effects documented.
Optional core biopsy performed.
Week 6 Return to clinic. Any side effects documented.
Ultrasound scan and clinical examination performed.
Potential surgery discussed
Month 3 Return to clinic. Any side effects documented.
Ultrasound scan and clinical examination performed.
Mammograms performed.
Surgery performed or continue on letrozole.
.7.7 Study endpoints
Characterising the clinical response to primary systemic endocrine therapy with
letrozole in large operable and locally advanced breast cancer
Comparison of the rate of breast conserving surgery after letrozole compared with
the initial surgery that would have been required prior to neoadjuvant treatment.
The effect of letrozole on ER, PgR and proliferation as assessed by Ki67. Other
immunohistochemical analyses were also performed including erbB2 and EGFR.
Further immunohistochemical analyses are being performed on these samples when
information from the microarray analysis becomes available.
Where fresh tissue is available, messenger RNA has been extracted from the primary
tumours to allow gene array expression to be assessed using microarray techniques.
Correlating biological results with clinical response to determine whether it is
possible to identify markers of tumour phenotype that can be used to predict
subsequent clinical response to treatment with 2.5mg letrozole for three months
Determining the effects of treatment on these biological markers after 10-14 days
and after 3 months and whether these changes relate to the clinical response seen
over that period
Identifying potential markers of resistance to endocrine therapy
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2.7.8 Statistical analysis
Correlation coefficients were used to examine the relationship between the measurement
methods and final pathological tumour size. However, since it is the magnitude of
difference that is important, an alternative statistic of the sum of the square of the
difference was calculated, along with the Mean Sum of Squares from the regression
without a constant term. Significance tests were not performed.
Correlation coefficients were also used to examine inter-observer and intra-observer
agreement on proliferation counts, while the kappa and weighted kappa were used to
examine agreement in Allred proportion and intensity scores.
The Kaplan-Meier method was used to produce survival plots and mean times to failure.
Contingency tables were analysed with the Fisher's Exact Test and/or x test.
Ki67 values were not Normally distributed at later time points (14 days and three
months), and were log transformed. Analysis of variance/ t-tests were used to analyse
this data.




All patients were recruited and treated in the Edinburgh Breast Unit at the
Western General Hospital, Edinburgh.
137 patients were recruited to the audit between 18th May 2001 and 23rd
September 2003.
Nine patients had bilateral cancers. Both cancers were sampled and monitored in
eight patients (35, 36, 46, 77, 78, 96, 104 and 127) and only one side was
monitored in the final patient (10).
Five patients had multifocal cancers within one breast. In these cases, each lesion
within the breast was measured separately in three patients (5, 18 and 127) and
the main lesion only was measured in two (75 and 112).
136 women and 1 man (patient 82) were included.
The mean age of the study population was 76 at the time of diagnosis (range 55
to 93).
Follow up data on patient survival were collected in May 2006 after a mean
follow up period of 39 months (range 4-58 months).
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3.2 Protocol violators
12 patients did not complete the three month treatment period for the following reasons;
• Five died before completing three months of treatment (1,9, 54, 80, 113).
• One patient could not attend the breast clinic for follow up measurements
because of poor health (37).
• One patient did not attend the breast unit for follow up after starting the audit and
refused any further visits and treatment (98).
• One patient had disease progression at six weeks and proceeded to have
chemotherapy instead (128).
• One patient was subsequently found to have a false positive ER value at
diagnosis and the tumour was subsequently shown to be ER negative (86).
• Two patients stopped treatment after two weeks due to side effects thought to be
related to starting letrozole (42 and 134).
• One patient elected to have surgery earlier than planned after only five weeks of
treatment (patient 88).
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3.3 Assessing clinical response
The detailed clinical response data (percentage reduction in tumour volumes on (i)
clinical measurement, (ii) ultrasound scan and (iii) mammography over the three month
treatment period) can be seen in Appendix 14. In general, there was agreement across
the three modalities of tumour measurement about the degree of response to treatment.
In each case where there was discrepancy between the results, the case was re-examined
by all investigators. Where there was consensus, the patient was assigned to the most
representative clinical response category. If no consensus was reached, the patient was
excluded from the analysis.
Appendix 15 shows the comparison between ultrasound measurement and final
pathological tumour size in the excised specimen of the first 50 patients. It shows the
USS measurement before treatment, the USS measurement after treatment and the
measured pathological size of the excised specimen. The pathological volume is likely
to be an overestimate as only one tumour measurement (the largest) is recorded on the
majority of pathology report forms and the volume calculated is therefore an estimate of
the largest possible volume. Some tumours were not excised at the end of the treatment
period so only cores were available.
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Correlation coefficients were used to examine the relationship between the measurement
methods and final pathological tumour size (Table 10). However, since it is the
magnitude of difference between measurements that is important, an alternative statistic
of the sum of the square of the difference was calculated (Table 10). Correlation alone
was not used because, for example, if one measurement method always overestimated
the final tumour size by a fixed amount, the correlation between methods of




Sum of (method- final
path)2
Pre clinical 0.690 (<0.001) 108.24
Pre mammogram 0.703 (<0.001) 62.35
Pre ultrasound 0.642 (<0.001) 25.93
Post clinical 0.215 (0.22) 50.77
Post mammogram 0.311 (0.07) 27.35
Post ultrasound 0.230(0.19) 23.37
Table 10: Correlation of non-invasive measurements with Inal pathological size
Comparing the volumes seen on clinical assessment, ultrasound measurement and
mammographic measurement with final pathological size, it can be seen that
tridimensional ultrasound was the most accurate way ofmeasuring tumour response as it
had the lowest deviance from the final pathological size.
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3.3.1 Clinical response categories
On the basis of clinical response, patients were divided into the five response categories
described earlier (on page 91). Figure 18 summarises the number of patients in each
response category. 83 patients had a partial response, 25 had a minor response, 10











□ % of pts
PR MR NC PD
'igure 18: Clinical response to treatment (PR= partial response, MR= minor response,
«JC= no change, PD= progressive disease)
For the purpose of analysis, those patients achieving a greater than 50% reduction in
tumour volume were categorised as responders (R). All other patients were categorised
as non-responders (NR). Therefore 67% of cases were considered responders and 33%
non-responders in this series.
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3.3.2 Suitability for breast conservation
Of the 98 patients who went on to have surgery at the end of the treatment period, 41
patients were considered suitable for breast conservation at the outset of treatment
(Figure 19 and Table 11).












at start of after 3 months final surgery
treatment letrozole
Figure 19: Effect of three months treatment with neoadjuvant letrozole on type of breast
surgery performed. BCS = breast conserving surgery Mx = mastectomy
After the three month treatment period, 79 patients were able to have breast conserving
surgery performed. However, 13 of these patients required a re-excision because of
positive excision margins (16%). Of these, six patients had a mastectomy performed
while another six had a re-excision of the cavity with clear margins. One patient who
had involved margins was not considered fit to have a re-excision and therefore
continued on letrozole with no clinically evident local recurrence to date.
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At time of diagnosis After three months of
neoadjuvant letrozole






No with inoperable tumour 6 0
Patients meeting criteria for
Axillary node sample*
10 61
Patients meeting criteria for
axillary node clearance*
88 28
No axillary surgery done N/A 9
Table 11: Effect of three months treatment with letrozole on type of surgery performed
^Edinburgh Breast Unit protocol is to perform axillary node sample for tumours under
2cm and axillary node clearance for tumours over 2cm or clinically involved nodes.
This means that 32 patients (63% of those patients who required mastectomy at the
outset) had their surgical procedure downstaged from mastectomy to breast conserving
surgery after three months of treatment with neoadjuvant letrozole.
Of the six initially inoperable tumours, four were ultimately able to have breast
conserving surgery while two were downstaged to requiring mastectomy.
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3.3.3 Axillary surgery
The majority of patients (90%) had large tumours prior to starting treatment and
therefore would have had an axillary node clearance performed in combination with
their breast surgery as part of Edinburgh Breast Unit protocols in place at that time.
However, after treatment, 51 patients who would have been selected for an axillary
clearance were considered suitable for axillary node sampling. In total, less than one
third of patients (29%) had an axillary node clearance performed (Figure 20).





a- 60 —■ 9
0 40—I §gf
■Q 20— ■
1 oP I I I—I I <—I—I
axillary axillary no axillary
node node surgery
clearance sample
Figure 20: Axillary surgery planned prior to treatment and after three months
treatment with neoadjuvant letrozole
There was a small group of patients (6%) at the start of treatment who were not suitable
for surgery because their tumour was considered inoperable. Ultimately they all went on
to have surgery. There were a small number of patients (9%) who did not have any
axillary surgery performed along with their breast surgery. This was because they were
frail and had excisional surgery performed under local anaesthetic.
□ at start of treatment
period
■ after 3 months letrozole
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3.3.4 Completeness of tumour excision and incidence of
local recurrence
Only seven local recurrences (5%) have occurred in the series to date.
■ Patient 20 had a local recurrence in her mastectomy wound nine months after
initial surgery and subsequently died with evidence of distant metastases the
following year with the cause of death being recorded as breast cancer.
■ Patient 2 had a recurrence 13 months after her original wide local excision. This
was treated with re-excision and radiotherapy. There had been a question about
her original excision margins at the time of initial surgery. She died in January
2006 after 52 months of treatment with letrozole the cause of death being
recorded as breast cancer.
■ Patient 3 had suspected bony metastases at the time of her original diagnosis.
This was later confirmed and she developed evidence of local recurrence in her
wound 15 months after starting letrozole and one month before her death.
■ Patient 11 developed local recurrence 22 months after starting letrozole and also
developed bony metastases. She died eight months later from breast cancer.
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Patient 17 developed evidence of local recurrence after being on letrozole for 36
months. This was treated surgically and she remains alive and well.
■ Patient 83 developed a local recurrence 39 months after starting letrozole and
remains alive and well with no evidence ofmetastases.
■ Patient 102 developed local recurrence which was also treated surgically and she
too remains alive and well with no evidence ofmetastases.
Figure 21 shows the Kaplan-Meier curve for time to local recurrence. Mean time to
failure (recurrence) = 38.03 months (se = 0.45) 95% CI (37.14, 38.92).








Time to Failure (months)
Figure 21: Kaplan-Meier curve for time to local recurrence.
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3.3.5 Survival
Of the 125 patients who completed the three month audit period by May 2006 with a
mean follow up period of 39 months (range 4-58), 42 patients had died. This is not
surprising as the patients were elderly with significant comorbidity in addition to their
advanced breast cancer at the time of initial diagnosis. Figure 22 shows the Kaplan-
Meier survival curve for time to death. Mean time to failure (death) is 44 months (se =
1.42) 95% CI 41.2-46.8. It is not yet possible to calculate median survival time as the
probability of death has not yet fallen below 50%. The lower quartile (25%) survival
time is 31 months (ie the point at which 25% of patients had died, 75% survived).
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Figure 22: Kaplan-Meier survival curve for time to death.
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Of the 42 patients who died, 23 had evidence of recurrent breast cancer at the time of
death. Eighteen died of causes unrelated to their breast cancer. Figure 23 shows the
Kaplan-Meier curve for time to breast cancer recurrence (local or metastatic) or death.
Mean time to failure (cancer recurrence / death) is 39.9 months (se = 0.77) 95% CI 38.4-




Figure 23: Kaplan-Meier survival curve for time to breast cancer recurrence or death.
83 patients remain alive, and 16 patients continue to take letrozole as the only treatment
that they have had for their breast cancer with their disease under control.
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3.4 Assessing biological markers of response
When determining the group used to compare clinical response with biological markers
the following patients were excluded,
• Patients who did not have triple biopsies of fresh and frozen tissue at the time of
diagnosis, at 10-14 days and at three months. They did not have enough cancer
in the biopsies to allow all immunohistochemical staining to be performed and
assessed.
• Any patient where there was doubt about the accuracy of the assessment of
response eg invasive lobular carcinomas, mucinous carcinomas, multifocal
tumours.
Since the 14 day tumour biopsy was optional, not all patients elected to have this
performed. The final group analysed for markers therefore consisted of 62 patients who
had a complete set of clinical and biological results available for comparison.
Appendix 14 shows a summary of the clinical, ultrasonic and mammographic responses
to treatment for this group. Each of the 62 biological tissue study patients was assigned
a response status on the basis of the modified WHO criteria across all three modalities
and taking final pathological size into account (Appendix 16). Pathological response was
also assessed according to the changes in histological features described on page 90.
Each patient was also assigned to a pathological response category (See appendix 16).
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3.5 Clinical response to letrozole
Overall, there were no complete responses (CR), 49 partial responses (PR), 11 minor
responses (MR), 2 no change (NC) and no patient had progressive disease (PD) (Figure
24). For the purpose of analysis those patients achieving a greater than 50% reduction in
tumour volume were categorised responders (R). All other patients were categorised as
non-responders (NR).


















Partial response Minor response No change
Figure 24: Clinical response to letrozole in biological subgroup of 62 patients
Using these criteria, 48 (77%) patients were considered clinical responders (>50%
reduction in tumour volume at three months by serial ultrasound).
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3.6 Histopathological assessments and changes
Marked changes in tumour morphology were seen after treatment with letrozole.
Pathological changes were detected in more than two thirds of cases after drug treatment
although these changes were not always consistent. In the majority of cases this
comprised a decrease in cellularity and an increase in fibrosis but other patterns were
also seen.
The following pathological features were specifically assessed in serial biopsies by the
author together with a consultant pathologist (Prof T J Anderson),
o The proportion of cancer in the biopsy slides being assessed
o Cellularity, fibrosis, elastosis, lymphocytic infiltrate, necrosis, nuclear
pleomorphism, the presence/absence of glands, mitosis.
These results can be seen in table 12.
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Nuclear pleomorphism Decrease 33
No change 54
Increase 2





Table 12: Percentage of cases showing a change after three months of letrozole
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Some features such as elastosis, showed no obvious pattern with a third of patients
showing an increase, a third a decrease and the final third no change. More than a third
of tumours showed an increase in lymphocyte infiltrate and only 4% had increased
tumour necrosis. There were a small number of cases where there was almost complete
pathological response to treatment with only microscopic foci of residual disease
remaining. However, none of the patients in this series had a complete pathological
response to three months of letrozole which might be seen more frequently after
neoadjuvant chemotherapy.
The pathological changes were used to give each tumour a pathological response
category similar to the clinical response category (See appendix 16). 46 (75%) of the 61
assessable tumours displayed evidence of a pathological response (Figure 22).
Pathological response to letrozole in biological
subgroup patients
Figure 22: Pathological response categories after three months treatment with
neoadjuvant letrozole
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The decreases seen in nuclear pleomorphism and mitosis indicate that letrozole is
capable of modulating cellular populations within individual tumours. These changes
are generally towards a less aggressive phenotype. These changes are however minor
when compared with the effects on Ki67.
There was a reduction in tumour grade seen after treatment which was usually a
reflection of a reduction in mitotic index. A decrease in mitosis was seen in 17% of
cases with only 2% increasing mitotic rate with treatment and the majority being
unchanged.
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3.7 Relationship between clinical and pathological response
The relationship between pathological response and ultrasound volume change can be
seen in table 13. Overall looking at the whole group there was a significant correlation
between changes in ultrasound volume and pathological changes. However,
pathological changes were seen after treatment in some tumours that did not have a
significant shrinkage in ultrasound volume (five cases) and conversely, there were a
small number of tumours (seven cases) which did show a major shrinkage in ultrasound
volume but did not have any evidence of pathological changes.
Clinical response > 50% Clinical response < 50%
Pathological response 41 (66%) 5 (8%)
No pathological response 7(11%) 8 (13%)
Total 48 (77%) 13 (21%)
Table 13: The relationship between clinical and pathological response
Looking at the relationship between clinical and pathological response, one is seen to be
a good predictor of the other (i.e. there is a lack of independence, p= 0.0015 by Fisher's
exact test). In 80% of cases the responses agree.
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Looking at the percentage reduction in tumour size on tridimensional ultrasound, the
data are not Normally distributed and therefore require transformation for further
analysis. The simple log transformation of fall = loge(l01-reduction) converts the data
to a more Normal distribution. Simple analysis of variance of the data reveal that a
positive response from both the clinical and pathological tests are significant (p<0.0001
and 0.0002, respectively). The means and 95% CIs for the transformed data can be seen
in tables 14 and 15:







Table 14: Ultrasound response in relation to clinical response (p<0.0001)







Table 15: Ultrasound response in relation to pathological response (p=0.0002)
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3.8 Oestrogen receptor (ER)
All tumours in the study were ER rich (Allred score 6, 7 or 8) prior to starting
treatment. It was suggested in the P024 study 41 that patients with lower levels of ER do
respond to letrozole but not to tamoxifen. However, the numbers in the low ER groups
were small in that study. The policy in the Edinburgh Breast Unit is to only treat ER
rich tumours with neoadjuvant endocrine therapy as those are the most likely to respond
and to receive clinical benefit (high ER levels have a greater percentage reduction in
tumour volume). Raw data for all ER scores in all biopsies can be seen later (Appendix
In the biological subgroup of 62 patients that were studied in more detail, all tumours
were either ER 7(16 patients) or 8 (46 patients) (Figure 23).
ER at baseline
Allred score
Figure 23: Baseline ER status
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3.8.1 Effect of neoadjuvant letrozole on ER expression
The majority of cases (51%) showed no change in ER expression from baseline after
three months treatment. Seven cases (11%) showed an increase of one Allred score from
7 to 8 with treatment (a change in intensity of staining). 24 cases showed a decrease in
Allred score. In 21 of these this was a drop from ER 8 to 7, again a change only in the
intensity of staining. The remaining three cases showed a drop of two Allred scores,
from 5 to 4 for proportion and 3 to 2 for intensity. Table 16 shows the change in ER
expression for the whole group.








Number of patients 7 32 24
% of patients 11% 51% 38%
Table 16: Effect on ER expression of three months neoadjuvant treatment with letrozole
It is possible that the changes that were observed were partly due to the fact that the
diagnostic and 10-14 day biopsies were core biopsies and the three month sample was
cut from tissue blocks from the surgically excised sample in the majority of cases. The
penetrance of fixative is better in core biopsies than in surgical specimens and this may
be reflected in the decrease in intensity of staining in the surgical blocks which is
reflected by a drop in Allred score. However, there were small changes in the ER score
between the initial core biopsies and the 10-14 day core biopsies as well.
3.8.2 Effect of baseline ER on clinical response
Looking across the whole group, there were 83 patients whose baseline ER score could
be correlated with clinical and ultrasound response accurately. This excludes protocol
violators and patients with, for example multifocal disease or lobular carcinoma where
the tumour measurements were felt to be unrepresentative. Of these, 60 had a baseline
ER of 8, 3 were ER 6 and 20 were ER 7. For the purpose of comparison ER 6 and 7
were combined because of the small number of cases that were ER 6. Table 10 shows







Median % reduction in
tumour volume
Clinical USS
8 60 48 (80%) 76* 67*
6 + 7 23 17 (74%) 63 48
Table 17: Response in 83 patients treated with three months of neoadjuvant letrozole
subdivided according to ALLRED ER score. * P < 0.05
Response rates were similar in ER categories 8 and 6 +7 but there was a greater
percentage reduction in tumour volume in patients whose tumours had the higher ER
expression. This difference was significant (p< 0.05).
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3.9 Progesterone receptor (PgR)
3.9.1 Baseline PgR expression
Of the 62 tumours, 56 (90%) were assessed as being PgR positive prior to treatment.
Figure 24 shows the baseline PgR Allred score for the group and table 18 shows the










Baseline PgR Allred score
JUL
3 4 5 6
Allred score (PgR)
Figure 24: Baseline PgR expression categorized by Allred score
PgR Allred score 0 2 3 4 5 6 7 8
Number ofpatients 6 0 2 8 7 11 10 18
% of patients 10 0 3 13 11 17 16 29
Table 18: Percentage of patients in each Allred category score for PgR at baseline
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3.9.2 Clinical and pathological response in relation to
baseline PgR status
67% of the PgR positive tumours displayed a pathological response and 68% showed a
clinical response (Figure 25). Of the six PgR negative tumours, four showed evidence of
a pathological response and five showed evidence of a clinical response.





clinical clinical non pathological pathological
responder responder responder non-
responder
Figure 25: Clinical and pathological response to treatment in relation to baseline PgR
As can be seen the percentage of patients showing clinical and pathological responses
were similar in both PgR positive and negative patients at baseline. Therefore,
assessment of PgR adds nothing to ER in terms of selecting patients suitable for
neoadjuvant endocrine therapy in this ER rich group. It may be that PgR positivity is
more helpful in patients that have lower ER expression or are ER negative.
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3.9.3 Effect of neoadjuvant letrozole on PgR expression
Treatment with letrozole caused a marked reduction in expression of PgR in 45 of the 55
receptor positive tumours (81%). In 38 cases (61%) this was a total loss of PgR
expression and in 29 cases (47%) this occurred after only 14 days. This reduction in
























12 0 1 2
Clinical
response
30 6 7 5
No clinical
response
8 1 3 2
Table 19: The relationship between change in PgR and clinical and pathological
response
There is no evidence of a statistically significant difference in the response rates in the
clinical responders vs non responders (p=0.85) or between the pathological responders
vs non-responders (p=0.19). There was no evidence of a trend in either group.
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PgR PgR No change
expression expression PgR
lost decreased
Figure 26: Change in PgR expression in relation to pathological response
Therefore it can be seen that the clinical utility of PgR as a predictor of response was
limited. Some PgR positive tumours failed to respond to treatment while other tumours
which were initially PgR negative responded to therapy. Responses were observed with
all levels of initial PgR expression. Raw data for all PgR scores in all biopsies can be
seen later (Appendix 18).





















Figure 27: Changes in PgR expression in relation to clinical response
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3.10 Effect on treatment on tumour proliferation
The raw data from the Ki67 assessment can be seen later (Appendices 19 and 20). A
summary of the change in Ki67 expression in the biological subgroup of 62 patients with
triple biopsies over the treatment period is shown in Figure 26. Measurement 1 was at
baseline, 2 after 10-14 days and 3 after three months.
Ki-67 Expression (62 cases)
1 2 3
Figure 26: Summary of changes in tumour proliferation over three month treatment
period with letrozole. 1= at baseline, 2= after 10-14 days, 3= after three months.
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The data can be further broken down into the following subgroups;
• 22 patients in whom proliferation decreased at 10-14 days and then decreased
further at three months (Figure 27).
• 26 patients in whom proliferation decreased at 10-14 days and remained
down at three months (Figure 28).
• 11 patients in whom proliferation decreased at 10-14 days and then rose
again at three months (Figure 29).
• Three patients in whom proliferation increased at 10-14 days and then
decreased at three months (Figure 30).
Figure 27: Patients in whom proliferation decreased at 10-14 days and then decreased
further at three months. 1= at baseline, 2= after 10-14 days, 3= after three months.
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Figure 28: Patients in whom proliferation decreased at 10-14 days and then remained
down at three months. 1= at baseline, 2= after 10-14 days, 3= after three months.
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Figure 29: Patients in whom proliferation decreased at 10-14 days and then increased at
3 months. 1= at baseline, 2= after 10-14 days, 3= after three months.
Figure 30: Patients in whom proliferation increased at 10-14 days and then decreased at
three months. 1= at baseline, 2= after 10-14 days, 3= after three months.
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Treatment with letrozole was associated with a marked decrease in expression of Ki67.
59 of the 62 patients showed a clear decrease in Ki67 staining after 10-14 days of
therapy. This decrease was maintained or became greater in 48 cases; in the remaining
cases proliferation increased again (in some cases to levels equal to or higher than their
original proliferation). In the three cases that did not show a decrease at 10-14 days,
although the levels did subsequently drop by three months they still remained similar to
their initial pre-treatment values.
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3.10.1 Correlating changes in proliferation with clinical
response
Pre-treatment scores for Ki67 were similar in responders(R) and non-responders (NR).
The mean initial proliferation in the responders was 14.04% (SEM 1.08). In the non-
responders the mean initial proliferation was 15.79% (SEM 2.14).
156
3.10.2 Changes in proliferation at 14 days
Treatment was associated with highly significant decreases in all tumour sub-groups
(p< 0.005 by paired Wilcoxon rank test) at 14 days (Table 20).
Levels in Ki67 14 days into treatment were not significantly different in clinical
responders and non-responders (p=0.34), but scores were significantly higher in tumours
which subsequently did not change morphologically compared with those showing a






Clinical responders (n=49) 14.04 (1.08) 5.04 (0.96) P< 0.0001
Clinical non-responders (n=14) 15.79 (2.14) 7.08 (2.15) P< 0.0001
P=0.46 P=0.34
Pathological responders (n=47) 14.03 (1.09) 4.35 (0.89) P = 0.0002
Pathological non-responders (n=15) 15.97 (2.22) 9.35 (2.22) P< 0.0001
P=0.40 P=0.02
Table 20: change in proliferation compared to clinica and pathological response
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3.10.3 Correlating changes in Ki67 at three months with
clinical response
In the clinical responders group, 46 of the 49 patients showed a reduction in Ki67 from
baseline at 3 months. Their mean drop in proliferation was 81.4% (SD 25.1). The three
patients that showed an increase had a mean increase of 19% in proliferation (SD 10.3).
Looking at the results for the whole group, there was a 75.23% decrease in proliferation
(SD 34.5).
In the group of clinical non-responders, 12 out of 13 tumours showed a reduction in
proliferation after three months of treatment. Their mean reduction in proliferation was
75.5% (SD 28.0). In one tumour the rate of proliferation increased by 43.1%. Taking the
results for the whole group, the mean reduction in proliferation was 66.4% (SD 42.4).
There was no significant difference in proliferation between the two groups (p=0.43,
Student's two tailed T test).
The log transform loge(ki67+0.1) was used to Normalise the data prior to analysis
(Table 21).
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3 months Fall from pre-treatment
Clinical responders 0.21 (0.25) 2.27 (0.22)
Clinical non-responders 0.85 (0.46) 1.78 (0.40)
Significant difference? P=0.22 P=0.28
Pathological responders 0.03 (0.24) 2.46 (0.21)
Pathological non-responders 1.40 (0.43) 1.22 (0.37)
Significant difference? P=0.0068 P=0.0047
Table 21: Change in proliferation at 3 months
There is a statistically significant difference between pathological responders and non-
responders in terms of the transformed ki67 value. This is evidenced in both the final 3
month value and in the difference between the pre-treatment value and the 3 month
value. However, no significant difference was seen between clinical responders and non-
responders.
159
3.10.3 Correlating changes in Ki67 at three months with
cause specific survival
There was no significant difference in cause specific survival in relation to baseline Ki67
(p=0.6).
3.10.3.1 Proportional hazards analysis
To identify variables that may be associated with cause specific survival, the possible
prognostic variables looked at were: year of treatment, age, size of tumour, grade, ER
status, US response, baseline Ki67, % reduction in Ki67, operation and number of +ve
nodes. Only 70 patients have data on all these variables. % reduction in Ki67 was the
only one to show significance (p=0.01).
Removing operation and number of +ve nodes (as not all patients went on to surgery)
allowed 84 patients to be included in the analysis. Again, only the reduction in Ki67
showed a significant correlation with cause specific survival (p=0.007).
If the percentage reduction in Ki67 was divided into two groups (<40% drop over three
months and >40% drop) there was a significant difference in cause specific survival on
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Figure 31: Cause specific survival in relation to drop in Ki67 (%) with treatment. Green
line represents patients with >40% decrease in proliferation (83 patients) and black line
represents patients with <40% decrease in proliferation (14 patients)
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3.11 Optimum duration of treatment with letrozole
In this study, 42 patients were either deemed unfit for surgery, refused surgery, had
responded but still required mastectomy or were still inoperable after three months
treatment. They therefore continued letrozole for at least a further three months. 22 of
the 42 were still taking letrozole at 12 months. It is useful to look at this group
separately to assess whether these unselected tumours continue to respond to
neoadjuvant letrozole for periods longer than three to four months. The following
reductions in clinical tumour volume were calculated:-
% reduction in first three months, (volume at three months/volume at diagnosis x 100%)
% reduction between three to six months (volume at six months/volume at three months
x 100%)
% reduction between 6-12 months (volume at 12 months/volume at six months x 100%).
Median % reduction in the tumour volumes from 0-3 months, from 3-6 months and
from 6-12 months are shown in table 22.
Number of Patients Median % reduction 95% CI
% reduction from 0-3 months 42 52
37-62
% reduction from 3-6 months 42 57
26-100
% reduction from 6-12 months 22 66
22-100
Table 22: Median percentage reduction in tumour volumes over treatment period
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Tumours continued to reduce in volume during the 12 months study period. At three
months there were 4/42 (9.5%) complete responses, by six months there were 12/42
(29%) and by 12 months 8/22 (36%). Only one patient who was responding at three
months had disease progression at 12 months.
Neoadjuvant letrozole therefore produces ongoing tumour shrinkage in postmenopausal
women over 12 months in these large operable or locally advanced ER + breast cancers.
Patients whose tumours are responding to letrozole at three months can expect further
reduction in tumour volume with continued treatment.
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3.12 The effect of treatment on HER 2 (erbB2) status
The HER2 status of all tumours was checked on all three consecutive biopsies. There
was no change in the expression of HER2 during treatment with letrozole. Those
tumours which were positive on initial diagnostic biopsy were positive on all subsequent
biopsies. Those that were negative remained negative after treatment with letrozole. All
diagnostic biopsies had FISH performed by Yu Tao and Matt Ellis in Duke University to
confirm the immunohistochemical findings.
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3.12.1 Clinical response in HER 2 positive cancers
There were 12 cases (19%) in the biological subgroup of 62 patients which over-
expressed HER 2 (Table 23). This is a slightly higher percentage than might be
expected for an ER rich group (-10%) but the tumours were all locally advanced at
presentation so perhaps more aggressive which might account for the higher than
expected rate of over-expression of HER 2. The average age of the HER 2 +ve group
was 73 compared with an average age of 76 for the whole group.
Audit number Patient age Path Resp Clin Resp Survival
20 55 PR PR Died
35 78 PR PR
51 55 PR PR
52 79 PR NC/MR Died
57 76 PR NC
84 82 MR NC
94 80 PR PR
95 67 NC NC
109 79 MR NC
120 65 PR PR
125 86 PR NC/MR
136 77 MR PR
Table 23: Patients over-expressing HER2
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The response rate is shown in Table 24. The response rate was lower in the group that
over-expressed HER2 than the negative group but this was not significant. Therefore in
this series HER2 status does not aid prediction of clinical response to letrozole.








Positive 8 (67%) 4 (33%) 6 (50%) 6 (50%)
Negative 42 (82%) 9(18%) 41 (82%) 9(18%)
Table 24: HER 2 expression in relation to clinica and pathological response
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Section 4: Discussion
The aims of this thesis were,
• to further characterise the clinical response to primary systemic endocrine
therapy in breast cancer in the setting of a clinical trial
• to determine whether it is possible to identify biological markers of tumour
phenotype that can be used to predict subsequent clinical response to
neoadjuvant treatment with 2.5mg letrozole for three months;
• to determine the effects of treatment on biological markers after 10-14 days and
after three months and investigate whether these changes correlated with clinical
responses seen over that period; and
• to identify potential markers of resistance to endocrine therapy.
The discussion will first review the current status of neoadjuvant endocrine therapy and
the role of letrozole in this setting. It will compare and contrast the findings of this study
with other similar work in this field. It will discuss various methods of assessing clinical
response and whether biological markers and short term clinical response might predict
for longer term disease recurrence and disease free survival. Biological responses to
neoadjuvant endocrine therapy after 10-14 days and three months treatment will be
described as will the optimal time of drug treatment prior to surgery. The conclusions
will summarise the study findings and suggest potential areas for future work.
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4.1 Neoadjuvant endocrine therapy
Neoadjuvant therapy to treat breast cancer has to date predominantly consisted of
chemotherapy. Neoadjuvant treatment with tamoxifen has been used in the past but it
has been shown to have poorer outcomes in terms of disease recurrence and survival
than when used in combination with surgery 34. Neoadjuvant chemotherapy is often
poorly tolerated in elderly patients where the morbidity of treatment and their co¬
morbidity are significant factors. This age group currently comprises a third of all breast
cancer so it is important to find well tolerated effective treatment for them.
Clinical response rates can be compared with neoadjuvant chemotherapy regimes, which
generally have a response rate of around 80% regardless of the regime used 140. A
Russian group have presented a study suggesting that there were similar clinical
outcomes following neoadjuvant endocrine therapy or chemotherapy ll5. In their study,
121 postmenopausal women with ER +/- PgR positive breast cancer were randomized to
receive neoadjuvant chemotherapy (four cycles every three weeks of doxorubicin and
paclitaxel) or neoadjuvant endocrine therapy with either anastrozole or exemestane for
three months prior to surgery. All baseline characteristics were similar in the groups
apart from a slightly higher number of elderly patients (aged over 70) in the endocrine
treated group (32% compared with 20%). Both clinical and mammographic response
rates were similar for both groups with a trend towards increasing breast conservation
surgery in the endocrine treated group. There was no significant difference in local
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recurrence rates after a mean follow up period of 34 months. However, more toxicity
was reported in the chemotherapy group with significant numbers of women reporting
alopecia (79%), neutropenia (43%), neuropathy (30%) and cardiotoxicity (7%). Side
effects that were reported with endocrine therapy included hot flushes (23%), fatigue
(15%), vaginal bleeding (7%) and arthralgia (7%). Despite the small numbers, these
results were encouraging in suggesting that neoadjuvant endocrine therapy has a similar
response rate to chemotherapy with less associated toxicity. This may be particularly
important in elderly patients who are less likely to tolerate chemotherapy.
In the current study, neoadjuvant treatment with letrozole has been shown to be effective
in the population group studied with 67% of patients responding positively to treatment.
This was an elderly group with a mean age of 76 yet treatment was well tolerated with
only two patients stopping treatment because of side effects. 32 patients (63%) were
able to have their surgery down-staged from mastectomy to breast conserving surgery,
another factor in this population since mastectomy has a 1% associated mortality in this
age group.
Response rates to treatment appear better than those seen previously with neoadjuvant
tamoxifen. The response rate of 67% in this study is similar to the response rate of 60%
seen in the P024 study 41 with neoadjuvant letrozole compared to a 41% response rate
for tamoxifen in that study and in earlier studies 38. This study selected patients whose
tumours were ER rich which may partially explain the higher response rate.
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Differences in response to letrozole compared with tamoxifen may be related to
increased efficacy. Letrozole causes oestrogen levels to be suppressed almost
immediately whereas tamoxifen takes weeks to reach steady-state levels. 141
Letrozole also appears to have fewer side effects than tamoxifen and is better tolerated
142. It does not have the increased rate of endometrial cancer or thrombo-embolic events
that are associated with tamoxifen 142. However, there are concerns about the potential
long term effects of the profound drop in oestrogen caused by aromatase inhibitors and
their effect on bone, lipid and coagulation markers. Studies are ongoing to further
investigate these potential side effects and morbidities.
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4.2 Assessing clinical response to primary endocrine therapy
Neoadjuvant therapy allows direct assessment of tumour sensitivity to endocrine therapy
by monitoring tumour response in situ. There are several methods of assessing response
including clinical examination by measuring with callipers, mammographic
measurements and serial ultrasound scans. Ultrasound scanning has been previously
shown to correlate most closely with pathological size in the excision specimen 135.
However, ultrasound scanning is operator dependent so it was important to check its
accuracy. In this study, ultrasound scanning was the modality that corresponded most
closely with pathological size.
In the majority of cases, there was satisfactory correlation between all modalities used to
measure a tumour. However, some patients' tumours presented a challenge. Multifocal
tumours were difficult to assess, especially once they had shrunk considerably. Invasive
lobular carcinomas were difficult to measure accurately either clinically or using
imaging. In some patients, it was impossible to assess the tumour using all three
modalities at all time points. For example, in very large ulcerating tumours an accurate
ultrasound measurement was not possible. Additionally, some patients were not able to
tolerate mammography.
Accurate assessment of response was particularly important when comparing clinical
response with corresponding biological responses. For this reason, patients were
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excluded from the final series where it proved difficult to assess clinical response
accurately.
It was also important to assess tumour response using pathological determinants in
addition to the more traditional clinical tumour measurements. This is because some
tumours may have responded, not by getting smaller but by reducing cellularity and
becoming fibrotic.
There was correlation between clinical and pathological response in the majority (84%)
of cases. However, pathological changes were seen after treatment in some tumours that
did not have a significant shrinkage in ultrasound volume (four cases) and conversely,
there were a small number of tumours (six cases) which did show a major shrinkage in
ultrasound volume but did not have any evidence of pathological changes. This could be
explained if tumours shrank without altering their microscopic structure. A similar
effect has been described in patients being treated with neoadjuvant chemotherapy.
When looking at endpoints such as proliferation, it was important to look at both clinical
and pathological responses separately since, in some cases, there was a significant
correlation with one but not the other. For example, tumours in which there was a
pathological response had a significant drop in proliferation compared to pathological
non-responders but this was not the case when looking at clinical response categories.
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4.3 Clinical response to neoadjuvant letrozole
There have been few published studies examining the use of letrozole as neoadjuvant
therapy in breast cancer. Small pilot studies in Edinburgh showed letrozole to be
effective and well tolerated in this setting. The patients selected were postmenopausal
and had large operable or locally advanced ER positive breast cancer. In one of the
earliest studies, 24 postmenopausal patients were treated with 3 months of letrozole prior
to surgery. A clinical response rate of 92% was seen and 15 of the patients who required
mastectomy preoperatively were able to have breast conserving surgery after
neoadjuvant treatment 101. The P024 study 41 is the only other large neoadjuvant trial
using letrozole which has reported its findings. The study design and findings are
discussed in detail on pages 54 and 55.
67% of tumours in this current study responded to treatment with neoadjuvant letrozole
when assessed by ultrasound compared to a 35% clinical response when assessed by
ultrasound in the P024 study (see table 4). It is important, however, when comparing
results of different studies to look at the differences between the methods used in clinical
assessment.
In the P024 study, the clinical response rate varied from 55% when using calliper
measurement to 34% when using mammography and 35% when using ultrasound.
Calliper measurements have been shown to be operator dependent and not to correlate as
173
accurately with final pathological size as ultrasound measurements 135. In the P024
study, the calliper measurements were performed by many different individuals in
different centres and are therefore even less likely to be accurate and reproducible. There
was no mention of comparison with final pathological tumour size or why calliper
assessment was chosen as the primary endpoint. Additionally, the US measurements in
the P024 study were also performed in several institutions by many different clinicians.
In the study described in this thesis, all measurements were performed in one centre by
one of two trained clinicians using a single machine and probe.
It remains to be seen whether the degree of short term response predicts for overall
disease free survival in this study group as the follow up period is currently still
relatively short (mean follow up period of 39 months). Indeed, early promising results
from treatment with neoadjuvant tamoxifen have produced disappointing long term
results. The most recent update on a large study comparing tamoxifen treatment alone
with surgery plus tamoxifen, shows that although most tumours initially respond, local
disease control is poor when treated with endocrine therapy alone and survival from
breast cancer is poorer in the tamoxifen alone group 40.
For that reason, the majority of patients in this study had surgery after three months.
Many patients would have been quite happy to continue on letrozole when their tumour
was responding and thus avoid surgery. However, it was felt that, for those patients who
were fit enough to undergo an operation after three months treatment, this would be the
optimal treatment. Only patients who refused surgery, were not fit enough for surgery
174
or still had inoperable cancers continued on letrozole for longer than the three month
study period.
From the tamoxifen trials, it would appear that most patients will derive benefit from
having surgery and that the majority will eventually acquire resistance and require
surgery at some stage. However, the fact that patients can be treated successfully with
neoadjuvant letrozole for longer periods may relate to the improved efficacy in
comparison with tamoxifen. This means that some patients may be treated for long
periods with letrozole with no adverse effect on their local disease control and survival.
Additionally, more patients may be able to have their surgery downstaged from
mastectomy to breast conserving surgery which is important in an elderly population
with significant co-morbidity. In this study, 58% of patients treated with letrozole went
on to have breast conserving surgery performed (74% of those undergoing any type of
surgery). This compares with 48% of patients receiving letrozole in the P024 study who
underwent BCS and 36% of those treated with tamoxifen. BCS has a lower attached
morbidity and mortality and if necessary can be performed under local anaesthetic.
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4.4 Biological response to neoadjuvant endocrine therapy
Several studies have linked the rate of tumour proliferation to the response seen with
neoadjuvant therapy 143"145. Tumours with high rates of proliferation tend to have a good
response to neoadjuvant chemotherapy 146. They have also been shown to respond to
neoadjuvant endocrine therapy. It has also been shown that successful neoadjuvant
treatment is accompanied by a decrease in tumour proliferation 147. To date, it has not
been demonstrated whether early changes in proliferation predict for subsequent clinical
response.
Tumour cell proliferation was assessed in this study to allow the use of proliferation as
both a predictor and reflector of tumour response to be analysed. Ki67 has been shown
to be an accurate and reproducible way of assessing proliferation in breast cancers. It
can be assessed using immunohistochemistry on paraffin embedded slides. This study
has demonstrated that tumours which respond to neoadjuvant endocrine therapy have a
wide range of initial proliferation values. The proliferation has been shown to drop
significantly as early into treatment as 10-14 days after treatment with letrozole.
Looking at the results in terms of a group of responders and non-responders,
proliferation drops more in the tumours which show a clinical response. However, this




All tumours in this study were ER rich with an Allred score greater than 6. Even within
this select group of ER rich tumours, response to endocrine therapy was shown to vary
with level of ER expression. Response rates were similar in ER categories 8 and 6 +7
but there was a significantly greater percentage reduction in tumour volume in patients
whose tumours had the higher ER expression (p< 0.05).
When looking at clinical response in patients with lower ER scores (patients with ER 3-
5) in the P024 study 41 there was response to letrozole but not to tamoxifen. Elowever,
the numbers were very small so the authors acknowledged that this would require
confirmation. Both agents showed a decreasing likelihood of response with decreasing
ER score. For both drugs, the relationship between ER expression and log odds of
response fitted a linear model that was significant by logistic regression within treatment
groups (letrozole P=0.0013 and tamoxifen p=0.0061). Letrozole response rates were
numerically superior to tamoxifen in every Allred category from 3 to 8 but this was not
statistically significant.
This finding suggests that only patients whose tumours expressed a very high level of
ER (Allred score 6 or above) are likely to derive benefit from neoadjuvant treatment
with endocrine drugs. This is in keeping with the results of the study reported here
where a higher response rate was seen in tumours with higher ER expression. Further
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work needs to be performed to ascertain the role of neoadjuvant aromatase inhibitors in
tumours that express lower levels of ER.
It is very important in the elderly population, who are most likely to be treated with
neoadjuvant endocrine therapy, that there is a high likelihood of response to treatment.
A delay in surgery should be avoided in this population. Therefore, baseline ER
expression can be used to accurately target the group most likely to derive benefit from
this treatment.
The lack of a consistent effect on ER expression seen in this study is similar to that
reported in other studies using the aromatase inhibitors148. It is also the same as was
reported in the P024 study. Elowever, it is different from the response that has been seen
with tamoxifen which tends to reduce ER expression l49.
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4.6 Progesterone receptor
PgR is regulated by oestrogen and is also a marker for ER mediated transcription.
The progesterone receptor can be regarded as a marker of oestrogenic activity as the
protein is expressed as a result of oestrogen signaling which is mediated by a functional
oestrogen receptor. For this reason, it has been suggested that PgR may be useful as a
predictive parameter for response to endocrine treatment.
Change in PgR expression can also be used as evidence of the anti-oestrogenic
mechanism by which aromatase inhibitors work. In this study, 47 of 57 PgR positive
tumours showed a reduction in staining after treatment, many after as little as 14 days.
In two thirds of cases PgR became undetectable after three months of therapy. In
contrast, the most consistent effect on PgR seen with neoadjuvant tamoxifen treatment,
was an increase in the PgR expression [See table 25]. 150
Treatment Decrease in PgR No change in PgR Increase in PgR
Letrozole 44 (73%) 16(27%) 0
Tamoxifen (ref) 12(23%) 13 (25%) 27 (52%)
Table 25: Comparison of the effects of Letrozole and Tamoxifen on PgR expression
(tamoxifen data from previous Edinburgh series 15°. Percentages refer to % of patients
showing change in PgR.
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Makris et al reported that 41% of patients in their series showed an increase in PgR
expression after 14 days neoadjuvant treatment with tamoxifen l25. Another 17% showed
no change in PgR expression with treatment. Therefore, tamoxifen and letrozole have
significantly different effects on PgR expression.
After three months treatment with letrozole, 82% of cases in this series showed a marked
decrease in PgR expression. In two thirds of cases, this was a decrease to zero.
Decreases in staining were seen even in the absence of pathological response. This is in
contrast to changes seen after treatment with neoadjuvant tamoxifen where the most
common change was an increase in PgR expression.
Despite significant decreases in expression of PgR being observed as early as 14 days
into treatment with letrozole, it was not possible to detect any consistent pattern in PgR
changes between clinical or pathological responding and non-responding tumours. The
decrease in PgR was seen in tumours which responded to treatment and tumours which
did not. Therefore, lack of clinical or pathological response is not because the tumour
fails to recognize letrozole as an oestrogen depriving therapy.
The initial PgR status was not predictive of the clinical or pathological response to
treatment. Some tumours that were PgR negative exhibited clear evidence of response.
The effect of letrozole on PgR is clear evidence of a different mode of action from
tamoxifen which has variable effects on PgR expression including increased expression.
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Looking at PgR expression in the P024 study, the authors also noted that letrozole
induced profound down regulation of PgR. In contrast, tamoxifen demonstrated a mixed
agonist/ antagonist effect on PgR. This confirmed the profound differences in the
molecular effects of the two drugs. The degree of PgR suppression was greater for
tumours in which a mammographic response was documented. The authors speculated
that PgR expression in post-treatment samples could be a useful biomarker for the
effectiveness of oestrogen deprivation therapy 129. However, this was not confirmed in
this study.
In the P024 study, peak response rates were seen to occur in tumours that scored PgR
Allred 4 or 5 with both tamoxifen and letrozole. Both high and low levels of PgR
expression were associated with a lower chance of response compared with intermediate
scores 141. Unlike ER, the relationship between PgR Allred score and response did not fit
a linear model. The model that best fitted the data was an inverse V-shaped model with
the peak response to letrozole seen at PgR score 5 and to tamoxifen seen at PgR 4.
This relationship was more complex than expected from prior information about the
predictive properties of PgR in breast cancer 151. The authors acknowledged that it had
been assumed that the relationship between PgR expression and response would be
linear as with ER since PgR is generally accepted as a marker for oestrogen dependent
cancers with a functional ER because PgR requires activated ER for expression. This
conventional model explains the initial increase in response rates seen from PgR Allred
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score 0 to 5. However, it does not explain the subsequent decline in response seen from
PgR score 6 to 8. The authors speculated that PgR rich tumours may be associated with
sufficiently high levels of aromatase activity or hypersensitivity to oestrogen that they
might blunt the efficacy of oestrogen deprivation therapy. Another theory is that it is
possible that PgR rich tumours carry a mutation in the ER which cause cancer cells to
become hypersensitive to oestrogen 14!. It is also important to remember that just
because a tumour is oestrogen sensitive it doesn't mean that it will definitely respond to
treatment. In almost all cases, the genes that change most will not consistently predict
response because at most only 70-80% of tumours will respond to treatment. The
ATAC study reported a better response for anastrozole compared with tamoxifen,
particularly in patients who were ER positive and PgR negative94. However, in contrast,
BIG 1-98 showed the best outcome to be in those patients who were both ER and PgR
positive93. Therefore there is confusion about the effect of AIs on the different tumour
phenotypes in the available literature in the adjuvant setting.
The Oxford overview analysis did not show PgR to be a useful predictor for the adjuvant
benefit of tamoxifen. 75. It may be that tamoxifen and letrozole have different
relationships to PgR expression because they have a different mode of action. This
means that the value of PgR as a predictive biomarker is uncertain and more work needs
to be undertaken in order to fully understand the mechanism and implications of the
effect seen on PgR. The difference in tumour phenotype after treatment may have
clinical relevance in terms of resistance to treatment and in making decisions about
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further treatment choices. Aromatase inhibitors have been shown to have therapeutic
• 1S?
benefit in patients whose tumours have acquired resistance to tamoxifen
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4.7 Effects on proliferation
Pre-treatment scores for Ki67 were similar in responders and non-responders so baseline
level of proliferation did not appear to predict response. It has been suggested that
tumours which have higher proliferation are more likely to respond to neoadjuvant
chemotherapy 146 but this does not seem to be the case for neoadjuvant endocrine
therapy.
Treatment with letrozole for as short a period as 14 days was associated with highly
significant decreases in proliferation in all tumour sub groups in this study. However,
there was no significant difference between clinical responders and non-responders.
Interestingly, there was a significant difference between pathological responders and
non-responders implying that morphological features of response might be more
accurate than clinical ones at identifying responders to neoadjuvant endocrine therapy.
After three months of treatment with letrozole, there was no significant difference
between clinical responders and non-responders. The mean reduction in proliferation for
clinical responders was 75% and 66% for non-responders.
The consistent decreases in proliferation with letrozole and also described for the other
aromatase inhibitors, was not the pattern consistently seen with tamoxifen 145>153.
Tamoxifen treatment was also associated with an increase in proliferation markers,
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particularly in non responding tumours 148. These changes may reflect differences in the
mechanism of action between tamoxifen and the aromatase inhibitors.
In this study, 12 out of 13 clinical non-responders showed a reduction in proliferation
and only one tumour showed an increase in proliferation of 43% after treatment.
Interestingly, although the majority of clinical responders showed a drop in proliferation
with treatment, there were also three patients in that group whose tumours increased in
proliferation over the treatment period (mean increase 19%). Therefore, change in
proliferation does not appear able to discriminate between tumours likely to respond and
those not likely to.
In the P024 study 41, the fall in Ki67 was significantly greater in responders than non-
responders (p=0.025 by Mann-Whitney test) confirming the effect of response on
tumour proliferation. However, the response modality used in P024 to categorise
responders and non-responders was the change in caliper tumour size which is different
to the US response used in this study. Table 26 shows the effect of letrozole and
tamoxifen on Ki67 in P024.
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No % decrease in the
geometrical mean Ki67
Wilcoxon signed rank test
P
All cases Letrozole 93 87 <0.0001
Tamoxifen 92 75 <0.0001
Table 26: effect of letrozole and tamoxifen on Ki67 41
For all cases, letrozole had a significantly greater effect on proliferation than tamoxifen
(p=0.0009). In another study looking at proliferation in patients treated with neoadjuvant
tamoxifen, Makris et al showed that 79% of tamoxifen treated tumours showed a
decrease in Ki67 after 14 days treatment 125. Interestingly, 100% of responders showed a
decrease in proliferation, while a third of non-responders showed an increase in
proliferation after treatment with tamoxifen.
The effects of letrozole on Ki67 expression were striking implying that one important
effect of letrozole is to remove tumour cells from the cycle of division. However,
whether or not this translates to a clinical or pathological response is more complex and
involves other factors. Proliferation is likely to be oestrogen dependent. Therefore, any
agent which reduces oestrogen should consequently reduce proliferation. However,
clinical response is clearly more complex than simply switching off proliferation. In
terms of correlating changes in proliferation with clinical response, any factor which
decreases in such a large percentage of patients is unlikely to be helpful in predicting
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response. The practical implication is that, on an individual basis, measurement of Ki67
is not helpful in predicting or monitoring response.
This study did not look at the effects of letrozole on cell death for several reasons.
Firstly, the estimation of cell apoptosis is laborious and notoriously difficult to estimate
accurately. Secondly, studies which have attempted to compare apoptosis rates between
Als and tamoxifen, for example the IMPACT study, have not found any significant
difference113.
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4.8 HER 2 (erbB2)
It has been suggested that the over expression of HER 1 or HER2 may be associated with
an increase in the likelihood of response to letrozole compared to tamoxifen. In the
P024 study, letrozole's ability to suppress the proliferation of ER+ breast cancer cells
was not affected by HER 1 or HER 2 over-expression 41. In contrast, HER 1 or HER 2
positive tumours exhibited evidence of resistance to the anti-proliferative effects of
tamoxifen (see table 27).
Number of
patients






Her1/2} Letrozole 78 86 <0.0001
negative} Tamoxifen 75 79 <0.0001
Her 1/2 } Letrozole 15 88 0.0166
positive} Tamoxifen 17 45 NS
Table 27: Effect of letrozole and tamoxifen on Ki67 according to HER 1/2 status 14y
There was an 88% response rate in the HER1 or 2 positive group treated with letrozole
compared with 21% when treated with tamoxifen. It may be that these patients are
resistant to tamoxifen but respond to aromatase inhibitors. This may explain why the
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aromatase inhibitors appear to have improved efficacy in direct comparison with
tamoxifen.
In this current series, positive membrane staining for HER2 over-expression was
detected in 12/63 (19%) of tumours which is slightly higher than the approximately 10%
that might be expected in a group of ER rich tumours. Neoadjuvant letrozole in this
series of ER + breast cancers was equally effective in both HER2 positive and negative
tumours. It reduced tumour volume at three months by at least 60% in both groups.
Looking at the whole series of letrozole treated patients, at 3 months by WHO criteria
106/154 (69%) Her 2 negative and 11/18 (61%) Her 2 positive tumours had a clinical
response (p=0.506, Fisher's exact test). In addition there was no significant difference in
the reduction in proliferation between groups. The efficacy of letrozole does not
therefore appear to be influenced by Her 2 status.
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4.9 Optimum duration of neoadjuvant endocrine therapy
Randomised studies of neoadjuvant aromatase inhibitors to date have treated patients for
either three or four months. By that time many patients' tumours have responded
sufficiently to downstage surgery from mastectomy to breast conserving surgery, but
some remain inoperable or still require mastectomy. Few studies have to date examined
this issue in detail.
In a series of 100 elderly patients treated with tamoxifen, Dixon et al suggested that
three months was long enough to distinguish between responders and non responders
and to achieve optimal tumour shrinkage preoperatively 118. Maximal response may,
however, take considerably longer than three months so the optimal period of treatment
depends on initial tumour size and the aim of the neoadjuvant therapy. If the aim is to
downstage the tumour to allow breast conserving surgery to be performed, this can be
achieved in the majority of patients in three to four months. There has been concern
that, when treating patients for longer than three months, tumours which initially
responded may acquire resistance and begin to progress.
This study looked in more detail at extending the use of neoadjuvant letrozole for longer
periods of time. 30% of patients in the study continued on letrozole for more than three
months. This was done for a variety of reasons. For example, they were deemed unfit
for surgery, refused surgery, had responded but still required mastectomy or were still
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inoperable after three months of treatment. One patient who was responding at three
months had disease progression at 12 months but the rest continued to respond to
letrozole over the treatment period. For up to a year, letrozole continued to be effective
at reducing the size of the tumour and few tumours stopped responding to treatment in
this timescale. Therefore, patients whose tumours are responding to letrozole at three
months can expect further reduction in tumour volume with continued treatment. Fewer
patients appeared to acquire resistance to letrozole over a 12 month period than did with
tamoxifen.
These findings suggest that neoadjuvant letrozole can be used safely for up to 12 months
to achieve optimal tumour shrinkage. It has to be borne in mind that similar responses
were seen with tamoxifen with a mean period of response of 24 months and that only a
small percentage of patients were long term responders not requiring surgery by 10
years. It is likely to remain difficult to identify which patients are going to be the long
term responders.
There is therefore no identified optimum duration for use of neoadjuvant letrozole
although it appears it can be used safely in women with responsive cancers for up to 12
months.
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4.10 Completeness of tumour excision and incidence of local
recurrence
Reducing the size of large or inoperable tumours in patients with early stage breast
cancer has been shown to increase the success of breast-conserving surgery (BCS)
ioi,154 p[owever? several series have described relatively high rates of positive margins
after neoadjuvant treatment with chemotherapy. In the Royal Marsden series, 28% of
patients who had breast conserving surgery had positive margins 30. In another series of
patients with locally advanced breast cancer treated with neoadjuvant chemotherapy,
62.5% of patients had multiple foci of tumour remaining after wide local excision l3S.
This may partly be due to the nature of response of the tumour to the chemotherapy. In
the Milan series, 16% of the 227 cases had evidence of tumour multifocality within the
wide local excision specimen 156.
In this study, when assessing the residual wide local excision samples histologically, the
nature of response to neoadjuvant letrozole appeared different from the response
previously described after chemotherapy. The whole tumour appeared to have shrunk
concentrically which is similar to the response to aromatase inhibitors previously
described ,18. However, there was a 13% positive margin rate that required further
surgery to be performed. Several of these cases were invasive lobular carcinomas which
were found to be extremely difficult to assess in terms of clinical response to treatment.
Since approximately half of invasive lobular carcinomas have involved margins after
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wide local excision (WLE) it was felt that these tumours were unsuitable for this type of
neoadjuvant endocrine therapy. Since they almost always require mastectomy for
adequate surgical treatment they were latterly excluded from the study.
After preoperative chemotherapy, local recurrence rates following WLE have been
reported to vary between 3.5% and 6% (after median three year follow up) 156;157.
However, in one study there was a 22% recurrence rate in the patients who had a
mastectomy after preoperative chemotherapy because their tumour had not responded
enough to allow BCS l55.
There is little available data on recurrence after BCS following neoadjuvant endocrine
therapy. Some data from patients previously treated in Edinburgh with tamoxifen and
Aromatase inhibitors are presented in table 28.
Agent No. of No. with No. with No. with No. with Median
patients No XRT Local recurr XRT local recurr F/up (mths)
Tamoxifen 47 13 4 34 0 84
Letrozole 34 10 4 24 1 70
Anastrozole 21 0 0 21 1 51
Exemestane 10 4 1 6 0 42
Total 112 27 9 85 2 62
Table 28: Local recurrence in patients treated with neoadjuvant endocrine therapy in
relation to whether or not they had post operative radiotherapy (XRT)
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As can be seen from table 28, the rate of local recurrence is much higher in those
patients who did not receive radiotherapy after their breast conserving surgery. There
was a 33% local recurrence rate in the patients who did not receive XRT vs a 2.4% local
recurrence rate in those that did 118. For comparison, local recurrence rates for patients
treated in the standard fashion by surgery followed by systemic therapy have been
reported to be 2.7% in one series 157.
With a mean follow up period of 39 months (4-58), the majority of local recurrences in
this study should have occurred. However, there have been only seven local recurrences
to date (5% of patients), several in patients with very aggressive advanced disease.
Three of the patients who developed local recurrence have been treated and remain alive
and well. Of the four who died, three had evidence of distant metastasis in addition to




With a mean follow up period of 39 months (4-58), it is still a relatively short period of
time to look at disease free (DFS) and overall survival. In this series, 42 patients died
(33% of the group). 23 of these deaths were from breast cancer and 18 from other causes
giving a disease free survival of 82% and an overall survival rate of 67%.
It is difficult to compare the DFS and the overall survival of this group with a series of
patients treated with adjuvant endocrine therapy. Despite having locally advanced breast
cancer, many of the patients treated with neoadjuvant endocrine therapy will die from
other causes as a result of their comorbidity. DFS and OS have been reported in other
studies to be similar in patients treated with neoadjuvant chemotherapy preoperatively
• • • 97 29 32and in patients treated with surgery followed by systemic therapy " ' .
Cameron et al reported a randomised trial comparing oestrogen receptor directed
primary systemic therapy with conventional therapy in operable breast cancer and
showed no difference in survival between groups treated with neoadjuvant endocrine or
chemotherapy and those having follow up systemic therapy after surgery 158.
It is of interest that a significant correlation was seen between the percentage drop in
Ki67 after three months of treatment with letrozole and disease free survival (p=0.007).
Patients who have a complete pathological response to neoadjuvant chemotherapy have
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been shown to have improved disease free survival compared to patients who do not.
However, complete pathological response to neoadjuvant endocrine therapy is rare so it
is difficult to relate response to treatment to prognosis. It may be that Ki67 has potential
to be used as a marker of response to endocrine therapy which correlates with long term
survival. However, at present it is not helpful and can not be used to predict outcome on
an individual patient basis.
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Section 5: Conclusions
This thesis has examined the response of breast cancer to neoadjuvant endocrine therapy
using several clinical methods and biological markers. In particular it has focused on
changes in tumour phenotype after two weeks and three months of neoadjuvant
treatment with the aromatase inhibitor letrozole.
Neoadjuvant endocrine therapy with letrozole was extremely successful in the selected
group of patients with ER rich tumours that took part in this study. Two thirds of
patients showed an overall response to treatment and two thirds of patients had their
surgery down-staged from mastectomy to breast conserving surgery.
The speed of response to treatment was variable. In general, it appeared somewhat
slower than with neoadjuvant chemotherapy but interestingly response to treatment with
neoadjuvant letrozole continued for 12 months or longer. Tumour response was seen
quickly using ultrasound scanning with responses being evident after as little time as
four weeks. By six weeks, it was usually possible to accurately predict whether or not
breast conserving surgery would be possible after three months of treatment.
A major issue in the use of neoadjuvant endocrine therapy is the selection of patients
who are likely to benefit most from treatment. This study has shown that patients with
ER rich tumours (Allred score 7 or 8) are the ones that are likely to respond best.
Tumours that score ER 8 were seen to achieve a greater percentage reduction in tumour
volume than those that were ER 7. It has also demonstrated that patients will still
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respond well to treatment even if they over express HER2 as long as their tumour is ER
rich.
Another aim of this study was to try to predict the degree of clinical response to
neoadjuvant treatment to allow the targeted selection of patients. Apart from ER, no
other baseline biological marker was shown to accurately predict the tumours most
likely to respond to treatment. There was a small decrease in ER expression over the
treatment period. This was probably related to fixation and therefore not clinically
relevant. Significant decreases in expression of PgR were observed at 14 days in all
patient groups but this did not correlate with clinical or pathological tumour response.
In the biological markers subgroup of 62 patients, 78% patients had a clinical response
(>50% reduction in tumour volume at three months by serial ultrasound) and 75% of
tumours displayed evidence of a pathological response (decreased cellularity / increased
fibrosis).
Proliferation has been shown to decrease during treatment with the aromatase inhibitors
letrozole and anastrozole, and occurs as early in treatment as 10-14 days. In this study,
pre-treatment scores for Ki67 were similar in responders and non-responders whether
assessed clinically or pathologically. Treatment was associated with highly significant
Ki67 decreases in all tumour sub-groups (all at least p< 0.005 by paired Wilcoxon rank
test) at 14 days. However, levels of Ki67 14 days into treatment were not significantly
different in clinical responders and non responders.
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When correlating the decrease in proliferation with pathological response, Ki67
expression at 14 days was significantly higher in tumours which subsequently failed to
show morphological evidence of response. These changes in morphology are associated
with differences in tumour behaviour and the magnitude of decrease in Ki67 after three
months has been shown to correlate with long-term outcome.
Proliferation as assessed by Ki67 has been shown to reduce significantly after a short
period of treatment but this does not directly correlate with clinical response over the
three month treatment period. However, correlation with morphological response to
treatment was demonstrated. The fresh tissue collected as part of this study is currently
being analysed by microarray and will hopefully suggest possible avenues for other
markers which may prove more helpful in predicting response to neoadjuvant endocrine
treatment on an individual patient basis.
This study has shown letrozole decreases the expression of both PgR and Ki67 in a
striking manner. This reflects the powerful anti-oestrogenic and anti-proliferative
potential of the drug. The intermediary mechanisms by which letrozole achieves a
clinical or pathological response remain unclear.
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Section 6: Future work
There are many aspects of this study which are ongoing and which will provide much
more information after a longer period of follow up. There is little information on the
local recurrence and long term survival of patients treated with neoadjuvant letrozole.
While initial results for the use of neoadjuvant tamoxifen were promising, the long term
local disease control proved poor. It will be interesting to see if this is the case with
letrozole in the small group of patients who continue on the drug, having had no other
treatment for their breast cancer.
At the time of taking serial tumour samples, in addition to paraffin embedded material,
extra core biopsies were taken and fresh frozen in liquid nitrogen to allow microarray
work to be performed. The preliminary results are available and some can be seen in the
papers and abstracts at the end of this thesis. While Ki67 has been shown to be a useful
marker of tumour proliferation, it does not help to predict on an individual basis which
tumours are likely to respond to neoadjuvant letrozole after 14 days. It would be useful
to identify markers which might be able to do this and therefore help to guide patient
selection for this treatment.
There is also no clear information on the effect of aromatase inhibitors in tumours which
express lower levels of ER (Allred score 2-6). Some data from P024 suggested that
letrozole but not tamoxifen may have a role in treating these patients. However, the
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We would like to invite you to take part in a medical audit looking at the
drug Letrozole. The audit will be conducted here at Edinburgh Breast Unit,
by the surgeons and medical oncologists. This audit has been approved by a
research ethics committee.
Introduction / Background
Approximately two thirds of all breast cancers, in women whose periods
have stopped, need the female hormone oestrogen to grow, therefore one
way of treating breast cancer is to use drugs which will deprive the cancer
of oestrogen. Letrozole works by stopping the body producing oestrogen
and deprives the breast cancer of the oestrogen it requires.
What are the options for your treatment?
Your doctor has told you that you have breast cancer and that there are
different treatments available. He / she has decided however, that the best
treatment for you would be hormonal therapy in the first instance. This will
mean you take drugs either before you have breast surgery or it may be that
you continue to take hormonal drugs without having an operation to your
breast. The majority of women who have hormone sensitive tumours over
2cm in size can be made smaller using this therapy so if you do need an
operation, then the amount of surgery which will follow the treatment is
likely to be less extensive than would have been required without this
treatment.
Purpose of the audit
Although the majority of tumours can be made smaller using hormone
therapy, we do not yet have a test which will allow us to tell within a few
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weeks of starting treatment whether it will be effective. At the present time
therefore, we give all patients three months of treatment and during this
time we carefully measure the size of the tumour monthly using clinical
measurements and ultrasound. During this study we would like to take a
sample of your breast cancer 14 days after you start Letrozole treatment.
Only a very small amount of tissue is needed and this can be removed with
a special automatic biopsy needle. The needle test is performed after the
breast and skin itself is numbed by injecting local anaesthetic.
It is then hoped you will continue taking hormonal treatment for 3 months.
At the end of 3 months you will either have another core biopsy or have an
operation.
By comparing the changes in the biopsy 10-14 days after treatment and
after 3 months of treatment with the initial sample obtained at diagnosis. It
should be possible for us to look at the changes in your tumour over the
whole of the 3 months treatment course.
Description of drug treatment
If you agree to take part in this audit, you will be given Letrozole 2.5mgs to
take once a day for 3 months in the first instance.
Participation in this audit
Participation is entirely voluntary and you are free to withdraw at
any time if you wish to do so. If you refuse participation or
withdraw from the audit, your medical care will not be affected in
any way. Your doctor may discontinue your participation in the
audit if he/she judges it to be in your best interest. Your doctor
will inform you of any significant new findings related to
Letrozole, which may relate to your participation in this audit.
When you consent, your GP will be told that you are taking part in
this audit. You should not have any additional costs as a result of taking
part in this audit because all the extra tests will be performed during
standard hospital visits.
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COMMENCE LETROZOLE 2.5mgs DAILY













CONTINUE TAKING LETROZOLE or TAMOXIFEN
AUDIT COMPLETE
Possible benefits
This treatment should reduce the size of your tumour which if you do have
an operation, should allow you to have less extensive surgery. If you do not
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proceed to surgery then the tablets will keep your breast cancer under
control. This audit will allow us to determine whether your tumour does
respond to Letrozole, and will help your doctor treat your cancer more
effectively.
Potential side effects of Letrozole
In trials in which patients were treated with Letrozole for breast cancer, side
effects were generally mild to moderate and rarely severe enough to require
stopping treatment.
The more common side effects that have been seen in patients treated with
Letrozole 2.5mgs are:
Tiredness, hot flushes or increased sweating, changes in weight, dizziness, itching and skin rash,
headache, changes in appetite, water retention, nausea and sickness, constipation or diarrhoea, stomach
upset or pain. Less common side effects are chest pain, viral infections, pain in the muscles, bones and
joints, shortness of breath and coughing.
DO NOT BE ALARMED BY THIS LIST OF SIDE EFFECTS. YOU
MAY NOT HAVE ANY OF THEM.
YOU SHOULD REPORT ANY DISCOMFORT OR PROBLEM


















Tel: 0131 537 2907
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Appendix 2: Patient information sheet and consent form for core biopsy
Edinburgh Breast Unit
Surgical and Associated Services Division
Western General Hospital, Crewe Road, Edinburgh, EH4 2XU
Consultants: Miss EDC Anderson, Mr U Chetty, Mr JM Dixon, Mr GT Neades, Mr RJ Salem
Unit Co-ordinator: Mrs S Watchman
General Office: 0131 537 1611 Ward 6: 0131 537 1631 Fax No: 0131 537 1004
Patient Information
Studies on Breast Disease
You are about to have a core biopsy performed to determine the cause of your breast lump. Following
injection of local anaesthetic, thin slivers of tissue obtained by a biopsy needle will be taken and sent to
the pathology department to diagnose the cause of your breast lump.
The Edinburgh Breast Unit is involved in a number of research projects looking at the effect of drugs on
breast lumps. We write to invite you to allow us to take extra slivers of tissue from your lump which
might be used in future research should you receive any drug treatment.
If a definite diagnosis is not obtained from the specimens we send to the pathology department, then the
stored samples will be made available to the pathology department to help diagnose the cause of your
breast lump.
Page 1 of 2
Generic Consent Form 120302
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Edinburgh Breast Unit
Surgical and Associated Services Division
Western General Hospital, Crewe Road, Edinburgh, EH4 2XU
Consultants: Miss EDC Anderson, Mr U Chetty, Mr JM Dixon, Mr GT Neades, Mr RJ Salem
Unit Co-ordinator: Mrs S Watchman
General Office: 0131 5371611 Ward 6: 0131 537 1631 Fax No: 0131 537 1004
Patient Consent Form
Studies on Breast Disease
Please Initial Boxes
I have read the attached information sheet.
I agree to undergo the procedure of core biopsy. I understand that the
purpose of the core biopsy is to determine the cause ofmy breast lump.
I agree to allow extra samples ofmy breast lump to be taken. 1 understand how the
sample will be collected and that giving this sample is voluntary and that I am free to
withdraw my approval for use of the sample at any time without giving a reason and
without my medical treatment or legal rights being affected.
I understand that the research performed on the extra sample may include research
to improve our understanding of how drugs influence breast disease.
1 understand that if these extra samples are used for research, ethical approval will
be obtained for the research project and that 1 will be asked to sign a separate consent
form giving permission so these extra samples can be used.
I have read and understood the consent form.




Consent Witnessed by Page 2 of 2
Generic Consent Form 120302
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Appendix 3: Determination of Histological Grade
Tissue used for grading was fixed in 10% neutral buffered formalin and 4pm sections
were stained with haematoxylin and eosin. Grading was carried out on invasive cancer
only using the modified criteria of Bloom and Richardson. It was assessed as follows,
Tubule formation
Care was taken to differentiate between clefts due to tumour tissue shrinkage and tubule
formation.
Score 1 - great majority of tumour composed of tubules with clearly visible lumina
2 - moderate amount of tubule formation but with areas of solid tumour growth
3 - little or no tubule formation, the cells mainly growing in sheets or cords.
Nuclear pleomorphism
The variability of both size and shape of tumour nuclei was assessed and scored.
Score 1 - little variation in size and shape of nuclei
2 - moderate variation without extremes of cell size or shape
3 - marked variation present with large bizarre nuclei and multiple nucleoli.
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Mitotic Rate
Using a magnification of x 300 the number of mitoses per 10 fields were counted.
Score 1 - <10 mitoses per 10 fields
2-10-19 mitoses per 10 fields
3 - > 20 mitoses per 10 fields
To obtain the overall tumour grade the scores for each category were added, giving a
possible score of between 3 and 9 points. Grade was then allocated on the following
basis;
Grade 1 - well differentiated - 3-5 points
Grade 2 - moderately differentiated - 6-7 points
Grade 3 - poorly differentiated - 8-9 points.
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Appendix 4: Preparation of blocks (Specimen Automated Processing Protocol)
Tissue was fixed in 4% buffered formalin for 24 hours before processing. The tissue
was then placed in a cassette and processed on a Vacuum Infiltrated Processor (VIP,
Tissue Tech VIP, E300 series, Miles Inc) overnight using the following protocol;
• Alcohol 50%, 2 hours at 35°C
• Alcohol 80%, 1 hour at 35°C
• Alcohol 95%, 1 hour at 35°C
• Alcohol 100%, 1 hour at 35°C
• Alcohol 100%, 1 hourat35°C
• Alcohol 100%, 2 hours at 35°C
• Xylene 100%, 3 changes of 1 hour each
• Paraffin, 4 changes of 1 hour each at 60°C
The tissue was then placed in mould and covered in paraffin wax.
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Appendix 5: Haematoxylin and Eosin staining methodology
Materials
Harris Haematoxylin (6765004) SHANDON
Eosin (CI 453380) SHANDON
Pertex mounting resin CELL PATH
Method
1) Dewax and rehydrate sections through graded alcohols to water
2) Immerse in haematoxylin (0.4%) for 30 seconds
3) Wash sections through 3 changes of tap water 1 minute each
4) Dip in acid alcohol (70% alcohol + 1% HC1) 4-5 times
5) Rinse in water
6) Immerse in Scott's tap water for 30 seconds to blue
7) Immerse in eosin (0.5% eosin Y solution) for 15 seconds
8) Wash sections in tap water for 1 minute
9) Dehydrate sections through graded alcohols to absolute alcohol (2 changes)
10) Sections through 3 changes of xylene and mount with pertex
Nuclear staining appears blue/purple. Cytoplasm, collagen, keratin and erythrocytes
stain pink.
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Appendix 6: En-Vision Immunohistochemistry Protocol
Materials
DAKO EnVision kit DAKOCYTOMATION
Serum Free protein block DAKOCYTOMATION







cupric sulphate (CUSO4) SIGMA
DAKO envision kit (K5007) DAKOCYTOMATION
Hydrogen peroxide H2O2 (HI009) SIGMA
Avidin / Biotin Block (Sp2001) VECTOR
Dako Protein Block (X0909) DAKOCYTOMATION
DAB & Substrate (K3468) DAKOCYTOMATION
Desired primary antibody:





(From mouse melanoma p3-NSl-Ag4-l)




Tri Buffered Saline (TBS)
Solution 1 (Tris/HCl)
• Add 30.25g Tris in dH20 + 200ml NHC1 (85ml/L FEO)
• Make up to 2L dH20
Solution 2 (Normal Saline)
• Dissolve 8.5g NaCl in 1L dH20
TBS Working Solution
• Add 100ml Tris/HCl to 900ml normal saline
Tris-EDTA Buffer (0.05M/ 50x Cone)
• Dissolve 1.85g EDTA + 2.75g Tris in 500ml dH20
• May take a few hours to dissolve completely
Working solution (0.001M)
• Add 30ml 50x solution to 1470ml dH20
Citrate Buffer (pH6 50x cone/ 0.5M)
• Dissolve 7.5g citric acid + 60.3g tri-sodium citrate (2H20) in 500ml dH20
Working solution (0.01 M)
• Add 30ml 50x solution to 1470ml dH20
3% H202
• Add 45ml H202 stock (30%) to 405ml dH20
Copper DAB Enhancement Solution
• Add 3g cupric sulphate (CUSO4) + 5.35g NaCl to 450ml dH20
Method
Preparation
• Prepare antigen retrieval buffer (citrate and EDTA), 3% H202 and TBS
• Bring antigen retrieval buffer up to pressure in the pressure cooker in the
microwave - 15 min at full power then 40% power until required
• Dewax sections in xylene for 5-10 min to allow all paraffin wax to dissolve
• Bring down through the alcohols to H20 and rinse for l-2min




• Place sections in antigen retrieval buffer and microwave for 6min at full power
(should reach full pressure for at least 2 min)
• Run cold H20 into hot antigen retrieval buffer in pressure cooker. When cool
place sections in water and rinse for 1 -2 min
• Put sections in sequenza trays and wash with TBS
Blocking
• Block endogenous peroxidase by adding 2-3 drops of protein block (DAKO:
X0909) to each section. Incubate for 5min.
• Wash with TBS
Primary Antibody
• Add lOOpl primary antibody at relevant concentration in antibody diluent
(DAKO:S2022) for desired time
• Wash with TBS
En-Vision
• Add 1 OOju.1 En-Vision chemmate solution (DAKO kit:K5007) for 30 min
• Wash with TBS
Chromogen
• Add lOOpl DAB solution (DAKO ki: K5007) and incubate in the dark for lOmin
• Wash with dH20
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• Place sections in a slide tray and rinse in H^O for l-2min
• Incubate for 5 min in CuSC>4 to enhance DAB staining
• Rinse in EEO
Counterstain
• Counterstain in haematoxylin for 30secs and wash in H2O
• Dip sections in Scott's Tap Water for a few seconds until blue
• Rinse in H2O
• Take up through graded alcohols to absolute alcohol and mount slides from
xylene then coverslip
Positively stained structures appear brown when viewed under direct light microscopy
Primary antibody concentrations and incubation periods















Appendix 7: Allred scoring of ER/PgR stained slides - results of blind scoring of
the same sections by two investigators at different time points
CASE scorer 1 scorer 2
NO Proportion Intensity Proportion Intensity
1 5 3 5 2
2 5 2 5 2
3 5 3 5 3
4 5 2 5 2
5 5 3 5 3
6 1 2 2 1
7 5 3 5 3
8 5 3 5 3
9 5 2 5 3
10 5 3 5 2
11 5 2 5 2
12 5 2 5 2
13 5 2 5 2
14 5 3 5 3
15 4 2 4 1
16 5 3 5 3
17 5 3 5 3
18 5 3 5 2
19 5 3 5 3
20 5 3 5 3
21 5 2 5 2
22 5 3 5 3
23 3 2 3 2
24 5 2 5 2
25 1 1 1 2
26 5 2 5 3
27 5 2 5 2
28 5 3 5 3
29 5 3 5 2
30 5 3 5 3
31 5 3 5 3
32 5 2 5 2
33 5 3 5 3
34 5 2 5 3
35 5 3 5 2
36 5 3 5 3
37 5 3 5 2
38 5 2 5 2
39 5 2 5 2
40 5 3 5 3
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41 1 1 1 1
42 5 2 5 2
43 5 3 5 2
44 5 2 5 2
45 5 3 5 3
46 5 2 5 2
47 4 2 4 2
48 5 3 5 3
49 5 2 5 2
50 5 2 5 2
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Appendix 8: Allred scoring of ER/PgR stained slides - results of blind scoring of
the same sections by one investigator at two different time points
CASE
NO
score 1 dec score 2 May
Proportion Intensity Proportion Intensity
1 5 3 5 3
2 4 2 4 2
3 5 2 5 2
4 5 2 5 2
5 3 1 2 1
6 5 3 5 3
7 5 2 5 2
8 5 3 5 3
9 5 2 5 2
10 5 2 5 2
11 5 2 5 2
12 5 2 5 2
13 5 3 5 3
14 5 2 5 2
15 5 3 5 2
16 5 1 5 1
17 5 2 5 2
18 4 2 4 2
19 5 2 5 2
20 5 2 5 2
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Appendix 9: Assessment of proliferation, results of blind scoring of the same
sections by two investigators
Re-scored cases
Case Pre 10-14d 3m
58 - countl 24.06 2.67 0.84
58 - count 2 19.34 3.46 2.03
difference 4.72 0.79 1.19
% variation 21.75 82.92
66 - countl 5.71 3.25 1.09
66 - count2 7.81 3.54 1.76
difference 2.1 0.31 0.67
% variation 31.65 9.13 47.01
51 - count 1 15.53 13.4 16.8
51 - count2 15.73 18.18
difference 0.2 1.38
% variation 1.31 7.89
2 - count 1 19.16 11.12 7.07
2 - count2 23.44 10.85 8.96
difference 4.28 0.27 1.89
% variation 20.09 2.45 23.58
10 - count 1 9.83 2.4 0.08
10 - count 2 14.71 2.02 0.73
difference 4.88 0.38 0.65





Appendix 10: Assessment of proliferation, results of blind scoring of the same
sections by one investigator on two separate occasions
Case count 1 count 2
Let 58a 24.06 19.34
Let 58b 2.67 3.46
Let 58c 0.84 2.03
Let 66a 5.71 7.81
Let 66b 3.25 3.54
Let 66c 1.09 1.76
Let 51a 15.53 15.73
Let 51b 16.8 18.18
Let 2a 19.16 23.44
Let 2b 11.12 10.85
Let 2c 7.07 8.96
Let 10a 9.83 14.71
Let 10b 2.4 2.02
Let 10c 0.08 0.73
Fem 10a 23.56 21.39
Fem 14a 26.92 21.92
Fem 17a 13.82 15.64
Fem 18b 11.22 13.02
Fem 35b 1.34 1.02
Fem 86b 1.21 2.16
Fem 15a 5.76 12.32
Pearson's correlation r = 0.9498
95% CI = 0.8782-0.9798, p= <0.0001
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Appendix 11: HercepTest immunohistochemistry for HER 2 (erbB2)
Materials:
Antigen retrieval solution 30ml Epitope retrieval solution [DAKO XI0 cone code
K5205 lot 023( 101 )]in 270mls distilled water
Wash buffer (10 x concentrated) DAKO code K5205 lot 494
Control slides code K5205 lot 023(201):
(Each slide contains sections of three formalin fixed paraffin embedded breast
carcinoma cell lines representing different levels of HER2 protein expression: MDA-231
(0), MDA - 175 (1+) and SK-BR-3 (3+)
DAKO HercepTest for Autostainer (for immunocytochemical determination of HER2
protein over expression in fixed, paraffin-embedded breast carcimonas) Contains:
• 45ml of Peroxidase blocking reagent : 3% hydrogen peroxidase containing 15
mmol/L NaN3
• 24ml Rabbit Anti-Human HER2 Protein: Antibody containing 15 mmol/L NaN3
• 45ml Visualisation Reagent: Dextran polymer conjugated with horseradish
peroxidase and goat anti-rabbit immunoglobulins
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• 24ml Negative control reagent Immunoglobulin fraction of normal rabbit serum
containing 15 mmol/LNaN3
• 50ml DAB buffered substrate substrate buffer solution containing hydrogen
peroxide
• 2ml DAB Chromogen 3,3' Diaminobenzidine chromogen solution
• DAB solution was made by using 10ml of dab substrate and 10 drops of dab
chromagen
Method
• Dewax paraffin embedded sections in xylene for 10 mins then take them down
through gradient alcohols ( 100% x3 then 90%, 80%, 70%) to distilled water.
• Heat a water bath to 97°C and fill baths with antigen retrieval solution (30ml
Epitope retrieval solution [DAKO X10 cone code K5205 lot 023( 101 )]in 270mls
distilled water).
• Put slides in antigen retrieval solution at 97°C for 45 minutes.
• Allow solution to cool to room temperature over 30 mins.
• Load the slides onto a sequenza.
• Wash with TBS.
• Incubate sections in peroxidase blocking reagent for 5 mins.
• Rinse with distilled water and then with wash buffer.
• Incubate in primary antibody for 40 minutes.
• Rinsed with wash buffer
• Incubate in the visualisation solution for 30 minutes.
• Rinse with wash buffer.
• Apply DAB solution to the sections for 10 minutes
• Rinse with distilled water.
• Remove the sections from the sequenza
• Counterstain with haematoxylin for 1 minute
• Place for 5 minutes in tap water.
• Take the slides back up through gradient alcohol solutions to xylene before
cover plating
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Appendix 12: Method for fluorescence in situ hybridization (FISH) of 2+
sections on immunohistochemistry using DAKO Herceptest
This technique uses Pathvysion HER-2 neu kit for use on paraffin embedded material
• Cut 4pm sections and pick up on charged slides.
• Air dry slides overnight at 37°C and bake the following morning at 56°C for 2
hours
• Dewax sections in xylene for 10 mins
• Rinse slides in absolute ethanol x 2 and then air dry
• Immerse slides in 0.2M HCL for 25 mins
• Rinse slides in distilled water and then immerse in 2 x SSC wash buffer ph7.0 for
3 mins
• Drain off buffer and then immerse slides in pre-treatment solution at 80°C for 40
mins
• Remove slides from pre-treatment solution and then immerse in distilled water
for one minute followed by 2x wash buffer for 3 mins
• Transfer slides to fresh pre-warmed wash buffer at 37°C for 15 mins
• Drain off excess buffer and then immerse slides in pre-heated protease solution
plus enzyme @ 37°C for twenty minutes (digestion times vary depending on the
material. Only add the protease enzyme to warmed protease buffer 4 minutes
before use)
• Terminate digestion in wash buffer two times 5 mins
• Drain off excess buffer and then immerse slides in denature solution at 72°C for
five minutes
Transfer slides immediately to 70%, 80% and then 100% ethanol
Air dry
Warm probe to room temperature, vortex, centrifuge and vortex once more
Add 10 microlitres of probe to section and then coverslip
Seal coverslip with rubber cement and then place in a dark incubating chamber at
37°C overnight
Next day soak off coverslips in post hybrid wash buffer in the dark at room
temperature
At the same time pre-warm post hybrid wash solution to 72°C in the water bath
Once coverslips are removed place slides in heated buffer for two minutes
Remove slides from buffer and allow the slides to air dry upright in the dark
Apply 10 microlitres ofDAPI counterstain to the section and recover with a fresh
coverslip
Keep slides in the dark until ready for viewing
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Appendix 13: Licensed indications for Letrozole (as of August 2001)
Letrozole is licensed for:
• Treatment of early invasive breast cancer in postmenopausal women who have
received prior standard adjuvant tamoxifen therapy
• First line treatment in postmenopausal women with breast cancer
• Treatment of advanced breast cancer in postmenopausal women in whom
tamoxifen or other anti-oestrogen has failed
• Pre-operative therapy in postmenopausal women with localised hormone
receptor positive breast cancer, to allow subsequent breast-conserving surgery in
women not originally considered candidates for breast-conserving surgery.
Subsequent treatment after surgery should be in accordance with standard of
care.
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01 4l3% nc 421% NC 458% NC 473% pr Not able to assesss
— died before 3
month assessment
02 4-64% pr 471% pr 468% pr 482% pr 464% pr 478% pr
03 478% pr 492% pr 4ioo%cr 4l00%CR 486% pr 494% pr

















06 448% MR 478% PR 451% PR 466% PR 476% PR 488% PR





















09 NA NA NA NA NA NA
10 477% PR 489% PR 4ioo%cr 4ioo%cr 474% PR 487% PR
11 428% MR 464% PR t2% NC t3% NC 427% MR 435% MR






13 446% MR J.57% PR 4,39% MR 4.51 % PR 4,41 % MR 478% PR
14 461% PR 464% PR 478% PR 490% PR 451% PR 466% PR
15 491% PR 496% PR 487% PR 495% PR 485% PR 494% PR
16 456% PR 468% PR 4lOO%CR 4ioo%cr 487% PR 495% PR
17 469% PR 476% PR 466% PR 480% PR 449% MR 460% PR














19 492% PR 497% PR 4100% PR 4100% PR 430% MR 440% MR




21 437% MR 468% PR 4ioo%cr 4ioo%cr 4ioo%cr 4100%
CR
22 447%mr 470% PR 468% PR 482% PR 420% NC 432% MR
23 454% PR 454% PR 450% PR 464% PR 457% PR 472% PR
24 479% PR 484% PR 477% PR 489% PR 470% PR 483% PR
25 484% PR 490%PR 460% PR 475% PR 430% MR 442% MR
26 449% MR 463% PR 479% PR 490% PR 457% PR 471% PR
27 426% MR 4l2%NC 4l9%NC 429%mr 4io%nc 4l6%NC
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Bidimentional Tridimention- Bidimentio¬ Tridimenti- Bidimentio¬ Tridimen-
% reduction / al % nal % onal % nal % tional %











28 t41%PD t34% PD 4o% NC 4o% NC 49% NC 42% NC
29 4,92% PR 4,96% PR 491% PR 497% PR 443% MR 459% PR
30 4,76% PR 4,88% PR 4ioo%cr 4ioo%cr 477% PR 489% PR
31 4,67% PR 4,69% PR 456% PR 467% PR 467% PR 479% PR
32 58% PR 4,51% PR 465% PR 485% PR 458% PR 473% PR
33 Node -133% Node -133% Mass - 4 Mass - Mass t 2% Mass 40%












35 4,41% MR 4,56% PR 4100% PR 4100% PR 438% MR 452% PR
4,78% PR 4,87% PR 4100% PR 4100% PR 47% NC 4ll%NC
36 4,67% PR 4,66% PR 457% PR 468% PR 441% MR T34%mr











study - poor health
38 4,35% MR |49%MR 445% MR 459% PR 467% PR 481% PR
39 4-70% PR 4,81% PR 450% PR 465% PR 487% PR 495% PR
40 t8% NC 4,37%mr 453%PR 4l3%NC 444% MR 459% PR
41 4,52% MR 4,50% MR 428% MR 450% MR 455% PR 470% PR
42 Withdrew side
effects
NA NA NA NA NA
43 4,25% MR 4,35% MR 423% MR 432% MR 436% MR 447% MR
44 4,85% PR 4,95% PR 472% PR 486% PR 467% PR 480% PR













47 4,93% PR 4,96% PR 484% PR 494% PR 486% PR 495% PR
48 4,60% PR 4,70% PR 457% PR 466% PR 466% PR 482% PR
49 4,55% PR 4,66% PR NA NA 440% MR 453% PR






51 4-86% PR 4,94% PR 4ioo%cr 4l00%CR 463% PR 477% PR
52 4,50% PR 4-57% PR 448% MR 461% PR 447%mr 461% PR
53 4,69% PR 479% PR 4io%nc 4l4%NC 461% PR 475% PR
54 NA NA NA NA NA NA
55 4,42% MR 442% MR 448% MR 464% PR
56 4,46% MR 461% PR 490% PR 497% PR 446% MR 461% PR
57 4,68% PR 477% PR 4ioo%cr 4ioo%cr 442% MR 456% PR

































59 4-75% PR 486% PR 464% PR 478% PR 458% PR 473% PR
60 4-50% PR 445% MR 466% PR 480% PR 451% PR 463% PR
61 484% PR 491% PR 489% PR 496% PR 463% PR 477% PR
62 4-58% PR 475% PR 4ioo%cr 4l00%CR 4l8%NC 425% MR
63 448% MR 459% PR 434% MR 447% MR 4l2%NC 4l7%NC
64
65 t 4% NC 4ll%NC 429% MC 441% MR t 7 % NC t 10% NC




67 456% PR 478% PR 456% PR 471% PR 456% PR 470% PR
68 T4% NC t23% NC 4l00%CR 4ioo%cr 464% PR 477% PR
69 480% PR 476% PR 480% PR 491% PR 466% PR 480% PR




451% PR 467% PR 456% PR 471% PR
71 484% PR 495% PR 489% PR 496% PR 457% PR 472% PR
























74 442% MR 457% PR 442% MR 457% PR 421% NC 430% MR
75 4l8%NC 426% MR 4ioo%cr 4ioo%cr 463% PR 477% PR

























79 429% MR 442% MR 476% PR 490% PR 45% NC 47% NC
80 NA NA NA NA NA NA













83 476% PR 484% PR 4ioo%cr 4ioo%cr 443% MR 457% PR
84 428% MR 4l6%PR 4l8%NC 425% PR 438% MR 451% PR
85 483% PR 493% PR 470% PR 484% PR 475% PR 486% PR
86 t 109% PD t 209% PD t 9% NC t 14% NC f 146% PD t 278%
PD
87 482% PR 492% PR 484% PR 493% PR 469% PR 483% PR
88 Not part of
clinical
measurements
89 467% PR 485% PR 4ioo%cr 4ioo%cr 431% MR 441% MR
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Bidimentional Tridimentional Bidimentio¬ Tridimentio¬ Bidimentional Tridimen¬
Pt % reduction / % reduction / nal % nal % % reduction / tional %
ID response response reduction / reduction / response reduction /
USS USS response response Mammo response
Calliper Calliper Mammo
90 470% PR 480% PR 4l00%CR 4l00%CR 465% PR 479% PR
91 428% MR 422% NC 4l9%NC 427% MR 442% MR 455% PR
92 |25% PD |47% PD |25% PD 442% PD 459% PD "f 101% PD
T71%PD f 103% PD NA NA NA NA
93 452% PR 452%PR *449% MR *465% PR Not assessable Not
on film assessable
94 471% PR 474% PR 449% MR 464% PR T2.3% NC 43% NC
95 4l6%NC 44% NC 422% NC 431%NC 10% NC 15% NC
96 480% PR 487% PR 4100% PR 4100% PR 438% MR 452% PR
f41%PD 424% NC 429% PD 446% PD NA NA
97 458% PR 467% PR 475% PR 488% PR 4l9%NC 4l9%NC
98 NA NA NA NA NA NA
99 49% NC 423% NC 421% NC 430% MR 432% MR 446% MR
100 436% MR 435% MR 475% PR 488% PR 463% PR 479% PR
101 487% PR 492%PR 4l00%CR 4l00%CR 452% PR 463% PR
102 463% PR 480% PR 474% PR 486% PR 4ll%NC 4l6%NC
103 4l5%NC 48% NC 431% MR 444% MR 424% NC 440% MR
104 479% PD 463% PD 119% NC T30% PD 429% MR 446% MR
46% NC 4l6%NC 438% MR 451% PR 4ll%NC 420% NC
105 431% MR 437% MR 4l9%NC 427% MR to.6% NC to.6% NC
106 436% MR 447% MR Cannot Cannot Cannot assess Cannot
assess assess assess
107 445% MR 456% PR 454% PR 469% PR 448% MR 463% PR
108 480% PR 489% PR 440% MR 453% PR 444% MR 455% PR
tl 8% NC 4l9%NC not not 4io%nc 4l4%NC
assessable assessable
109 442% MR 432% MR 452% PR 467% PR 440% MR 455% PR
110 443% (MR 476% PR 4ioo%cr 4l00%CR 463% MR 478% MR
111 462% PR 472% PR 4ioo%cr 4ioo%cr 454% PR 470% PR
112 493% PR 495% PR 4ioo%cr 4ioo%cr 469% PR 481% PR
113 NA NA NA NA NA NA
114 461% PR 484% PR Cannot Cannot Cannot assess Cannot
assess assess assess
115 487% PR 490% PR 4ioo%cr 4ioo%cr 4 74% PR 485% PR
116 485% PR 488% PR 4ioo%cr 4ioo%cr 443% MR 450% PR
117 460% PR 473% PR 443% MR 457% PR 467% PR 483% PR
118 441% MR 458% PR 451% PR 466% PR 456% PR 470% PR
119 476% PR 486% PR 461% PR 477% PR 445% MR 460% PR
120 467% PR 485% PR 455% PR 469% PR 464% PR 477% PR
121 422% NC 453% MR *430% MR *443% MR tl 8% NC t30% PD
122 436% MR 4l2%NC 43% NC 44% NC 449% MR 463% PR
123 4,20% NC J,53% PR J.63% PR 4.78% PR 458% PR 472% PR
124 45% NC 40.4% NC *416% NC *423% NC 4l2%NC 43% NC
125 4,81% PR 489% PR 482% PR 492% PR [66% PR 4,80% PR
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Bidimentional Tridimentional Bidimentio¬ Tridimention Bidimentio-nal Tridimen¬
Pt % reduction / % reduction / nal % -al % % reduction / tional %
ID response response reduction / reduction / response reduction /
USS USS response response Mammo response
Calliper Calliper Mammo
126 482% PR 495% PR 4l00%CR 4l00%CR 488% PR 496% PR
469% PR 493% PR NA NA 467% PR 481% PR
127 468% PR 481% PR 424% NC 435% MR 465% PR 478% PR
4l5%NC 441% MR 470% PD 494% PD 462% PR 477% PR
447% MR 448% MR 451% PR 465% PR unable to unable to
assess central assess
central
128 NA NA NA NA NA NA
129 452% PR 472% PR 461% PR 477% PR 453% PR 467% PR
130 169% PR J, 70% PR 450% PR 465% PR 453% PR 4 67% PR
131 193% PD 428% PD 437% MR 449% MR 422% NC 436% PD
132 |,50% PR 461% PR 461% PR 476% PR 448% MR 463% PR
133 J.76% PR |87% PR 483% PR 493% PR 442% MR 455% PR
134 NA NA NA NA NA NA
135 427% MR 445% MR 479% PR 491% PR 445% MR 459% PR
136 443% MR 442% MR 442% MR 456% PR 424% NC 4 34% MR
137 445% MR 446% MR 4ioo%cr 4l00%CR 468% PR 482% PR
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Appendix 15: Comparison of Initial (pre) and final (post) ultrasound (USS)
tumour measurements compared with final measured tumour size from
pathology specimen (in cm) where applicable
Patient Pre Post
Case No USS USS PATH
1 2 7.29 2.66 3.61
2 3 13.36 2.24 4
3 6 14.52 7.56 7.84
4 7 4.8 0.78 6.25
5 8 5.6 3.24 9
6 10 5.28 0.55 2.56
7 12 7.83 5.52 CORES
8 15 13.3 1.14 CORES
9 17 10.24 3.22 4
10 18 3.36 1.82 CORES
11 20 18.48 7.2 6.25
12 23 12.25 6.65 6.25
13 24 23.32 5 6.25
14 25 6.75 1.09 9
15 26 4.1 2.1 2.56
16 27 7.75 5.75 3.61
17 34 5.76 0.56 CORES
18 35 2.08 1.24 2.25
19 38 8.7 5.67 4
20 43 4.8 3.6 4
21 44 6.09 0.9 8.7
22 48 10.5 4.18 6.76
23 50 11.2 5.44 5.76
24 51 7.8 1.08 6.76
25 52 9.24 4.59 10.24
26 53 7.68 2.38 1.44
27 56 5.98 3.23 3.24
28 57 3.23 1.04 11.56
29 58 7.02 4.18 6.25
30 59 9.57 2.4 7.84
31 61 4.4 0.72 5.76
32 62 2.6 1.1 4.41
33 63 5 2.63 2.89
34 65 5.78 6 7.29
35 66 9.1 3.23 CORES
36 67 3.15 1.39 2.56
37 69 4.14 0.84 1.44
38 70 TOO LARGE CORES
39 71 12.48 1.96 >36 (lob)
40 72 TOO LARGE CORES
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41 74 2.89 1.69 6.25
42 75 0.57 0.47 0.3
43 76 10.73 7.6 CORES
44 77 8 5.06 4.41
45 78 1.82 0.52 2.56
46 79 2.88 2.04 5.29
47 84 4.75 3.42 5.29
48 85 4.14 0.69 0.36
49 86 7.02 14.7 16
50 87 6.5 1.17 0.81
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1 2 PR PR
2 3 PR PR
3 6 PR PR
4 7 PR PR
5 10 PR PR
6 12 PR PR
7 15 PR PR
8 17 PR PR
9 20 PR PR
10 23 PR PR
11 24 PR PR
12 25 PR PR
13 26 PR PR
14 27 NC NC
15 34 PR PR
16 35 PR PR
17 38 MR PR
18 43 MR MR
19 48 PR PR
20 50 PR PR
21 51 PR PR
22 52 PR NC/MR
23 53 PR PR
24 56 PR PR
25 57 PR NC
26 58 MR NC/MR
27 59 PR PR
28 61 PR NC/MR
29 63 PR PR
30 66 PR PR
31 67 PR PR
32 69 PR PR
33 74 PR/MR PR/MR
34 76 MR NA
35 77 PR PR
36 78 PR PR
37 79 MR PR
38 84 MR NC
39 89 PR PR
40 90 PR PR
41 93 PR NC/MR
42 94 PR PR
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43 95 NC NC
44 97 PR PR
45 100 MR MR
46 102 PR PR
47 105 MR PR
48 107 PR PR
49 109 MR NC
50 110 PR PR
51 111 PR PR
52 115 PR PR
53 116 PR PR
54 117 PR PR
55 118 PR NC
56 119 PR PR
57 120 PR PR
58 121 MR MR
59 125 PR NC/MR
60 130 PR PR
61 132 PR PR
62 136 MR PR
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no Pre 10-14d 3 m
ER p ER i ER p ER i ER p ER i
1 2 5 2 5 3 5 2
2 3 5 3 5 3 5 2
3 6 5 3 5 3 5 3
4 7 5 3 5 3 5 2
5 10 5 3 5 3 5 2
6 12 5 2 5 3 5 3
7 15 5 3 5 3 5 3
8 17 5 2 5 3 5 2
9 20 5 3 5 2 5 2
10 23 5 3 5 3 5 3
11 24 5 3 5 3 5 2
12 25 5 3 5 3 5 3
13 26 5 3 5 2 5 2
14 27 5 3 5 3 5 2
15 34 5 3 5 3 5 3
16 35 5 3 5 2 5 2
17 38 5 3 5 3 5 3
18 43 5 3 5 3 5 2
19 48 5 3 5 3 5 3
20 50 5 3 5 3 5 2
21 51 5 3 5 3 5 3
22 52 5 3 5 2 5 2
23 53 5 3 5 3 5 2
24 56 5 3 5 3 5 3
25 57 5 2 5 2 5 2
26 58 5 3 5 3 5 3
27 59 5 3 5 2 5 3
28 61 5 3 5 3 5 3
29 63 5 3 5 3 5 2
30 66 5 3 5 2 5 3
31 67 5 2 5 2 5 2
32 69 5 2 5 2 5 2
33 74 5 3 5 3 5 3
34 76 5 3 5 3 5 2
35 77 5 2 5 2 5 2
36 78 5 2 5 3 5 3
37 79 5 2 5 3 5 3
38 84 5 3 5 3 5 2
39 89 5 3 5 3 5 2
40 90 5 3 5 3 5 2
41 93 5 2 5 2 5 2
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Pt Audit
no no Pre 10-14d 3 m
ER p ER i ER p ER i ER p ERi
42 94 5 3 4 2 4 2
43 95 5 3 5 3 5 2
44 97 5 2 5 2 5 3
45 82 5 3 5 3 5 2
46 77 5 3 5 3 5 2
47 105 5 3 5 3 5 2
48 107 5 3 5 3 5 3
49 109 5 2 5 3 5 3
50 110 5 2 5 2 5 2
51 111 5 3 5 3 5 3
52 115 5 2 5 3 5 2
53 116 5 3 5 3 5 3
54 117 5 3 5 3 5 3
55 118 5 3 5 3 5 3
56 119 5 2 5 3 4 1
57 120 5 2 5 3 5 3
58 121 5 3 4 2 3 2
59 125 5 3 5 3 5 3
60 130 5 3 5 3 5 3
61 132 5 3 5 3 5 3
62 136 5 3 5 3 5 2
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no Pre 10-14d 3 m
PgRp PgRi PgR p PgR i PgR P PgRi
1 2 2 2 0 0 0 0
2 3 0 0 0 0 0 0
3 6 5 3 4 1 4 1
4 7 3 2 0 0 0 0
5 10 5 3 5 3 5 2
6 12 5 3 5 3 5 2
7 15 3 1 0 0 0 0
8 17 5 2 5 2 5 2
9 20 0 0 0 0 1 1
10 23 4 1 0 0 1 1
11 24 5 3 5 3 5 2
12 25 5 3 0 0 0 0
13 26 5 2 5 3 5 2
14 27 5 3 5 2 5 1
15 34 5 3 5 2 4 1
16 35 5 3 3 1 3 2
17 38 5 3 5 2 5 3
18 43 3 2 1 1 1 1
19 48 5 3 5 3 5 2
20 50 3 1 1 1 0 0
21 51 4 1 0 0 0 0
22 52 3 1 0 0 0 0
23 53 4 2 3 1 0 0
24 56 5 2 0 0 0 0
25 57 0 0 0 0 0 0
26 58 4 2 0 0 0 0
27 59 4 2 2 1 0 0
28 61 4 2 0 0 0 0
29 64 5 2 0 0 0 0
30 66 4 2 0 0 0 0
31 67 3 2 0 0 0 0
32 69 5 3 2 2 3 2
33 74 5 2 4 2 0 0
34 76 4 2 0 0 0 0
35 77 5 2 5 2 3 1
36 78 5 3 0 0 0 0
37 79 0 0 0 0 0 0
38 84 4 2 0 0 0 0
39 89 5 3 1 1 0 0
40 90 1 2 1 1 0 0
41 93 0 0 0 0 0 0
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Pt Audit
no no Pre 10-14d 3 m
PgRp PgR i PgR p PgRi PgR p PgRi
42 94 0 0 0 0 0 0
43 95 3 1 0 0 0 0
44 97 5 2 0 0 0 0
45 100 2 2 0 0 0 0
46 102 2 2 0 0 0 0
47 105 0 0 0 0 0 0
48 107 5 3 4 3 5 3
49 109 2 2 0 0 0 0
50 110 4 2 2 2 2 1
51 111 5 3 1 2 0 0
52 115 5 2 3 1 0 0
53 116 4 2 0 0 0 0
54 117 3 3 0 0 0 0
55 118 3 3 0 0 0 0
56 119 3 2 3 2 3 2
57 120 5 2 0 0 0 0
58 121 3 2 0 0 0 0
59 125 0 0 0 0
60 130 5 3 4 2 0 0
61 132 5 3 3 1 0 0
62 136 5 3 5 2 4 2
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Appendix 19: Raw data for proliferation from Letrozole Audit
Case Pre
10-
14 d 3month %decrease %increase %decrease %increase %decrease %increase







2 19.16 11.12 7.07 41.97% 63.20% 21.23%
3 28.14 0.7 0.28 97.51 99 1.49
6 7.51 0.45 0 94.01 100 5.99
7 12.16 1.84 0.64 84.87 94.79 10.1
10 9.83 2.4 0.08 75.59 99.18 23.59
12 8.15 1.64 5.25 79.88 35.9 43.98
15 21.8 1.3 0 94.04 100 5.96
17 6.34 3.91 0.25 38.33 96.06 57.73
20 17.79 32.87 22.88 83.63 28.61 55.02
23 4.98 4.55 1.18 8.64 76.31 67.67
24 10.8 1.75 2.29 83.8 78.79 14.08
25 14.48 7.26 5.32 49.97 63.26 13.29
26 19.73 1.47 0.93 92.55 95.29 2.74
27 22.06 7.74 3.21 66.69 85.45 18.76
34 17.57 8.93 0.8 49.18 95.45 46.27
35 11.97 2.95 1.08 75.54 90.98 15.44
38 15.78 4.33 8.19 72.57 48.1 24.47
43 10.08 3.59 1.98 74.49 81.36 6.87
48 11.69 1.65 0 85.89 100 14.11
50 19.76 3.49 15.79 82.34 10.22 72.12
51 15.53 13.4 16.8 13.72 8.17 14.8
52 17.85 10.69 9 40.12 49.58 9.46
53 6.27 2.84 0.68 54.71 89.16 49.04
56 1.64 1.09 0 33.6 100 66.4
57 22.32 24.78 15.54 11.02 30.38 31.49
58 24.06 2.67 0.84 88.91 96.51 7.6
59 5.25 2.36 0.22 55.05 95.51 40.46
61 9.43 0 0.77 100 99.23 0.77
63 15.12 1.96 3.35 87.04 77.85 9.19
66 5.71 3.25 1.09 43.09 80.91 55.83






3month %decrease %increase %decrease %increase %decrease %increase







69 9.37 2.73 0.36 70.87 96.16 28.75
74 9.3 18.85 5.02 102.6 44.1
76 10.28 1.03 0.64 89.99 93.78 3.79
77-L 9.27 2.66 3.39 71.33 63.44 7.85
78-L 11.84 2.9 1.94 75.51 83.62 8.11
79 17.12 0.66 0 96.14 100 3.86
84 31.82 21.86 18.22 31.31 42.74 11.43
87 16.14 19.71 22.11
89 6.51 0.74 0 88.64 100 11.36
90 22.35 9.81 3.11 56.11 86.09 29.98
93 4.76 1.91 1.27 59.88 73.32 13.44
94 28.86 16.11 22.93 44.18 20.55 23.63
95 8.63 1.71 12.35 80.19 43.1
97 5.86 1.07 0 81.75 100 18.25
100 4.03 0 0 100 100 0
102 3.51 0.53 0 84.9 100 15.1
105 10.98 0.93 2.24 91.54 79.6 11.94
107 8.81 0 0.54 100 93.87 6.13
109 27.79 20.01 25.46 28 8.39 19.61
110 17.44 1.86 0 89.34 100 10.66
111 8.76 1.26 0.65 85.62 92.58 6.96
115 28.18 1.57 1.47 94.42 94.78 0.36
116 9.45 2.36 0.43 75.03 95.45 20.42
117 23.18 1.33 2.73 94.27 88.23 6.04
118 21.28 3.22 12.24 84.67 42.49 42.18
119 5.06 0.41 0 91.9 100 8.1
120 28.26 12.83 20.02 54.61 29.16 25.45
121 15.38 14.33 2.29 6.83 85.11 78.28
125 10.74 8.93 13.47 16.86 20.87 42.27
130 23.64 2.76 1.18 88.33 95 6.67
132 28.24 2.88 1.08 89.81 96.18 6.37
136 13.85 1.38 2.11 90.04 84.76 5.28
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Appendix 20: Raw data for Ki67 for biological subgroup
Patient number Audit number Ki-67 (%)
Pre 10-14d 3 mth
1 2 19.16 11.12 7.07
2 3 28.14 0.7 0.28
3 6 7.51 0.45 0
4 7 12.16 1.84 0.64
5 10 9.83 2.4 0.08
6 12 8.15 1.64 5.25
7 15 21.8 1.3 0
8 17 6.34 3.91 0.25
9 20 17.79 32.87 22.88
10 23 4.98 4.55 1.18
11 24 10.8 1.75 2.29
12 25 14.48 7.26 5.32
13 26 19.73 1.47 0.93
14 27 22.06 7.74 3.21
15 34 17.57 8.93 0.8
16 35 11.97 2.95 1.08
17 38 15.78 4.33 8.19
18 43 10.08 3.59 1.98
19 48 11.69 1.65 0
20 50 19.76 3.49 15.79
21 51 15.53 13.4 16.8
22 52 17.85 10.69 9
23 53 6.27 2.84 0.68
24 56 1.64 1.09 0
25 57 22.32 24.78 15.54
26 58 24.06 2.67 0.84
27 59 5.25 2.36 0.22
28 61 9.43 0 0.77
29 64 15.12 1.96 3.35
30 66 5.71 3.25 1.09
31 67 15.66 0.49 1.1
32 69 9.37 2.73 0.36
33 74 9.3 18.85 5.02
34 76 10.28 1.03 0.64
35 77 9.27 2.66 3.39
36 78 11.84 2.9 1.94
37 79 17.12 0.66 0
38 84 31.82 21.86 18.22
40 89 6.51 0.74 0
41 90 22.35 9.81 3.11
42 93 4.76 1.91 1.27
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Estrogen-Independent Proliferation Is Present in
Estrogen-Receptor HER2-Positive Primary Breast Cancer
After Neoadjuvant Letrozole
Matthew J. Ellis, Yu Tao, Oliver Young, Sharon White, Alan D. Proia, JullietteMurray, Lorna Renshaw,
Dana Faratian, Jeremy Thomas, Mitch Dowsett, Andreas Krause, Dean B. Evans, William R. Miller,
and J. Michael Dixon
ABSTRACT
Purpose
To investigate the impact of human epidermal growth factor receptor {HER) 1 and HER2 gene
amplification on endocrine therapy responsiveness, a fluorescence in situ hybridization (FISH)
study was conducted on tumor samples from 305 postmenopausal patients with stage II and III
estrogen receptor (ER) -positive (ER > 10%) breast cancers treated on two independent
neoadjuvant endocrine therapy trials.
Patients and Methods
FISH analysis focused on HER1 and/or HER2 immunohistochemistry (IHC) -positive patients and
a random selection of HER1/2 IHC-negative patients. HER2 FISH status was correlated with
response and changes in the proliferation marker KI67.
Results
HER1 was rarely amplified (< 1%), and HER2 amplification was observed in 9.2% of patients.
Letrozole response by clinical measurement (71% HER2 FISH positive v 71% HER2 FISH
negative), mammogram (44% HER2 FISH positive v 47% HER2 FISH negative), or ultrasound
(47% HER2 FISH positive v54% HER2 FISH negative) was not impaired by HER2 FISH-positive
status. In contrast, HER2 FISH-positive tumors showed higher histologic grade (P = .009), higher
pretreatment Ki67 (P= .005), and less Ki67 suppression after letrozole when compared with HER2
FISH-negative tumors (P = .0001). Similar observations regarding Ki67 were made in a smaller
cohort of tamoxifen-treated tumors.
Conclusion
Neoadjuvant letrozole is clinically effective in ER-positive HER2 FISH-positive tumors, indicating
sensitivity to short-term estrogen deprivation. However, continued proliferation despite ongoing
letrozole or tamoxifen treatment in the majority of ER-positive HER2 FISH-positive samples (88%)
could imply therapeutic resistance that may manifest later in the clinical course of the disease.
Discordance between clinical and biomarker findings in this study serves to emphasize the need
for surrogate end point validation in neoadjuvant endocrine trials through correlation with
information on long-term outcomes.
J Clin Oncol 24:3019-3025. © 2006 by American Society of Clinical Oncology
Most studies' have concluded that estrogen receptor
(ER) -positive breast cancers exhibiting human epi¬
dermal growth factor receptor (HER) 2 protein
overexpression have diminished responsiveness to
tamoxifen. The exceptions have tended to occur in
the setting ofadjuvant studies where chemotherapy
usemay obscure the interaction.2 In contrast, a neo¬
adjuvant study that compared tamoxifenwith letro¬
zole indicated that preoperative regression of ER-
positive tumors in response to 4 months ofletrozole
was not impeded by overexpression ofHER1 and/or
HER2,3 A similar conclusion was reached in a pre¬
operative study of anastrozole versus tamoxifen,4
but the size of the ER-positive, HER2-positive sub¬
sets in both these studies was too small for defini¬
tive conclusions. Small sample size is a consistent
problem with the literature because ER-positive,
H£R2-positive tumors are uncommon, with only
10% of ER-positive disease showing evidence of
HER2 gene amplification.5 Nonetheless, studies
that focus on the correct endocrine approach for
ER-positive HER2-positive disease are important
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because half ofHER2 fluorescence in situ hybridization (FISH) -pos¬
itive primary breast cancers exhibit some degree ofhormone receptor
expression.
Since our initial publication,'' FISH testing has replaced immu-
nohistochemistry (IHC) as the gold standard for HER2 assessment.
Therefore, we re-examined our tumor bank using HER1 and HER2
FISH probes. Treatment-associated changes in Ki67 staining are
also presented because this proliferation biomarker provides useful
additional information on endocrine responsiveness in the preop¬
erative setting.16,7 To increase our sample size, we combined clinical
information and tumor samples from two independent studies of
preoperative endocrine therapy.
Study Population and Tumor Bank
The P024 protocol was a double-blind randomized trial that compared 4
months ofpreoperative letrozole with tamoxifen in postmenopausal women
with stage II and III breast cancers who were ineligible for breast conservation.
The clinical findings and tumor bank characteristics have been described
previously.3'6'" TheP024 letrozole cohortwas expanded with an additional 106
samples from a consecutive series of patients treated with preoperative letro¬
zole in the Edinburgh Breast Unit." Eligibility criteria and tumor assessments
for patients treated on the Edinburgh studywere similar to those used in the
letrozole P024 trial. However, some of the tumors treated in the Edinburgh
cohort were smaller than 3 cm, and the Edinburgh patients were treated for a
shorter period (typically approximately 12 weeks rather than 16 weeks). All
studies were conducted with approval from the institutional review boards or
ethics committees ofthe institutions involved in either enrolling patients or in
sample analysis.
Biomarker Analysis: IHC
Details of the HER1, HER2, ER, progesterone receptor (PgR), and Ki67
IHCmethodologies used for the P024 samples have been published previous¬
ly.3-'' When the additional samples were received from Edinburgh, they were
initially assessed byHER2 IHC using the 3B5 antibody using the sameprotocol
reported for P024.3 Data on F,R, PgR, Ki67, and histologic grade were already
available from the Edinburgh database. ER and PgR IHC used clinical grade
reagents and controls, and Ki67 IHC was based on theMIB1 antibody (diluted
X 50; Europath Ltd, Cornwall, United Kingdom). Reactivity was detected
according to the method described by Going.10
Biomarker Analysis: FISH
HER1 and HER2 FISH analyses were conducted using PathVysion
HER1 and HER2 DNA probe kits according to the manufacturer's instruc¬
tions (Vysis, Downers Grove, IL). HER2 FISH scoring with a fluorescent
microscope (Olympus BX51; Olympus, Tokyo, lapan), was conducted
manually by a board-certified pathologist (A.D.P.) who was blind to treat¬
ment, biomarker status, and clinical outcome. One hundred forty-three
patients were subjected to HER2 FISH analysis, including all patients who
exhibited HER2 2+ and 3+ IHC staining in either the pre- or post-
treatment sample. No samples (zero of 70 samples) ofHER2 gene ampli¬
fication were observed from a random sample ofHER2 IHC-negative (0 or
1+) samples (from the P024 study). Twenty-seven percent of samples
exhibiting 2+ staining were found to be FISH positive (16 of 60 samples),
and of samples with 3+ staining, 86% (12 of 14 samples) were positive.
FISH analysis was not conducted on the remaining IHC-negative samples
because the 3B5 antibody efficiently screened out tumorswith a low chance
ofHER2 gene amplification.
Biostatistical Analysis
Ail the P values reported are two sided, and a P = .05 was considered
significant. No adjustment for multiple testing was conducted. Fisher's exact
and y2 testswere used to define associations between HER2 gene amplification
status and clinical, mammography, ultrasound, and cell cycle responses. The
nonparametric Mann-Whitney U test was applied to compare differences in
Table 1. Baseline Clinical and Biomarker Characteristics of the HER2





Baseline Characteristic Median Range Median Range P
Age. years 71 51-88 71 44-93 .3710
Clinical size, cm 4.6 1.5-8.0 4.2 2-15 .7761
Ultrasound size, cm 3 1 6-8.0 2.9 0.3-14.0 .3216
Mammogram size, cm 4 1.4-8.0 3.5 1.2-14.0 .2845
ER, Ailred 8 4-8 8 4-8 .2811
PgR, Ailred 4 0-8 5 0-8 .1205
KI67, % 16.6 0-53.6 7.7 0-53.8 .005
Histologic grade, %
1 0 14.6
2 53. 3 58.6
46.2 26.8 .0088
Abbreviations: HER2, human epidermal growth factor receptor 2; FISH,
fluorescence in situ hybridization; ER, estrogen receptor; PgR, progester¬
one receptor.
Ki67 changes between HER2-positive and H£jR2-negative tumors. The differ¬
ences between baseline and post-treatment Ki67 values within each HER2
group (amplified or not amplified) were assessedby theWilcoxon signed rank
test. The 95% CI ofthe geometric Ki67meanwas calculated to show the size of
effects in pair-wise comparisons. All statistical analyses were performed using
SAS 9.1.2 (SAS Institute Inc, Gary, NC).
Definition of Cell Cycle Complete Response
Theoretically, if the tumor cell q'de is fully estrogen dependent, then
tumor proliferation should be completely arrested by potent endocrine treat¬
ment. In published exploratory analyses, the antiproliferative responses to
letrozole or tamoxifen were categorized as exhibiting a cell cycle complete
response (CR) when the post-treatment Ki67 staining was 1% or less in the
infiltrating component ofthe tumor. "We prospectively applied this cut point
to the current data set.
Clinical and Biomarker Characteristics of ER-Positive,
HER2 Gene-Amplified Tumors and HER1 FISH Analysis
HER2 gene amplificationwas detected in 9.2% of the samples (28
of305 samples). The baseline clinical and biomarker characteristics of
Table 2. Baseline Clinical and Biomarker Characteristics According to
Treatment With Letrozole or Tamoxifen
Letrozole Tamoxifen
Baseline Characteristic Median Range Median Range P
Age, years; 73 44-93 67 48-89 .0017
Clinical size, cm 4.1 1.5-12.0 4.5 2.0-15 .3302
Ultrasound size, cm 2.8 0,3-8.0 3.0 1.3-14 .1547
Mammogram size, cm 3.4 1.2-8.35 st•stcoco .0938
ER, Ailred 8 4-8 8 4-8 .1415
PgR, Alfred 6 0-8 4 0-8 .0663











Abbreviations: ER, estrogen receptor; PgR, progesterone receptor.
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Table 3. Analysis of Clinical, Ultrasound, and Mammogram Response Data According to HER2 FISH Status in Tamoxifen-Treated Patients










No. % Fisher P
Clinical 3 9 33 44 90 49 .49
Ultrasound 3 9 33 26 74 35 .99
Mammography 1 9 11 22 90 24 .68
Abbreviations: HER2, human epidermal growth factor receptor 2; FISH, fluorescence In situ hybridization.
the HER2 FISH-positive versus HER2 FISH-negative population are
outlined in Table I. The clinical characteristics of patients with ER-
positive, HER2 FISH-positive disease were not statistically different
from patientswith ER-positive, HEP2-negative disease. In terms ofthe
biomarker status, EIER2 FISH-positive tumors exhibited higher pre-
treatment Ki67 levels than HER2 FISH-negative tumors (Mann-
Whitney U test, P = < .005) and higher histologic grade (P = .0088).
No statistically significant differences in clinical or biomarker status
could be detected between the patients treated with tamoxifen and
patients treated with letrozole, except that the tamoxifen-treated pa¬
tients were slightly younger (Table 2). HER1 FISH analysis was con¬
ducted on all patients from the P024 study (nine cases in total) who
had HER1 based on IHC 2 or 3+ staining. Only one case with 3+
staining exhibited HER1 gene amplification. Interestingly, this case
exhibited gross amplification, with HER1 gene copies too numerous
to count.
Effect of HER2 Gene Amplification on the Clinical
Efficacy of Neoadjuvant Endocrine Therapy
HER2 FISH analysis ofspecimens from the tamoxifen arm of the
P024 study identified nine HER2 FISH-positive tumors, and 90 were
designated HER2 FISH negative. Tamoxifen-treated tumors harbor¬
ing HER2 gene amplification exhibited lower response rates than
HER2 FISH-negative tumors by two of the three criteria examined
(Table 3). These differences were not statistically significant, and the
sample size provided limited statistical power to address the interac¬
tion. Tomore adequately examine the impact ofEIER2 FISH status on
the effectiveness of letrozole, additional samples from a single-arm
neoadjuvant letrozole study were analyzed. The combined 202-
sample letrozole data set included 17 HER2 FISH-positive tumors
and 185 HER2 FISH-negative tumors. The letrozole response data,
outlined in Table 4, indicated that the presence of HER2 gene ampli¬
fication did not substantially reduce the clinical effectiveness of neo¬
adjuvant letrozole treatment, although the relatively small number of
HER2 FISH-positive tumors does not rule out a limited effect. The
95% CI for the letrozole clinical response in HER2 FISH-positive
tumors was 71% ± 23%. Thus, despite the sample size, a clinical
response rate to letrozole of less than 48% in ER-positive, HER2
FISH-positive disease can be excluded by these data. An exploratory
analysis was conducted to compare the efficacy of tamoxifen and
letrozolewithin subsets defined byHER2 FISH status (Tables 5 and 6).
These results should be interpreted with caution because the
additional letrozole samples were not drawn from the original
P024 double-blind randomized trial. Nonetheless, these find¬
ings do not contradict our earlier conclusions that letrozoie is
clinically more effective neoadjuvant therapy than tamoxifen.
This advantage seems to be preserved in the EIER2 FISH-
positive subset.3,8
HER2 Gene Amplification and the Antiproliferative
Effects of Letrozole
An examination of the raw Ki67 data revealed that most HER2
FISH-negative tumors showed a dramatic decline in Ki67 on treat¬
ment (Fig 1A). The geometric mean baseline Ki67 level in the HER2
FISH-negative samples was 6.25 (95% CI, 5.16% to 7.58%); this level
decreased to 0.68% after treatment (95% CI, 0.53% to 0.87%). This
decrease was significant (Wilcoxon signed rank test, P = .0001; Fig
IC). In contrast, an examination of the HER2 FISH-positive group
showed that the impact of letrozole was blunted, with few samples
decreasing close to 0% (Fig IB). At baseline, the geometricmean Ki67
score in theHER2 FISH-positive group was 14.73% (95% CI, 9.67% to
22.44%), and after treatment, the geometric mean decreased to
8.1% (95% CI, 4.16% to 15.75%). In contrast to the HER2 FISH-
negative samples, this decrease was not statistically significant (Fig
ID). The Mann-Whitney U test, which was applied to determine
whether the paired Ki67 values in the HER2 FISH-positive group were
different from the values in the HER2 FISH-negative cohort, was
significant (P = .0001).
Table . Analysis of Clinical, Ultrasound, and Mammogram Response Data According to HER2 FISH Status in Letrozole-Treated Patients













Clinical 12 17 71 131 185 71 .98
Ultrasound 8 17 47 91 170 54 .61
Mammography 7 16 44 84 178 47 .79
Abbreviations: HER2, human epidermal growth factor receptor 2; FISH, fluorescence in situ hybridization.
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Table 5. Comparison of Clinical, Ultrasound, and Mammogram Response Data According to Treatment With Letrozole or Tamoxifen in
HER2 FISH-Negative Tumors
Letrozole Tamoxifen
Response No. of Total No. of Total Mantel-Haenzel
Category Responses No. % Responses No. % P
Clinical 131 185 71 44 90 49 .0004
Ultrasound 91 170 54 26 74 35 .0083
Mammography 84 178 47 22 90 24 .0003
Abbreviations: HER2, human epidermal growth factor receptor 2; FISH, fluorescence in situ hybridization.
HER2 Gene Amplification and the Antiproliferative
Effects of Tamoxifen
The 87 tamoxifen-treated HER2 FISH-negative tumors with
paired Ki67 data showed marked and statisticaDy significant decreases
with treatment (Fig 2A). The baseline geometric mean Ki67 level was
5.79% (95% CI, 4.43% to 7.56%); this level decreased to 1.29% (95%
CI, 0.88% to 1.88%) on treatment (Wilcoxon signed rank test,
P = .0001; Fig 2C). In contrast, the Ki67 score in the tamoxifen-treated
HER2 FTSH-positive group did not show a statistically significant
decrease; the baseline geometric mean was 6.9% (95% CI, 1.81% to
26.4%), and it was 6.5% (95% CI, 1.7% to 24.78%) in the post-
treatment samples (P = .65; Fig 2B). A statistical comparison between
the Ki67 changes in the HER2 FISH-positive samples and the HER2
FISH-negative samples did not reach significance (P = .0925; Fig 2D)
presumably because of the small sample size; however, overall, the
pattern of the results was similar to the letrozole result, which is
consistent with prior conclusions that HER2 gene amplification re¬
duces the antiproliferative effects of tamoxifen as well as letrozole.12
HER2 Gene Amplification Prevents Cell Cycle CR
Table 7 examines the relationship between cell cycle CR and
HER2 gene amplification in tumors treated with letrozole. HER2
FISH-positive tumors only occasionally exhibited a cell cycle CR
(12%), underscoring the failure of letrozole to induce complete cell
cycle arrest in most of the ER-positive HER2-positive tumors treated.
In contrast, themajority (60%) of the HER2 FISH-negative letrozole-
treated tumors met the definition of a cell cycle CR at the time of
surgery. This difference was statistically significant (P = .0001). A
second exploratory analysiswas conducted that restricted the compar¬
ison to samples in which the baseline Ki67 was at least 5% in both
EIER2 FISH-negative tumors and EIER2 FISH-positive tumors in an
attempt to adjust for the fact that HER2 FISH-positive tumors had
higher levels of Ki67 at baseline than HER2 FISH-negative samples
(Table 1). The relationship between cell cycle CR and HER2 status
remained significant in this subset (P = .0012; data not shown),
indicating that the low rate of cell cycle CR in HER2 gene-amplified
tumorswas not simplyexplained by the higher baseline Ki67 level. The
relationship between cell cycle CR and HER2 status on the tamoxifen
arm was similar, with only one (11%) of nine HER2 FISFI-positive
tumors exhibiting a cell cycle CR compared with 37 (42%) of87HER2
FISH-negative tumors. In Table 8, a combined analysis is presented,
drawing on the entire data set, regardless of whether the tumor was
treated with letrozole or tamoxifen. The high level of correlation
between the lack of cell cycle CR and the presence of a positive HER2
FISH test (P = .0001) is consistent with the conclusion that the
presence ofHER2 gene amplification generates resistance at the level
ofcell cycle progression regardless ofwhich endocrine therapy is used.
This studywas designed to investigate the relationship between HER2
gene amplification and the efficacy ofneoadjuvant endocrine therapy.
By combining two sample sets, we confirmed that the clinical efficacy
of letrozole in the neoadjuvant setting was not obviously compro¬
mised by the presence HER2 gene amplification. This findingmight be
most helpful when considering a preoperative protocol for a post¬
menopausal patient with ER-positive HER2 FISH-positive disease for
whom a more toxic preoperative regimen is not suitable because of
extreme age, frailty, or the presence of cardiac disease. The combina¬
tion of letrozole and trastuzumab for the neoadjuvant treatment
of postmenopausal women with ER-positive HER2 FISH-positive
disease is an appealing research question, although the relative scarcity
of these tumors will make study accrual a challenge.
The finding that ER-positive HER2 FISH-positive tumors and
ER-positive HER2 FISH-negative tumors respond similarly to letro¬
zole at the clinical level is a striking contrast to the consistent finding
that ER-positive HER2 FISH-positive tumors are less sensitive to the
cell cycle-inhibitory effects of letrozole (as well as other endocrine












No. % Fisher P
Clinical 12 17 71 3 9 33 .10
Ultrasound 8 17 47 3 9 33 .68
Mammography 7 16 44 1 9 11 .18
Abbreviations: HEP.2. human epidermal growth factor receptor 2; FISH, fluorescence in situ hybridization.
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Fig 1. Paired Ki67 data before and after letrozoie therapy according to human
epidermal growth factor receptor 2 (HER2) fluorescence in situ hybridization
(FISH) status: (A) Ki67 values in the HER2FISH-negative group; (B) KI67 values in
the HER2 FISH-positive group; geometric mean levels in the (C) HER2 FISH-
negative group and (D) HER2 FISH-positive group.
therapies). Dowsett et al12 have reported similar Ki67 results after a
much briefer exposure to a selective estrogen receptor modulator or
an aromatase inhibitor (several weeks only). Together, these results
suggest that the disparity between the data on tumor regression and
Ki67 changes in the present studymaybe aprimary influence ofHER2
gene amplification on the endocrine responsiveness of the initial tu¬
mor cell population rather than an acquired propertyof a subpopuia-
tion ofestrogen-independent tumor cells that selectively emerge after
several months of therapy. The discordance between the data on
tumor response and Ki67 changes raises several provocative questions.
The first is a biologic issue. How can major responses to estrogen
deprivation occur in ER-positive HER2-positive tumor despite poor,
transient, or absent cytostatic effects? Second, which end point, Ki67
changes or tumor regression (or some combination of the two end
points), will best predict the likelihood that the patient will do well on
long-term adjuvant endocrine treatment?
Estrogen deprivation-induced tumor regression must be a com¬
plicated event, presumably involving not just the induction of cell
cycle arrest, but also the involvement of other processes such as
apoptosis, normalization of the tumor vasculature,13 and other
changes in the composition of the tumor mass. Certainly, there are
Fig 2. Paired Ki67 data before and after tamoxifen therapy according to human
epidermal growth factor receptor 2 (HER2) fluorescence in situ hybridization
(FISH) status; (A) Ki67 values in the HER2 FISH-negative group; (B) Ki67 values in
the HER2 FISH-positive group; geometric mean levels in the (C) HER2 FISH-
negative group and (D) HER2 FISH-positive group.
considerable data that tumor angiogenesis can be estrogen dependent,
perhaps through direct regulation of vascular endothelial growth fac¬
tor, 14,15 and letrozoie therapy can reduce tumor gadolinium contrast
accumulation on breast magnetic resonance imaging, implying an
effect of estrogen deprivation on the tumor vasculature." With re¬
spect to apoptosis, this has been quite difficult to assess in neoadjuvant
endocrine studies because cells staining for apoptosis markers are rare at
baseline and not obviously modulated by endocrine therapy.16 We have
Table 7. Cell Cycle CR (Ki67 = 1 % or less in post-treatment sample) by
HER2 FISH Status in Letrozole-Treated Patients
No. of HER2 No. of HER2
FISH-Positive FISH-Negative Total
Response Patients Patients No. Fisher P
Cell cycle CR
Yes 2 111 113
No 15 73 88
Total 17 184 201 .0001
Abbreviations: CR, complete response; HER2, human epidermal growth
factor receptor 2; FISH, fluorescence in situ hybridization.
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Table 8. Cell Cycle CR (KI67 = 1% or less in post-treatment sample) by


















Total 26 271 297 .0001
Abbreviations: CR, complete response: HER2, human epidermal growth
factor receptor 2; FISH, fluorescence in situ hybridization.
presented preliminary data on tumor grade and have uncovered potential
differences in themorphologic response to tamoxifen and letrozole. Spe¬
cifically, letrozole seems to reduce nuclear grade to a greater extent than
tamoxifen,1' Whether these changes contribute to relative differences in
treatment-induced decrease in tumor size is unclear.
The data presented in this article serve to emphasize a need to
critically evaluate neoadjuvant endocrine therapy end points in rela¬
tion to relapse risk. The few studies that have addressed this issue do
support the notion that a neoadjuvant response, whether defined
clinically or on the basis ofKi67, does portend a better prognosis.18'19
Only when the relationships between short-term neoadjuvant out¬
comes and the risk of relapse are better understood will we be able to
incorporate information on the short-term success of neoadjuvant
endocrine therapy into planning other aspects of the adjuvant treat¬
ment plan, such as the need to administer chemotherapy or trastu-
zumab. Data on the influence ofHER2 status on the relative benefits of
tamoxifen and letrozole as adjuvant therapy in the Breast Interna¬
tionalGroup (BIG) I -98 trial are, therefore, ofconsiderable interest. A
recent preliminary report indicated that MTL2-positive status was
associated with a significantly higher relapse rate in the BIG 1-98 trial,
regardless ofwhether letrozole or tamoxifenwas used.20 This conclusion,
if consistent in further follow-up, supports the validity of the Ki67-based
predictive models presented in this article. An answer to the question of
whether letrozole maintains a therapeutic advantage in the adjuvant set¬
tingdespiteHER2 FISH-positive status (suggested by the clinical response
data) also awaits longer follow-up of the BIG 1-98 trial population.
This investigation supports the notion thatwell-designed neoad¬
juvant endocrine therapy studies could be useful to identify novel
molecular explanations for endocrine therapy resistance. The data
outlined in Table 7 suggest that the majority of cases of endocrine
resistance detected at the level ofKi67 remain unexplained because 73
(40%) of 184 ER-positive HER2-negative tumors failed to achieve a
cell cycle GR and, therefore, display some degree ofletrozole resistant-
cell cycling. The combination of candidate gene sequencing, array-
based comparative genomic hybridization, and gene expression
profiling should allow the identification of these additional causes of
endocrine therapy resistance and ultimately foster additional targeted
approaches to the problem ofendocrine therapy failure.
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Neoadjuvant endocrine therapy models.
Murray J. Miller WR. Dixon JM.
Edinburgh Breast Unit, Western General Hospital, UK.
Neoadjuvant therapy is therapy administered before surgical intervention and
while the tumor remains in the breast. It may be given to treat large, locally
advanced tumors, with the aim of shrinking them and thus making their
surgical excision either simply possible or less radical. Most neoadjuvant
therapy is chemotherapy, but adjuvant endocrine therapy is increasingly used
in hormone-sensitive tumors; for example, those responsive to tamoxifen.
Repeat biopsies aimed at assessing response to treatment—for example, by
examining estrogen receptor status or markers of proliferation in tumor
tissue—may be taken during the course of adjuvant therapy. In this chapter,
the essential protocols associated with designing neoadjuvant trials are
described, methods of assessing response to neoadjuvant therapy are
detailed, and various approaches to collecting appropriate clinical samples
and their assessment are presented.
PMID: 16491621 [PubMed - indexed for MEDLINE]
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"Yoliferation, steroid receptors and clinical/pathological response
i breast cancer treated with letrozole
WR Miller*'1, S White1, JM Dixon', J Murray', L Renshaw' and TJ Anderson'
'The Edinburgh Breast Unit, Western General Hospital, Edinburgh EH4 2XU, UK
Sixty-three postmenopausal women with large primary breast cancers were treated with neoadjuvant letrozole (2.5 mg daily) for 3
months. Tumour samples were taken at diagnosis and after 10—14 days and 3 months treatment. Immunohistochemical staining for
Ki67, oestrogen receptor (ER) and progesterone receptor (PgR) was performed and related to clinical (ClinR) and pathological
responses (PathR) after 3 months treatment. ClinR was observed in 48 of 63 cases (76.2%) and PathR in 47 of 62 (75.8%).
Pretreatment Ki67 scores were similar in responders (R) and non-responders (NR). Highly significant Ki67 decreases occurred in all
tumour subgroups at 10- 14 days (P<0.005). A significant difference in Ki67 scores at 10- 14 days (P<0.007) was found between
PathR and PathNR but not between ClinR and ClinNR. At 3 months, decreases from pretreatment Ki67 scores were highly significant
in all tumour subgroups irrespective of response status. However, whereas Ki67 scores were significantly different between
pathological R and NR (P = 0.009), the corresponding comparison of ClinR status was not Significant decreases between 10-14 days
and 3 months were found only in ClinR and PathR (P = 0.02 and 0.045, respectively). Treatment significantly reduced PgR expression
at 14 days and 3 months (both P< 0.0001), but the level of changes was not different between response status groups. In summary,
letrozole produces rapid and profound decreases in expression of Ki67 and PgR but changes do not always correlate with clinical and
pathological responses.
British Journal of Cancer advance online publication, 14 March 2006; doi; 10.1038/sj.bjc.6603001 www.bjcancer.com
© 2006 Cancer Research UK
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etrozole is a third-generation aromatase inhibitor, which in
inical trials has been shown to be highly effective in post-
tenopausal women with oestrogen receptor (ER)-positive breast
incer (Eiermann et al, 2001; Mouridsen et al, 2001; Goss et al,
003; Rose et al, 2003). Previous studies using neoadjuvant therapy
ave shown that letrozole may produce profound changes in
imour pathology and immunohistochemical markers (Dixon
t al, 2001; Ellis et al, 2001, 2003; Miller et al, 2003; Anderson et al,
004). Furthermore, it is clear that the clinical effects of
eoadjuvant treatment with third-generation aromatase inhibitors
* postmenopausal women are not dissimilar to those seen with
eoadjuvant chemotherapy (Dixon et al, 2001) and are achieved
nth less morbidity. Comparative studies have also shown that the
-ffects of third-generation aromatase inhibitors are more consis-
;nt and greater than tamoxifen on proliferation (as measured by
367) and markers of oestrogen action (progesterone receptors
PgR) and trefoil factor 1) (Ellis et al, 2003; Miller et al, 2003;
.nderson et al, 2004). It is therefore interesting that in the
eoadjuvant setting, letrozole yields significantly superior clinical
esults than tamoxifen and also appears to be more effective in
articular subgroups such as tumours with low ER levels and
verexpression of HER-2 (Ellis et al, 2001). However, the timescale
f these effects and their relationship to clinical and pathological
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response as assessed at the end of treatment has yet to be fully
defined. The aim of the present study was therefore to assess the
effects of letrozole on the proliferation marker Ki67 and receptors
for oestrogen and progesterone by immunohistochemical assess¬
ment in serial biopsies from primary breast cancers taken before,
at 10-14 days and at 3 months into treatment.
MATERIALS AND METHODS
Patients
A total of 63 postmenopausal women presented to the Edinburgh
Breast Unit with large (>3 cm) primary breast cancer, which were
ER-rich (Allred score 5-8). (However, review of the cases in the
research laboratory showed that all patients recruited to the study
had ER scores of 7 or 8.) All patients apart from 12 were technically
operable. The primary clinical objective was to downstage tumours
such that those who were inoperable became amenable for surgery
and those who would have required mastectomy could become
candidates for breast conservation. This series represents con¬
secutive patients recruited but excluding cases in which the
tumour was shown to be multifocal or of special histological type
(e.g. mucinous, tubular/cribriform and lobular). All patients gave
informed consent to be included in the study, which had been
approved by the local ethics committee (2001/W/BU/09 and 2001/
W/BU/10).
Letrozole, proliferation and response in breast cancer
WR Miller et at
Treatment
All patients received letrozole (2.5 mg, daily) for 3 months. Serial
measurements of the primary tumours were taken before, at 6
weeks and at 3 months by calliper and ultrasound as described
previously (Forouhi et al, 1994; Dixon, 2001). The tumour was also
imaged mammographically before and at 3 months. Core biopsies
were taken at the start, after 10-14 days and at 3 months of
treatment as described previously (Iqbal et al, 2002). All patients,
apart from eight patients (who electively continued on treatment),
received definitive surgery at 3 months.
Response assessment
Tumour volumes were determined from ulstrasound measure¬
ments as described by Forouhi et al (1994). Reduction in volume
over a 3 month period >50% was regarded as clinical response;
this includes both complete and partial responders.
Pathological response was determined by comparing biopsies
taken before and after 3 months of treatment. Only marked
reduction in cellularity and/or a clear increase in fibrosis were
used as evidence of pathological response. Although these changes
are essentially subjective, they were confirmed by two observers
working independently. The criteria may underestimate actual
morphological changes occurring to a lesser degree, but these were
excluded because of the difficulty in comparing histological
appearances on limited tissue such as in core biopsies with those
in the more substantial material obtained at tumour excision. No
case was classified as a complete PathR, residual evidence of
malignant cells being evident.
Immunohistochemistry
Immunohistochemistry staining with antibody to MIB1 (Ki-67)
antigen (Europath Ltd, Cornwall, UK) diluted x 50 was used as
a measure of tumour cell proliferation. Reactivity was detected by
an ABC -peroxidase-antiperoxidase (PAP) method, and scored
according to the method described by Going (1994). A change of
>40% between different paired biopsies was taken as being
meaningful (Ellis et al, 1998; Iqbal et al, 2002) and a value of <1%
was regarded as indicating a lack of proliferation.
Reactivity for ER or PgR was performed by the PAP method,
after microwave antigen retrieval, using ERa antibody clone 6fl 1/2
(Novocastra Ltd, Newcastle, UK) and PgR antibody clone PgR636
(DAKO Labs, Ely, UK) using the DAKO EnVision system
according to the manufacturer's instruction. Results were scored
on a scale of 0-3 for staining intensity (with each successive
score denoting increasing intensity), and on a score of 0-5 for
increasing proportion of positive cancer nuclei (0 = none,
1 = < 1%, 2 = 1-10%, 3=11-33%, 4 = 34-66%, 5= >66%).
The values were then summed into a category score within a
range of 0-8 (Allred et al, 1998).
Statistics
Non-parametric comparisons using either Wilcoxon rank or
Spearman paired testing was employed and, where appropriate,
3 x 2 x2 testing.
RESULTS
Clinical and pathological response
Of the 63 patients, 48 (76.2%) were classified as clinical responders
(ClinR). With regard to pathological response, one case was not
assessable because of insufficient material after biopsy at 3
months. Of the remaining 62 cases, 47 (75.8%) had clear evidence
of pathological response. Although response rates were similar,
there was not exact concordance between clinical and pathological
outcomes. Thus, 42 of 48 ClinR were also pathological responders
(PathR) (six were pathological non-responders (PathNR)) and
nine of 15 clinical non-responders (ClinNR) were also PathNR. Of
the remaining six cases, five were PathR and one case was
pathologically not assessable.
Proliferation (Ki67)
The tumour Ki67 scores for pretreatment, 10-14 days and 3
months samples, subdivided according to clinical and pathological
response status, are shown in Table 1.
No significant differences were apparent for pretreatment group
scores between responders (R) and non-responders (NR) whether
assessed clinically or pathologically. However, at 10-14 days,
whereas there was no difference between ClinR and ClinNR, the
PathNR were significantly higher than PathR (P = 0.024). Similarly
at 3 months, although there was no significant difference between
ClinR and ClinNR, values in PathNR were significantly higher than
in PathR (P = 0.009).
With regard to group changes in Ki67 with treatment, the scores
at 10-14 days and 3 months were highly significantly decreased, as
compared with those in paired pretreatment biopsies. These
changes were irrespective of clinical or pathological response
status. In terms of changes occurring between 10-14 days and 3
months, a significant decrease was seen in ClinR (P= 0.02) and
PathR (P= 0.045). However, values were not significantly different
between 10- 14 days and 3 months in ClinNR and PathNR.
Changes in Ki67 with treatment in individual tumours are
summarised in Table 2. In terms of >40% change criteria for
ClinR, 52 of 63 cases (82.5%) showed a decrease at 10-14 days,
and 53 of 63 tumours (84%) showed a reduction at 3 months.
These reductions were seen in both ClinR and ClinNR groups, and
there was no significant difference between them. However, for
pathological assessments, there was a significant difference
between PathR and PathNR at 10-14 days (P= 0.034) but not at
3 months. Treatment effects were also assessed on the basis of
reducing Ki67 scores to < 1%. It can be seen that whereas 11 cases
(17.5%) were reduced to <1% by 10-14 days, these numbers
markedly increased to 27 (42.9%) by 3 months. Whereas the
reduction to < 1% was seen in both responding and non-
responding tumours, the increase in numbers between 10-14
days and 3 months is predominantly associated with responding
tumours.
Different patterns of changes in Ki67 over the treatment period
could be detected. These are shown in Figure 1. The largest cohort
of tumours (47) showed substantial decreases at 10-14 days,
which were maintained or fell further at 3 months (in these
tumours, changes in Ki67 at 10-14 days were predictive of those at
3 months). However, there was a small cohort of five patients in
which a decrease at 10- 14 days was followed by a substantial rise
Table I Ki67 scores in tumour taken before and after 10-14 days and 3
months of treatment, subdivided according to response status
Ki67 scores (mean+ s.e.m.)
Pretreatment 10-14 days 3 months
Clinical responders (48) 14.17± 1.10 5.1 I ±0.98+ 4.l3±0.96+>
Clinical non-responders (15) 15.29 + 2.06 6.72+ 2.04+ 5.85+ 1.91*'°
P = 0.70 P= 0.77 P = 0.13
Pathological responders (47) 14.03+1.09 4.02+085+ 3.47+ 0.90+ 4 *
Pathological non-responders (15) 15.97+2.22 9.35 ± 2.22** 8.11 + 2.01 ***'°
P = 0.52 P = 0.024 P= 0.009
Compared with pretreatment tumour +P<0.000l; *P = 0.003; **P = 0.007;
***P = 0.009 Compared with tumour taken after 10-14 days of treatment
*P= 0.02; **P= 0.045: °P= NS.
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—ible 2 Changes in tumour Ki67 scores with treatment
No. of patients
Changes at 10-14 days Changes at 3 months
Decrease Decrease
Increase No change
by 40% to < 1%
Increase No change
by 40% <1%
inical responders (48) 1 6 41 (8) 0 7 41 (23)
inical non-responders (15) 1 3 1 1 (3) 1 2 12 (4)
ital 2 9 52 (II) 1 9 53 (27)
P= 0.49 P = 0.20
thology responders (47) 1 4 42 (9) 0 6 41 (23)
thology non-responders (15) 1 5 9 (2) 1 3 1 1 (3)
xtal 2 9 51 (II) 1 9 52 (26)
P= 0.034 P = 0.15





■igure I Tumour Ki67 scores before and after 10-14 days and 3 months treatment with letrozole. (A) Cases that show decreases (>40%) at both 10-
4 days and 3 months. (B) Cases that show decreases (> 40%) at 10-14 days but not at 3 months. (C) Cases that show no change at 10-14 days but a
ecrease (>40%) at 3 months. (D) Cases that show no decrease at either 10-14 days or 3 months.






l score at 3 months (in these tumours, changes in Ki67 at 10-14
ays did not therefore concur with those at 3 months). Of the 11
hat did not decrease at 10-14 days, six decreased at 3 months
Ki67 changes therefore did not concur at 10-14 days and 3
nonths) and five were not reduced at 3 months (lack of change in
li67 at 10-14 days was predictive of no change at 3 months),
hese patterns of Ki67 did not correlate with ClinR and PathR
ihenotype (Figure 2).
'rogesterone receptors
)f the 63 cases, 57 (90%) were PgR + ve; of the six negatives, five
/ere ClinR and four were PathR. The changes with treatment of
PgR staining subdivided according to ClinR and PathR status are
summarised in Table 3.
Treatment reduced PgR scores such that, at 10- 14 days, values
were significantly lower than those in the paired pretreatment
biopsy (P<0.0001). This decrease was found in all tumour
subgroups irrespective of clinical or pathological assessment
status. Similar highly statistically significant decreases were also
seen when pretreatment values were compared with corresponding
pairs at 3 months (PcO.0001). Of note is the high proportion of
positive tumours that decreased to 0 by 10-14 days (45.6%). This
percentage rose to 66.7% at 3 months. A comparison of 10- to 14-
day biopsies with those at 3 months showed significant decreases
with extended treatment with the groups of ClinR and PathR,
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(but this represents a small number of pairs). In terms of
comparisons between tumours R or NR assessed either clinically
or pathologically, no significant differences were detected either at
pretreatment, 10- 14 days or 3 months in absolute values (data not
shown).
Oestrogen receptors
There was no significant difference in ER score pretreatment, after
10-14 days and after 3 months. Neither was there a significant
change with treatment with all biopsies scoring 7 or 8 throughout
(data not shown).
DISCUSSION
The observation that neoadjuvant treatment with letrozole is
associated with a marked reduction in the immunohistochemical
expression of Ki67 and PgR confirms our previous findings (Miller
et al, 2003; Anderson et al, 2004) and those of others (Ellis et al,
2001, 2003). However, the present study extends our previous work
by demonstrating that such effects are evident as early as 10-14
10-14 days 3 months
Cases I >3)
No change/increase ► No change/increase
11 5
CR/PR 5 \ CR/PR 2
CNR/PNR 4 \ CNR/PNR 2
CR/PNR 2 \ CR/PNR 1












CR/PR 37 CNR/PR 1
CNR/PNR 5
CR/PNR 4 Decrease/no change
CNR/PR 5 47





Figure 2 Flow diagram indicating number of cases grouped according to
Ki67 changes at I0-I4 days and 3 months and further subdivided
according to final clinical/pathological response.
days into treatment in over 80% of cases. Similar results have
recently been presented for anastrozole (Dowsett et al, 2005a, b).
The same group have also presented results from a randomised
neoadjuvant trial comparing the aromatase inhibitor vorozole with
tamoxifen. Ki67 levels fell within 2 weeks of treatment and
remained suppressed at surgery 3 months later (Harper-Wynne
et al, 2002). These effects are therefore apparent before evidence of
morphological changes in tumour pathology and clinical evidence
of changes in tumour volume. It was of interest in the present
paper to determine whether changes in proliferation and PgR
expression related to and/or predicted for subsequent ClinR and
PathR.
In terms of assessing proliferation status with Ki-67 scores, we
have analysed results in three ways: (i) comparison of tumour
scores at individual time points grouped according to response
status at 3 months, (ii) classifying a >40% change in Ki-67
between different time points as evidence of a meaningful change
in proliferation and (iii) comparing the number of cases in which
proliferation is reduced to < 1%, a value that we have regarded as a
state of virtual non-proliferation. By using these multiple analyses,
we hoped to derive impressions not only of group trends but
effects and degree in individual cases.
Group comparisons of mean Ki-67 scores at individual study
time points revealed interesting differences according to whether
response was assessed clinically or pathologically. Thus, the only
detectable significant differences were in groups subdivided by
pathological assessment in which higher mean scores were found
in non-responding tumours at both 10-14 days and 3 months.
Interestingly, the same general pattern was evident when
categorising individual cases according to >40% reduction (the
only significant difference was seen between PathR and PathNR at
10-14 days). The restriction of significant effects to pathological
assessment probably reflects the closer association between two
histological assessments rather than that between histology and
tumour size. It is also worth noting that the tumour morphology
after treatment will be determined by factors in addition to
proliferation, such as cell loss. In this respect, although Ki67 is a
primary marker of proliferation, it can also be a secondary
reflection of cell death (Archer et al, 2003).
A reduction of >40% in Ki-67 was apparent in most cases at
10-14 days, and extended treatment to 3 months was associated
with only minor changes in the proportion of tumours that
displayed a > 40% decrease in proliferation. This is in contrast to
the results based upon the more profound criteria of a decrease to
an absolute value of <1%. These results show that, remarkably,
even after 10-14 days of treatment, 17% of tumours have reached
this state of virtual non-proliferation, and this was irrespective of
whether tumours subsequently displayed evidence of clinical or
pathological response. However, the proportion of cases falling
to <1% proliferation increases further to 43% by 3 months.
Interestingly, this incremental effect with time appears restricted
to those tumours that had either a pathological or clinical response
Table 3 Changes in tumour PgR score with treatment
No. of patients
Changes at 10 - 14 days Changes at 3 months
Increase No change Decrease (Decrease to 0) Increase No change Decrease (Decrease to 0)
Clinical responders (48) I 1 1 36 (18) 0 9 39 (29)
Clinical noo-responders (15) 0 2 13 (8) 0 2 13 (9)
Pathology responders (47) I 11 35 (16) 0 9 38 (26)
Pathology non-responders (15) 0 2 13 (9) 0 2 13 (ID
PgR= progesterone receptor.
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itus at 3 months. It is clear that letrozole is capable of producing
creased suppression of proliferation when used over an extended
•riod.
The overall perspective therefore is that letrozole is capable of
oducing a rapid reduction in tumour proliferation that is seen in
ost tumours irrespective of subsequent clinical and pathological
sponse, but that incremental effects on proliferation (as
onitored by scores of < 1%) are additionally seen in the period
itween 10-14 days and 3 months, and these are largely restricted
PathR or ClinR.
Whereas changes in Ki-67 levels have been revealed by group
imparisons, the strength of neoadjuvant studies is that it is
jssible to examine differences in individual cases and classify
mours according to sequential changes in proliferation. Thus,
insistent with the general trends discussed above, most tumours
splayed a substantial decrease in proliferation >40% by 10-14
lys and this was sustained at 3 months. However, it was also
xssible to identify (i) a small cohort that initially had decreased
'oliferation at 10-14 days but which largely disappeared by 3
onths, (ii) tumours that failed to demonstrate a decrease in
oliferation at 10-14 days but had a delayed decrease apparent
3 months and (iii) cases that failed to display a decrease in
•oliferation at both 10-14 days and 3 months. It is therefore
iportant not only to discuss relationships between clinical/
ithological response and proliferation at individual time points,
it also to take into account the patterns of change in response to
eatment.
Statistically significant differences were detected between PathR
id PathNR in (i) group levels of Ki67 at 10-14 days and (ii) the
roportion of cases decreasing in Ki67 >40% between pretreat-
lent and 10-14 days. However, there was a large overlap in values
10-14 days between PathR and PathNR, and individual tumours
)uld display an increase, no change or a decrease in Ki67
respective of being PathR or PathNR. Consequently, measure-
lents of Ki67 in individual cases do not accurately predict for
lbsequent pathological (or clinical) response. A similar lack of
rediction between Ki67 changes and clinical response to
nastrozole has been observed in the recently reported IMPACT
eoadjuvant trial (Dowsett et al, 2005a) (although the short-term
-hanges in proliferation did parallel recurrence-free survival
etween the three treatment groups, anastrozole, tamoxifen and
rimidex combined with tamoxifen) (Dowsett et al, 2005b). As a
onsequence, consideration therefore needs to be given as to why
lear decreases in cellular proliferation at 10-14 days do not
anslate into pathological response and why conversely respond-
tg cases can show no change or even an increase in Ki67 with
•eatment.
It is possible that lack of correlation in some cases relates in part
a imprecise measurements of proliferation or misclassification of
esponse. In terms of immunohistochemical assessment of Ki67,
re have already published data on reproducibility in breast cancer
biopsies (Iqbal et al, 2002). These showed that, because of inherent
eterogeneity, marked variation in Ki67 score may be observed in
he same tumour without intervening treatment. However, this is
estricted to occasional tumours, and the number of cases in the
'resent study with discordance between proliferation changes and
linical/pathological response is greater than would have been
xpected. Furthermore, in order to reduce spurious results, we
lave used three different criteria for assessing changes in Ki67. In
erms of the impact of assessment of clinical response, potential
ources of inconsistencies have been considered elsewhere and
•ary according to the technology employed (Forouhi et al, 1994).
n the present studies, clinical responses were based primarily
ipon ultrasound measurements, but they were substantiated by
larallel calliper and mammographic measurements in all cases,
'or ease of presentation, clinical response was dichotomised and it
s possible that the use of continuous variables might have been
nore informative. However, preliminary analyses using conti-
S 2006 Cancer Research UK
nuous variables did not reveal better relationships between
proliferation and response (data not shown). There are also
limitations to the assessment of pathological response in that the
pretreatment assessments (and some of the post-treatment) were
performed on core biopsies, which are not guaranteed to be
representative of the total tumour mass. It is also possible that
assessment of ClinR/PathR at the single time point of 3 months is
associated with chronological inaccuracy in that certain tumours
classified as NR may go on to respond with extended treatment
(Dixon et al, 2005). There is no doubt that response is not
complete by 3 months and treatment up to 12 months may be
associated with (a) further tumour shrinkage and (b) an increased
incidence of complete ClinR.
Although methodological imprecision might be influential in
some cases, it is unlikely that these totally account for the lack of
association between proliferation and response. Other reasons
need to be considered including the possibility that reduction in
proliferation alone may not produce tumour shrinkage and cell
death or apoptosis may be equally influential. Although we have
not measured apoptosis in tumour samples from the present
study (because assessment in core biopsies was not sufficiently
reproducible), we did not find apoptosis to be predictive of
response in other tumour samples from patients offered neoadju¬
vant endocrine therapy (Anderson et al, 2002). However, this may
be because differences are small and transient; primary effects on
apoptosis may also be masked by those occurring secondarily (e.g.
as a result of decreased proliferation).
Another cause for a reduction in proliferation at 10-14 days not
translating into subsequent tumour response could be that the
effect is transient and not maintained over a sufficiently extended
period to produce tumour shrinkage. However, in the present
study, four of the five non-responding tumours with a reduction in
Ki67 had a sustained decrease in proliferation to 3 months. A
disconnect between changes in proliferation as observed at 10-14
days with subsequent clinical/pathological response could also be
explained if the proliferation response was delayed. Interestingly,
six of 11 tumours showed a delayed reduction in Ki67 scores; three
of these were classified as PathR/ClinR.
It is worth noting that in 11 of 63 (17%) cases, change in
proliferation at 10-14 days failed to predict that at 3 months.
Furthermore, most importantly, change in proliferation at 10-14
days failed to predict clinical response in 18 out of 63 (29%) cases
and pathological response in 14 out of 62 (23%) tumours. Change
in proliferation at 10-14 days is therefore not an accurate
surrogate of clinical/pathological response at 3 months.
The other marker that showed major changes with therapy was
PgR. Thus, 78% of cases displayed a reduction of at least 1 category
score by 10-14 days and was maintained to 3 months. Reduction
occurred irrespective of subsequent clinical/pathological response.
The extent of effect may be gauged by the percentage of cases
reduced to negativity (40% at 10-14 days and 60% at 3 months);
again the decrease to negativity was irrespective of clinical or
pathological response. As PgR is a marker of signalling from the
ER, these changes are clear evidence of the anti-oestrogenic effects
of letrozole and contrast with those of tamoxifen (Anderson et al,
2002; Miller et al, 2003).
Although we have not formally presented the correlations
between changes in PgR and proliferation, there was a positive
relationship between them. However, there were instances of
discordance whereby at both 10-14 days and 3 months, tumours
displayed either a phenotype of reduced proliferation but stable
PgR or unchanged proliferation and reduced PgR. As reduced PgR
expression is a marker of oestrogen deprivation, it is unlikely that
the lack of effect on Ki67/ClinR/PathR in these cases is because
of lack of aromatase inhibition. Hence, changes in PgR with
treatment, although marked and occurring early, are not predictive
of clinical or pathological response. It was also of interest to
examine changes in PgR score in tumours that initially displayed a
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decrease in Ki67 at 10-14 days but an increase at 3 months. This
phenotype could reflect adaptive changes leading to an oestrogenic
stimulation or a state of hypersensitivity to oestrogen (Santen et al,
2004); however, changes in PgR in this cohort of five tumours with
this phenotype revealed three cases that decreased between 10-14
days and 3 months and two cases that were negative at all time
points, providing no evidence for adaptive changes or hypersensi¬
tivity to a reduced oestrogenic environment.
In conclusion, the present study has provided evidence that
neoadjuvant letrozole produces marked effects on levels of Ki67
and PgR within 10-14 days. Although early changes in prolifera¬
tion are less likely to occur in tumours that show no pathological
response at 3 months, the effects can be seen irrespective of clinical
and/or pathological response in individual cases. Ki67 scores and
PgR expression are therefore of limited value as predictors of
response. They do however reflect the potent anti-oestrogenic and
anti-proliferative properties of the third-generation aromatase
inhibitors and it has been suggested that such changes may relate
to long-term outcome (Ellis et al, 2003; Dowsett et al, 2005b).
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Abstract
Marked cellular and molecular changes may occur in breast cancers following treatment of postmenopausal breast cancer patients with
aromatase inhibitors. Neoadjuvant protocols, in which treatment is given with the primary tumour still within the breast, are particularly
illuminating. In Edinburgh, we have shown that 3 months treatment with either anastrozole, exemestane or letrozole produces pathological
responses in the majority of oestrogen receptor (ER)-rich tumours (39/59) as manifested by reduced cellularity/increased fibrosis. Changes
in histological grading may also take place, most notably a reduction in mitotic figures. This probably reflects an influence on proliferation
as most tumours (82%) show a marked decrease in the proliferation marker, Ki67. These effects are generally more dramatic than seen
with tamoxifen given in the same setting. Differences between aromatase inhibitors and tamoxifen are also apparent in changes in steroid
hormone expression. Thus, immuno-staining for progesterone receptor (PgR) is reduced in almost all cases by aromatase inhibitors, becoming
undetectable in many. This contrasts with effects of tamoxifen in which themost common change on PgR is to increase expression. Changes in
proliferation occur rapidly following the onset of exposure to aromatase inhibitors. Thus, neoadjuvant studies with letrozole in which tumour
was sampled before and after 14 days and 3 months treatment show that decreased expression ofKi67 occur at 14 days and, in many cases,
the effect is greater at 14 days than 3 months. These early changes precede evidence of clinical response but do not predict for it. However,
this study design has allowed RNA analysis of sequential biopsies taken during the neoadjuvant therapy. Based on clustering techniques, it
has been possible to subdivide tumours into groups showing distinct patterns ofmolecular changes. These changes in tumour gene expression
may allow definition of tumour cohorts with differing sensitivity to aromatase inhibitors and permit early recognition of response and
resistance.
<£> 2005 Elsevier Ltd. All rights reserved.
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1. Introduction
Recently, a new generation of inhibitors have been devel¬
oped which block the aromatase enzyme with immense
potency and exquisite specificity [1-7]. Consequently, they
suppress aromatase activity and endogenous oestrogen levels
in postmenopausal women more effectively than ever before.
In translating these endocrine influences into cellular and
molecular effects, many of the data presented in this review
are derived from patients given neoadjuvant treatment during
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which aromatase inhibitors are given with the primary tumour
within the breast. This form of therapy can provide clinical
benefits in that patients with large tumours may have these
down-staged following successful therapy and the knowledge
of (non-) response of the primary tumour may be useful in
planning treatment in the adjuvant setting. However, there are
also major advantages of using neoadjuvant protocols in the
research setting. Because the primary tumour is available for
measurement, accurate assessment of response is possible.
These measurements may be correlated with putative biolog¬
ical markers in a pre-treatment biopsy of the same tumour.
Additionally, since most patients come to definitive surgery,
effects of treatment may be monitored by serial samples of
individual tumours [8],
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2. Materials and methods
2.1. Patientsfor neoadjuvant therapy
Postmenopausal patients with large (>3 cm) oestrogen
receptor-positive (>20fmol/mg cytosol protein or Allred
score 5-8) primary breast cancers (staged as T2, T3, T^,
No or N1, Mo) have been entered into a series of studies with
different endocrine agents. None had received prior treat¬
ment with hormonal agents for breast cancer or were taking
hormone preparations at the time of study. Tumour size was
monitored clinically (by callipers) and by breast ultrasound
before and at monthly intervals during treatment. All patients
received primary endocrine therapy comprising either letro-
zole (2.5 or 10 mg daily) or anastrozole (1 or lOmg daily) or
exemestane (25 mg daily) or tamoxifen (20mg daily).
2.2. Clinical response
Clinical response was based on change in tumour volume
taken at monthly intervals over the treatment period. Ultra¬
sound measurement of three orthogonal tumour diameters
produced an estimate of tumour volume [9]. Reductions in
tumour volume >25% were regarded as evidence of tumour
response, those >50% were categorised as major response.
2.3. Pathological response
Sections of the same tumours from pre-treatment and final
biopsies were assessed for changes in cellularity and degree
offibrosis. Pathologic response was categorised as: complete
when there was no evidence ofmalignant cells at the original
tumour site, microscopic residual when only scattered foci
of malignant cells were identified microscopically, partial
response when clear decreases in cellularity and/or increases
in fibrosis were seen, or no change. The same specimens were
evaluated independently for mitotic score [10].
2.4. Immunohistochemistry (IHC)
IHC staining with antibody to Ki67 (MIB1 antigen, Dako-
Cytomation, England) was used as a measure of tumour
cell proliferation. Reactivity was detected by an ABC-
peroxidase-antiperoxidase (PAP) method and the percentage
of cells staining in a minimum of 10 representative high-
power microscope fields was used to quantify expression
[11]. Reactivity for oestrogen receptor (ER) or progesterone
receptor (PgR) was performed by the PAP method, after
microwave antigen retrieval, using antibodies clone 6F11
(NovaCastra, England) and clone PGR636 (DakoCytoma-
tion, England), respectively, according to the manufacturers'
instructions and diaminobenzidine was used as the chro-
mogen. Results were scored on a scale of 0-3 for staining
intensity (with each successive score denoting increasing
intensity) and on a score of 0-5 for increasing proportion
of positive cancer nuclei (0 = none, 1 = <1%, 2=1-10%,
3 = 11-33%, 4 = 34—66% and 5 =>66%). The values were
then summed into a category score within a range of 0-8
[12], Scores were independently performed by two observers;
divergence scores were resolved by mutual agreement after
joint examination of the sections.
Clinical responses were analyzed using Fisher's Exact
Test. Differences in tumour histopathological parameters
were compared statistically using the Chi-square (x2) for
trend or Wilcoxon rank tests.
2.5. Oligonucleotide arrays
RNA was extracted from tumour biopsies, amplified and
subjected to microarray analysis on Affymetrix chips. Data
were analyzed and dendrograms derived. All samples were
clustered using hierarchical clustering and Euclidean dis¬
tances. In order to reduce noise from non-expressed genes,
pair-wise differences between samples were derived based
on only the present genes (according to Affymetrix' absolute
call values). For each individual gene, relative expression was
compared in pre-treatment and 10-14 days biopsies in eight
patients offered neoadjuvant therapy with letrozole.
3. Results
3.1. Histopathological changes
Letrozole, anastrozole and exemestane were all capable of
producing marked changes in tumourmorphology. Patholog¬
ical responses were detected in 66% of tumours treated with
the aromatase inhibitors (Table 1). Although in most cases
these responses comprised decreased cellularity/increased
fibrosis, in a minority of tumours (11%) only microscopic
foci of residual disease were evident after 3 months treat¬
ment [13], Complete pathological responses were rarely seen
within 3 months treatment, with only one recorded case in a
patient treated with letrozole.
Changes in histological grade often accompanied treat¬
ment; these usually resulted in a lower score and have been
reported elsewhere [13,14]. The grading feature most com¬
monly affectedwasmitotic score and changes associatedwith
letrozole are summarized in Table 2. Thus, 12 of 23 (52%)
tumours showed a marked reduction in mitosis. Interestingly,
in a similar group ofpatients treated over the same time period
with tamoxifen, the incidence of decrease was substantially
less (17% or 4/24).
Table 1
Pathological responses following neoadjuvant treatment with aromatase
inhibitors (letrozole n = 24, anastrozole « = 23, exemestane n — 12)
Complete 1
Minimal residual disease 6
Reduced cellularity 32
No change 20 (34%)
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Table 2
Changes in mitotic scores following 3 months treatment with either letrozole
or tamoxifen
Decrease No change Increase
Letrozole 12 10 1
Tamoxifen 4 18 2
p = 0.018 by Chi-squared test for trend.
Table 3
Changes in progesterone receptor expression following neoadjuvant treat¬
ment with aromatase inhibitors (letrozole, anastrozole, exemestane) or
tamoxifen
Decrease No change Increase
Aromatase inhibitor 46 3 1
Tamoxifen 12 13 25
p = 0.008 by Chi-squared text for trend.
3.2. Immunohistochemistry
The progesterone receptor is regarded as a classicalmarker
ofoestrogenic activity, the protein being expressed as a result
ofoestrogen actionmediated by a functional oestrogen recep¬
tor. The effect of aromatase inhibitor treatment for 3 months
on 50 PgR-positive breast cancers is shown in Table 3 and
an illustrative example is shown in Fig. 1. Thus, over 80%
of these tumours displayed a marked decrease in staining
with therapy and, in about one half of cases, the reduction
was to 0. Decreases in staining with treatment were irrespec¬
tive of the type of inhibitor and pathological response (data
not shown). In a small series ofPgR-positive cancers treated
with tamoxifen, a different pattern of change was seen. Thus,
only 17% of cases showed a decrease and the most common
changewas aparadoxical increase in staining. Changes in pat¬
tern of staining were irrespective of clinical or pathological
response [13,14], The changes in pattern of PgR expression
with tamoxifen were significantly different from aromatase
inhibitor treatment (x2 =23.67; /?<0.0001).
The effects ofaromatase inhibitors have also been studied
on proliferation by using immunohistochemical staining of
the marker Ki67. These results are summarized in Table 4 and
an illustrative example is shown in Fig. 2. Treatmentwith AIs
was associated with amarked decrease in expression (median
decrease 94% in 84% of cases). These effects were irrespec¬
tive of the type of inhibitor and generally more pronounced
than those seen in a matched group of tumours treated with
tamoxifen in which, although decreases in proliferation were
frequently seen, the incidence and degree of effect was less.
In order to determine the timescale of effects on prolifera¬
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Fig. 1. Progesterone receptor staining of the same tumour before (left) and after (right) treatment with exemestane, showing a major reduction in staining after
treatment (original magnification x200 upper panels, x500 lower panels).
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Table 4
Changes in proliferation as measured by Ki67 staining following neoadju¬
vant treatmentwith aromatase inhibitors (letrozole, anastrozole, exemestane)
or tamoxifen
Decrease
Cases (%) Score (%)
Aromatase inhibitor (115) 94 74
Tamoxifen (22) 82 51
The difference between aromatase inhibitors and tamoxifen did not reach sta¬
tistical significance (p = 0.07 by Fisher's Exact Test for % cases andp = 0.08
by Wilcoxon rank test for % score).
biopsies were taken before and after 10-14 days and 3 months
treatment with letrozole. Of 59 cases, 57 tumours showed a
clear decrease in Ki67 staining after 10-14 days of therapy.
This decrease was maintained or became even greater by 3
months in 48 cases; in the remaining 9 tumours, the scor¬
ing increased (in many cases to levels equivalent or higher
than pre-treatment values). In the 2 tumours which did not
show a decrease at 10-14 days, there were small decreases
at 3 months but the values were still amongst the highest on
treatment.
In order to discover novel candidate genes whose expres¬
sion might be associated or change with response to aro¬
matase inhibitors, tumour biopsies were sequentially taken
before and after 10-14 days and 3 months of treatment.
These were extracted and the mRNA converted to cDNA
and amplified before being subjected to micro-analysis on
Affymetrix chips. Microarray analysis of pairs of tumour
cores taken before and after 10-14 days of letrozole treat¬
ment were compared as shown in Fig. 3 which illustrates the
computer generated display for gene changes in 24 tumours.
It can be seen that gene changes differ in every single tumour,
indicating that there is no single gene signature for response
to letrozole. However, there was the suggestion that tumours
could be grouped according to amount and incidence of
change. Thus, clustering indicated that the cancers could be
grouped into 17 cases with greater gene change (left-hand
side of the figure) and 7 with lesser changes (right of figure).
It remains to determine whether this subdivision relates to
clinical/pathological response. Further clustering based on
a larger number of tumours (43) is shown in Fig. 4. This
suggests that the tumours may be divided into at least four
distinct groups of which two may be subdivided further.
4. Discussion
The neoadjuvant setting has proved to be invaluable
in terms of elucidating cellular and molecular effects of
aromatase inhibitors and evaluating predictive indices of
response. Marked changes in tumourmorphology and histol¬
ogy may follow the administration of aromatase inhibitors.
In ER-rich tumours, effects on histopathological features
include changes in cellularity, degree of fibrosis, histolog¬
ical grading features, markers of proliferation and cell death
and hormone receptor expression [13,14], Gross changes
in tumour morphology may be seen in the majority of
breast cancer by 3 months irrespective of the particular
inhibitor. Although these effects are striking, unlike with
chemotherapy, these rarely are complete and, at best, micro¬
scopic foci of disease remain. Whether with extended treat¬
ment more complete remissions would be obtained is still
Fig. 2. MIB1 staining of the same tumour before (left) and after (right) 3 months of treatment with letrozole, showing a major reduction in staining after
treatment (original magnification x200).
W.R. Miller el at. /Journal ofSteroid Biochemistry & Molecular Biology 95 (2005) 83-89 87
Fig. 3. Microarray analysis of tumour biopsies taken before and after 10-14 days neoadjuvant treatment with letrozole in 24 different patients. Diagrammatic
representation ofchanges in selected cohorts ofgenes (yellow represents no change in expression and red change in expression (either an increase or a decrease),
degree of change is represented by intensity of redness). Tumours are arranged by hierarchical clustering.
a matter of conjecture. Down-staging of histological grade
often accompanies gross morphological changes. With aro-
matase inhibitors, the particular histological feature most
often affected was mitotic figures, scores decreasing in
the majority of cases. These changes are in keeping with
those observed on the proliferation marker, Ki67, which is
markedly decreased in 90% of cases after 3 months treat¬
ment with an aromatase inhibitor. The higher incidence
of effect is probably because mitotic figures are relatively
transient events, whereas Ki67 detects cells not only in
the process of division but those recently completing the
process.
Interestingly, the influence of tamoxifen on mitotic and
Ki67 scores are less marked (whereas the effects on other
features of tumour histological grade such as tubule forma¬
tion appear greater) [13]. This probably reflects differences
in mechanism of action but differences in the timing or
duration of effects cannot be discounted. In this respect, it
was of interest to investigate changes occurring with time.
To do this, a neoadjuvant protocol was adopted in which
sequential biopsies were taken before and after 10-14 days
and 3 months of treatment with letrozole. These results show
that in almost all ER-rich tumours, marked decreases in pro¬
liferation may be seen within days of the onset of treatment.
With more extended treatment, proliferation continued to
decrease or was maintained in the majority. However, in
a subset of tumours, proliferation returned to or exceeded
pre-treatment levels. These patterns ofchange have also been
reported for anastrozole [15], We also have demonstrated
that paradoxical lack of change or an increase in proliferation
in tumours responding to tamoxifen is associated with early
recurrence following primary surgical management [16].
These paradoxical changes in proliferation may therefore
represent early evidence ofresistance to treatment. Follow-up
data subsequent to surgery are not yet available in the cohort
of patients treated with letrozole, but clinical and pathology
responses at 3 months have been assessed. Tumours failing
to show differences in Ki67 staining at either 10-14 days or
3 months still demonstrate substantial reductions in tumour
size with treatment. Conversely, reductions in proliferation
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Fig. 4. Hierarchical clustering of changes in gene expression in tumour biopsies taken before and after 10-14 days of neoadjuvant treatment with letrozole in
43 patients. The same dendrograms are plotted vertically and horizontally to produce squares. Colour represents similarity of change in expression with the
greatest intensity representing the highest degree of concordance.
did not always translate in clinical response. Clearly, other
factors beyond proliferation influence clinical response and
change in Ki67 is a poor surrogate for clinical response
and other changes in tumour pathology (the reduction in
proliferation index in pathological responders to letrozole
has been reported to be significantly greater than in those
without evidence of response).
Additionally, immunohistochemical staining for proges¬
terone receptors showed that aromatase inhibitors produced
marked reduction in the expression of progesterone receptor
and, in many cases, staining was not detectable following
treatment. These observations would be consistent with
oestrogen deprivation and contrast with the effect of tamox¬
ifen which often increased PgR expression [16-20]. Similar
effects have been noted on the expression of other oestrogen-
regulated markers such as pS2 [21], Interestingly, loss of
PgR expression occurred independently of pathological
response [13],
The use of microarray technology has great potential in
identifying novel genes which predict for response or are
early markers of response but this has yet to make a major
impact. However, the technology has not been used tomonitor
gene changes in substantial cohorts of patients treated with
aromatase inhibitors. To this end, we have studied patients
treated neoadjuvantly with letrozole and examined expres¬
sion changes occurring at 10-14 days. To put the effects
into perspective, it is worth noting that 22,283 gene sets are
expressed on the Affymetrix chip used and that on average
11,456 were expressed in the 59 cases included in the study.
Of these, only a single gene was changed by >two-fold in all
59 tumours with treatment. This reflects the observation that
every tumour was an individual with regard to a genetic sig¬
nature change with treatment. This is despite not all tumours
responding to treatment. At this time, while molecular clus¬
tering analysis is underway, clinical and pathology responses
in individual tumours are currently blinded to the investi¬
gators. However, as an exercise, it was of interest to look
at the pattern of gene changes occurring in at least 50%
of tumours (to take account of the expected incidence of
response). Interestingly, only 4 genes showed >2-fold change
(all decreases) in expression in more than 30 tumours whereas
181 showed a decrease and 334 an increase if the cut-offwas
relaxed to > 1.2-fold. Nevertheless, it was possible to identify
by cluster analysis distinct groups of tumours with partic¬
ular genetic changes with letrozole treatment. It remains to
determine whether the data relating to microarray analysis
correlate with clinical and pathological response. These anal¬
yses are underway. These may permit the early recognition of
response/resistance to aromatase inhibitors and help optimize
patient management.
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5. Summary
In hormone sensitive breast cancer, aromatase inhibitors
may produce marked changes in tumour morphology and
rapid and dramatic reduction in the expression ofmarkers of
proliferation and oestrogen action. Furthermore, microarray
analysis may subdivide tumours into distinct groups accord¬
ing to molecular changes.
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Abstract
There are important surgical issues related to the use of the third generation aromatase inhibitors in both the neoadjuvant and adjuvant
settings. Neoadjuvant hormone therapy is effective at downstaging tumours, particularly large tumours initially thought to be inoperable or
requiring mastectomy. Randomised trials have shown that the newer aromatase inhibitors letrozole and anastrozole increase the numbers of
women who are suitable for breast-conservation compared with tamoxifen, and that letrozole is superior to tamoxifen in terms of clinical
response.
Aromatase inhibitors are most effective in ER-rich tumours and are clinically and biologically effective in both HER2 positive and negative
tumours, whereas HER2 positive tumours show a level of resistance to tamoxifen.
In neoadjuvant studies comparing aromatase inhibitors with tamoxifen, the duration ofuse has been 3-4months, by which time any response
is usually evident but longer treatment periods produce continued shrinkage and response. The re-excision rate following breast conservation
surgery after neoadjuvant hormone therapy is favourable compared with the rates following immediate wide local excision. Local recurrence
rates are acceptable in patients undergoing neoadjuvant therapy and breast-conserving surgery providing post-operative radiotherapy is given.
Adjuvant aromatase inhibitors, as well as having an effect on metastatic disease and survival, reduce local and regional recurrence.
© 2005 Elsevier Ltd. All rights reserved.
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1. Introduction
There are important surgical issues related to the use
of the new generation of aromatase inhibitors in both the
neoadjuvant and adjuvant settings. Large operable and locally
advanced breast cancers continue to be common despite the
introduction of breast screening programmes [1]. Neoad¬
juvant (pre-operative or primary) systemic chemotherapy
often results in locally advanced and unresectable primary
breast tumours becoming operable [2,3]. Neoadjuvant hor¬
mone therapy has also been used more recently to shrink
large operable breast cancers that would normally require
mastectomy allowing them subsequently to be treated with
breast-conserving surgery [4-14]. When breast-conserving
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* Corresponding author. Tel.: +44 131 537 2907; fax: +44 131 537 2653.
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surgery is feasible for a patient, neoadjuvant therapy may
allow a less extensive resection and so improve the final cos¬
metic outcome.
Selecting which patients will benefit and the optimal agent
in this setting has been addressed in a number ofstudies com¬
paring tamoxifen and aromatase inhibitors. What is not clear
is how long patients should receive neoadjuvant hormone
therapy before operation. Most studies have treated patients
for 3-4 months and have reported high rates of conversion
frommastectomy to breast conserving surgery. There remains
as yet little data on the rates of complete excision and local
recurrence after down staging with neoadjuvant endocrine
therapy.
Randomised trials of aromatase inhibitors in both the
adjuvant and extended adjuvant settings have shown that
these agents reduce local recurrence after eithermastectomy
or breast conserving surgery and reduce the rate of new
breast primary cancers in both the treated and contra-lateral
breast [15,16], This is important both for the patient and sur-
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geon because it reduces the need for surgical intervention in
patients who are usually otherwise well and have no clinical
evidence of systemic metastases.
2. Selection for treatment
Patients selected for neoadjuvant treatment need to poten¬
tially gain benefit from therapy. Eligible patient groups are
outlined in Table 1. The greatest experience with neoadju¬
vant endocrine therapy has been in postmenopausal women
initiallywith tamoxifen but more recently with the third gen¬
eration aromatase inhibitors.
3. Selecting the optimal agent to use in neoadjuvant
endocrine setting
Four randomized trials comparing tamoxifen and the
newer aromatase inhibitors have been performed. The first
randomised trial (P024) compared 4 months of neoadjuvant
treatment with either letrozole or tamoxifen in 324 post¬
menopausal women with ER+ and/or PgR+ breast cancer.
Evaluation of all patients indicated that letrozole achieved
a significantly higher clinical response rate than tamoxifen
(55% versus 36%; /><0.001), enabling significantly more
letrozole-treated patients than tamoxifen-treated patients
to undergo breast-conserving surgery (45% versus 35%;
/>=0.022) (Fig. 1) [6]. In this study, even in patients with
locally advanced breast cancer significantly more patients
treated by letrozole were eligible for breast conserving
surgery (Fig. 2).
The second neoadjuvant study, designated IMPACT
(immediate pre-operative arimidex compared to tamoxifen)
compared anastrozole (1 mg daily) versus tamoxifen (20mg
daily) versus anastrozole plus tamoxifen [7]. This was a mul¬
ticentre, randomised, double-blind trial, with 330 patients.
Patients were postmenopausal, with ER+ and/or PgR+ breast
cancer that was large and operable (T2 or T3, N0-2, MO)
Table 1
Selection of patients for Neoadjuvant therapy based on likely benefit
Patients who will benefit
Locally advanced breast cancer who may become operable
Large operable tumours
Converting from mastectomy to breast-conserving surgery
Improving cosmetic outcome of patients with larger cancers
suitable for conserving surgery
Patients who are unlikely to benefit
Those who have operable disease but have multiple tumours who will
require mastectomy regardless ofpre-operative treatment success
Those who have tumours that respond very slowly or indiscernibly to
treatment, such as many of the invasive lobular carcinomas
Those with tumours where a reduction in tumour volume is not
achievable within a reasonable time period, such as invasive
mucinous carcinomas





Fig. 1. Rates of conversion to breast conservation in P024 study comparing
4 months of neoadjuvant letrozole and tamoxifen and IMPACT study com¬
paring 3 months of neoadjuvant anastrozole alone, tamoxifen alone, or the
two agents combined.
or potentially operable, locally advanced (T4b, NO-2, M0).
Treatment was for 3 months prior to surgery. Results pre¬
sented at San Antonio in 2003 demonstrated that although
there was no difference in response rates between groups
(using both ultrasound and caliper measurements, there was
a higher rate of conversion of patients from mastectomy to
breast-conserving surgery with anastrozole. Out of the 124
patients deemed by the surgeon to be suitable for a mastec¬
tomy at baseline, 45.7%, 22.2% and 26.2% in the Anastro¬
zole, Tamoxifen and Combined groups, respectively, became
eligible for breast-conserving surgery (Fig. 1).
A second European study comparing 3 months of neoad¬
juvant anastrozole and tamoxifen designated PROACT (pre¬
operative anastrozole compared with tamoxifen) recruited
451 patients [8]. Approximately 30% of patients received
concomitant neoadjuvant chemotherapy. This study failed
to show any statistical difference in response between the
two hormonal agents in the whole group and in patients who
received hormonal agents alone. Patients who were inoper¬
able or needed a mastectomy at baseline were more likely
either to become operable or have breast conserving surgery
if they were treated with anastrozole P= 0.003.
A small study from Russia involving only 73 patients com¬
pared 3 months ofneoadjuvant tamoxifen or exemestane. The
overall response rate and the rate ofbreast conserving surgery
were significantly greater (both P< 0.05) in patients treated
by exemestane [9],




Fig. 2. Outcomes of 83 patients with inoperable (locally advanced) breast
cancer in the P024 study which compared 4months ofneoadjuvant tamoxifen
and letrozole.
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Table 2
Responses in trial P024 comparing 4 months of neoadjuvant letrozole vs.
tamoxifen, relative to confirmed ER and/or PgR status [10]
Agent Marker status Response rate (%) /'-value








ER, oestrogen receptor; PgR, progesterone receptor.
Aromatase inhibitors are now the neoadjuvant hormonal
agents of choice in appropriately selected postmenopausal
women with hormone sensitive breast cancers. The data are
most impressive for letrozole. Apart from benefiting patients,
the neoadjuvant setting provides an opportunity to sample
tumours during treatment and correlate biological changes
with response. Not all treated patients do respond, so selection
for treatment is thus critical.
4. Predicting response to neoadjuvant endocrine
therapy
In early studies with tamoxifen, patients were not selected
for treatment on the basis of oestrogen receptor-positive
(ER+) or progesterone receptor-positive (PgR+) status,which
identifies those patients most likely to respond [10]. Never¬
theless, one early study concluded that tamoxifen provided an
alternative pre-operative treatment option for operable breast
cancer in elderly patients [11]. Subsequent studies in post¬
menopausal ER+ patients demonstrate substantial tumour
volume reductions over a 3—4 month treatment period using
a variety of endocrine agents, including tamoxifen and the
third-generation aromatase inhibitors, letrozole, anastrozole,
and exemestane [6,10,12-14],
In the P024 study, tumour responses to letrozole ver¬
sus tamoxifen were also evaluated according to biopsy-
confirmed ER and/or PgR status [10]. Both letrozole and
tamoxifen achieved significantly more responses in patients
with ER+ tumours than those with ER-negative tumours
(Table 2).
In both ER+ and ER-cancers (these cancers were PgR
positive), response rates were higher for letrozole, reflect¬
ing the significantly better overall response rate for letrozole
versus tamoxifen in biopsy-confirmed patients (60% versus
41%; P-0.004). Responses to letrozole were significantly
better forPgR+ tumours than for PgR-negative tumours, and a
similar butweaker trendwas also seenwith tamoxifen. Differ¬
ences in response rates between these two agents were most
marked for tumours that were both ER+ and/or PgR+ and also
positive for the markers ErbB-1 and/or ErbB-2 (response rate
to letrozole 88% versus 21% for tamoxifen; P— 0.0004) [10].
There was also some evidence of a direct correlation
between the degree of ER expression and the incidence
and extent of tumour response [17,18], This is true for
both postmenopausal and premenopausal women treated
by neoadjuvant endocrine therapy. ER-rich tumours can be
characterised by several criteria. In the P024 randomised
trial of pre-operative letrozole versus tamoxifen, clinical
responses were related to the level of ER expression as
determined by immunohistochemistry (IHC) using the
semi-quantitative Allred scoring system (0-8). There were
no tamoxifen-induced responses at ER levels below a score
of 6, in contrast to letrozole-induced responses of >30% at
a score of 3 (Fig. 3).
5. Response and HER2 status
As previously mentioned, the P024 study showed that
there appeared to be a particular difference in response rates
in tumours that were ER and/or PgR positive and also over
expressed erbBl and/or erbB2 (HER1 or HER2)[10]. Fur¬
thermore, it was noticed that there was a significantly lower
response to tamoxifen in erbBl and erbB2 positive tumours
than in erbBl and erbB2 negative cancers (14% versus 41%;
P = 0.01). In contrast, it was found that there was a less dra¬
matic difference in the effect of letrozole on erbB 1 and erbB2
positive or negative tumours (88% versus 54%).
Similar results have been shown in neoadjuvant use
of anastrozole. The IMPACT study found that for those
patients whose tumours had HER2 overexpression (34 of
% in each category
ER Score
Fig. 3. Clinical response rate vs. ER Allred score for letrozole and tamoxifen in the P024 randomised trial. Reprinted with permission from Ellis et al. [10].














Fig. 4. Clinical response to neoadjuvant anastrozole in HER2 positive (n—6)
and negative (n= 16) tumours [20].
239 tumours), anastrozole had a higher clinical response rate
(58%) than tamoxifen (22%; /J = 0.09) [7],
The relationship of response to aromatase inhibitors
and ErbB2 status has also been investigated in two Edin¬
burgh studies. One hundred and seventy-two postmenopausal
women with large operable or locally advanced ER-rich
(ER Allred score >6) breast cancers have been treated with
3 months of neoadjuvant letrozole [19]. ErbB2 status was
assessed by Hercept test and FISH for >2 samples, and
response assessed by clinical and ultrasound examination. Of
172 patients, 18 had tumours that were classified as ErbB2
positive. At 3-month assessment there was no significant
difference in clinical response between ErbB2 positive and
negative tumours (61% versus 69%; P = 0.506), confirming
the equal efficacy of letrozole in both ErbB2 positive and
negative cancers.
In a second series 24 postmenopausal women with oestro¬
gen receptor-rich, large, operable breast tumours received 3
months' neoadjuvant anastrozole [13]. Twenty-two patients
had sufficient tumour in all their specimens to allow staining
for erbB2 status prior to treatment and also to study changes
in proliferation as assessed by Ki67 antibody and PgR as
assessed by the DAKO antibody [20]. There were 6 erbB2
>3 tumours with the other 16 tumours being either negative
or >1. There was no difference in clinical response between
the two groups. Changes in proliferation and PgR receptor
did not differ between the different groups, demonstrating
that anastrozole is equally effective both clinically and bio¬
logically erbB2 positive and negative tumours (Fig. 4).
6. Duration of neoadjuvant endocrine therapy
The optimal duration of neoadjuvant endocrine therapy
has yet to be established. In early studies, patients usually
remained on tamoxifen until their tumours became unrespon¬
sive and grew [11,21]. In unpublished studies from the Edin¬
burgh Breast Unit, 3 months has been identified as the most
appropriate initial length ofpre-operative treatment. This was
determined in a consecutive series of 100 patients who were
more than 70 years old and who had ER-rich breast cancers
(>20 fmol/mg ofcytosolic protein). After 3 months of tamox¬
ifen, 72 patients had responded, based on a >25% ultrasound
tumour volume reduction, and 1 patient had progressing dis¬
ease. The remaining 27 patients were continued on tamoxifen
for an additional 3 months, during which 4 responded while
5 progressed. From these data, it is evident that if a patient
has not responded within 3 months, then the subsequent
poor response-to-progression ratio does not warrant more
prolonged treatment. By 3 months the numbers developing
disease progression seems to offset any benefit to the few
whose tumours respond after initially being static Therefore,
in Edinburgh, after 3 months ofpre-operative endocrine treat¬
ment response is formally assessed and patients who have not
responded are advised that continuation of the same treatment
is unlikely to be effective and an alternative treatment is nec¬
essary. Responders are advised either to have surgery or to
continue on hormone therapy.
Most neoadjuvant studies with aromatase inhibitors have
treated patients for 3 or 4 months, and by this time many
patients' tumours have responded sufficiently to downstage
the surgical procedure required to excise the cancer. Some,
however, remain inoperable or still require mastectomy. A
prospective audit of 142 postmenopausal women with large
operable or locally advanced ER-rich (ER Allred score >6)
breast cancer has been carried out in Edinburgh assess¬
ing clinical response to letrozole [22], After 3 months 100
patients had responded, this included some patients whose
disease was inoperable and were now suitable for operation
either bymastectomy or breast conserving surgery, and others
who had large operable cancers that had reduced in size suffi¬
ciently to allow breast-conserving surgery. Forty-two patients
had either disease that remained inoperable, had large can¬
cers not yet suitable for breast conserving surgery or refused
or were considered unfit for surgery because of other co¬
morbidities and continued on letrozole for at least 3 further
months. Twenty-two were still taking letrozole at 12 months.
The median % reduction in clinically measured tumour vol¬
umes in thesewomenwas 52% from 0 to 3 months. There was
a further 57% volume reduction from baseline at 3 months
between 3 and 6 months and another 66% reduction from
baseline at 6 months between 6 and 12 months, showing that
tumours continued to reduce in volume during the 12-month
study period. The complete response rate also increased over
time, with 9.5% at 3 months, 29% at 6 months and 36% at
12 months. Only one patient who had an initial response at
3 months had disease progression in this cohort. These data
suggest that letrozole can be used safely for up to 12 months.
The optimum duration ofneoadjuvant endocrine therapy has
yet to be defined and further studies are indicated.
7. Completeness of tumour excision and incidence of
local recurrence following neoadjuvant therapy
In study of neoadjuvant chemotherapy, the histology of
wide excision specimens following downstaging revealed
Her2- Her21
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Table 3
Outcomes for patients in Edinburgh having undergone initial wide local excision
Total WLE Re-excision n (%) Mastectomy n (%) Single BCS procedure (%)
No pre-operative treatment 1374 156(11.4%)a 78 (5.7%) 1140 (83%)b
Neoadjuvant Al 147 6 (4. l%)a 6(4.1%) 135 (92%)b
WLE, wide local excision; BCS, breast conserving surgery.
a P=0.007.
b P=0.006.
that in 16% of 221 cases there was evidence ofmultifocality
oftumour,with the frequency greatest for larger tumours [23].
A series of 25 patients in whom breast-conservation surgery
was performed after chemotherapy in Edinburgh revealed
similar results: 6 patients had diffuse or multifocal disease
on pathologic examination, even though there was no palpa¬
ble tumour in 5 of these.
Data from Edinburgh ofall wide local excisions performed
in patients who either did or did not have pre-operative treat¬
ment have been analysed, and have shown favourable results
for neoadjuvant endocrine therapy. Of 1374 patients who
underwent wide local excision without any pre-operative
treatment, 156 (11.4%) required re-excision ofmargins, and
78 (5.7%) required mastectomy. In a series of 147 patients
treated during the same time period who underwent breast
conserving surgery after neoadjuvant therapy significantly
less (« = 6 (4.1%); P = 0.007) of these women required a
re-excision; 6 patients (4.1%) in this group did require
mastectomy. There were a significantly greater proportion
of patients in the neoadjuvant group who had successful
breast conservation at a single procedure than in those who
had no pre-operative treatment (92% versus 83%; P = 0.006)
(Table 3).
Several studies have examined rates of tumour recurrence
following neoadjuvant therapy and surgery (and in some
cases local radiation therapy). Veronesi et al. reported 12
cases of local recurrence in 203 patients (6% incidence) at a
mean follow-up of 3 years after pre-operative chemotherapy
followed by quadrantectomy and local radiotherapy. This
was considerably better than the 22% recurrence rate among
comparable patients who underwent mastectomy [23]. In
another trial, recurrence rates were similar for patients
receiving chemoendocrine therapy pre-operatively and for
those receiving only adjuvant treatment (3.5% and 2.7%,
respectively, at 48 months' median follow-up) [24], The
importance of surgically removing tumours following
complete responses to treatment is emphasised by a report
that the rate of recurrence was significantly higher for com¬
plete responders who then received radiotherapy without
surgery, as compared to partial responders who had surgery
[25],
As yet there are few reported data on local recurrence
after breast-conserving surgery in large numbers of patients
following neoadjuvant endocrine therapy. Fig. 5 shows local
recurrences in the series of patients treated in Edinburgh,
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Fig. 5. Effect of radiotherapy on local recurrence in patients treated with
neoadjuvant endocrine therapy followed by breast-conserving surgery.
versus surgery plus radiotherapy following pre-operative
treatment.
At 5 years there was only a 2.8% local recurrence rate in
patients treated with neoadjuvant endocrine therapy and then
breast conserving surgery followed by radiotherapy, com¬
pared with a 27.8% rate of local recurrence in those treated
by breast conserving surgery without radiotherapy. It is now
our policy to give radiotherapy after operation to all women
deemed fit enough.
8. Adjuvant aromatase inhibitors
Two large trials have presented data on the effects of
adjuvant or extended adjuvant therapy on local and regional
recurrences. These have important implications for surgeons.
In the ATAC trial, 9366 patients who had completed primary
therapy andwere eligible for adjuvant endocrine therapywere
treated with either anastrozole or tamoxifen alone, or a com¬
bination of both [15]. Results at 4 years revealed that anas¬
trozole had a significantly longer disease free survival period
than tamoxifen, and in hormone receptor tumours there was
a significant reduction in development ofnew primary breast
cancer with anastrozole compared with tamoxifen (Fig. 6).
Similar results have been found with letrozole. The MA 17
trial randomised 5187 postmenopausal women who had fin¬
ished primary treatment for operable breast cancer and 5 years
adjuvant tamoxifen to receive 5 years letrozole or placebo
[ 16]. At interim analysis there were fewer locoregional recur¬
rences and fewer new primary tumours in the contralateral
breast in the letrozole group than in the placebo group.





















Fig. 6. Results of adjuvant studies ATAC and MA 17: locoregional recurrence and incidence of new primary breast tumour.
9. Conclusions
Neoadjuvant hormone therapy is effective at downstaging
tumours, particularly large tumours initially thought to be
inoperable or requiring mastectomy. Randomised trials have
shown that the newer aromatase inhibitors letrozole and anas¬
trozole increase the numbers ofwomen who are suitable for
breast-conservation compared with tamoxifen, and that letro¬
zole is superior to tamoxifen in terms of clinical response.
Careful selection of those likely to benefit from neoadju¬
vant therapy is required. Aromatase inhibitors are most effec¬
tive in ER-rich tumours, although letrozole is effective at even
low ER Allred scores (<5), whereas tamoxifen is not. The
aromatase inhibitors are clinically and biologically effective
in both I1ER2 positive and negative tumours, whereas HER2
positive tumours show a level of resistance to tamoxifen.
In neoadjuvant studies comparing aromatase inhibitors
with tamoxifen, the duration of use has been 3-4 months,
by which time any response is usually evident. In patients
who show a response to letrozole but were unfit for surgery
or continued because their disease remained inoperable at
3-4 months, letrozole used for up to 12 months is associated
with continued response.
Reports to date suggest that the re-excision rate in neoad¬
juvant hormone therapy groups is favourable compared with
groups undergoing standard treatment with wide local exci¬
sion, with significantly more neoadjuvant patients having
successful breast conservation with a single procedure. Local
recurrence rates are acceptable in patients undergoing neoad¬
juvant therapy and breast-conserving surgery if this is com¬
bined with post-operative radiotherapy.
Adjuvant aromatase inhibitors, as well as having an effect
on metastatic disease and survival, reduce local and regional
recurrence, which is important both for the patient and the
surgeon.
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Neoadjuvant tamoxifen and aromatase inhibitors:
comparisons and clinical outcomes^
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Abstract
Neoadjuvant hormonal therapy for oestrogen receptor (ER) and/or progesterone receptor (PgR) positive large operable or locally advanced
breast cancer is effective and a safe alternative to chemotherapy in postmenopausal women. A randomised trial has demonstrated that the
response rate and the incidence and degree ofdownstaging with the aromatase inhibitor letrozole is significantly greater than with tamoxifen
[J. Clin. Oncol. 19 (2001) 3808]. Tumours at all levels of ER appear to respond better to letrozole than tamoxifen but at low levels of ER
responses are seen only with letrozole and not with tamoxifen. Patients most likely to benefit from neoadjuvant therapy and those who
achieve the greatest reduction in tumour volume are those patientswith tumours that express very high levels ofER (ALLRED category score
8). Both letrozole and anastrozole appear effective in both erbB2 positive and negative breast cancers. Three months of treatment is adequate
to determine if a tumour will respond. Following breast-conserving surgery and radiotherapy, local recurrence rates appear satisfactory.
© 2003 Elsevier Ltd. All rights reserved.
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PERGAMON
1. Introduction
Until recently neoadjuvant therapy of breast cancer has
been used predominantly as cytotoxic chemotherapy [1^1].
Endocrine treatment is now emerging as an attractive alter¬
native in hormone receptor positive postmenopausal women
many of whom who could not tolerate the toxicities of
chemotherapy. There have been few controlled studies of
neoadjuvant endocrine therapy. In early studies, tamoxifen
was used but patients were not selected on the basis of hav¬
ing oestrogen receptor (ER) or progesterone receptor (PgR)
positive breast cancers to identify those most likely to re¬
spond [5],
1.1. Studies with tamoxifen
Randomised trials comparing primary endocrine therapy
with tamoxifen alone with surgery± tamoxifen have all been
in elderly patients [6-9]. Patients in these studies were not
routinely selected on the basis of having ER or PgR positive
breast cancer. In two of the studies, tamoxifen was compared
with immediate surgery alone and in the other two, tamox-
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ifen was compared with surgery and tamoxifen [6,7], The
time to relapse or first event was significantly shorter in the
tamoxifen alone arm, as would be expected. A more recent
combined analysis of these trials [10] showed that this trans¬
lated to a significant reduction in breast cancer deaths in the
immediate surgery group. However, none of these trials were
designed to see whether there was a difference in survival
between patients treated by neoadjuvant endocrine therapy
before surgery or surgery followed by endocrine therapy.
In Edinburgh, small studies have been performed com¬
paring neoadjuvant tamoxifen with aromatase inhibitors. Al¬
though patients were not randomised and the numbers were
small, impressive results were achieved. Table 1 shows the
number of patients who had reductions in tumour volume
of more then 50% as assessed by ultrasound scan. As can
be seen, 46% ofpatients treated with tamoxifen, 88% of pa¬
tients treated with letrozole and 78% of patients treated with
anastrozole had a reduction in tumour volume of greater
than 50%. Of the whole group, only two patients progressed
while on treatment.
There are no large randomised studies comparing neoad¬
juvant endocrine therapy with chemotherapy and little work
has been done in this area since the patient populations who
are most commonly treated with neoadjuvant chemotherapy
tend to be premenopausal women with large ER negative
tumours, in contrast those treated with endocrine therapy
tend to be elderly postmenopausal women with ER positive
tumours.
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Table 1
Median percentage in tumour volume as assessed by ultrasound
Drug No. No. >50% No. <50% No. >25%
reduction reduction and increase
<25% increase
Tamoxifen 65 30 34 1
Letrozole 24 21 2 1
Anastrozole 23 18 5 0
Table 3
Responses in trial P024 comparing 4 months of neoadjuvant letrozole vs.
tamoxifen, relative to confirmed ER and/or PgR status [7]
A potential problem with using tamoxifen as neoadjuvant
therapy is the long time period required to reach steady state
plasma levels—up to 5 weeks [11]. In contrast, the newer
aromatase inhibitors build up rapidly reaching therapeutic
concentrations within days.
1.2. Studies with letrozole
Initial studies performed in Edinburgh with letrozole, a
highly selective aromatase inhibitor, suggested that there
may be benefits of using aromatase inhibitors rather than
tamoxifen in postmenopausal ER positive patients [12],
This led to randomised studies. The P024 trial compared
4 months of neoadjuvant letrozole with tamoxifen in post¬
menopausal women with large breast cancers which re¬
quired mastectomy or were locally advanced and inoperable
and were ER or PgR positive [13]. This study demonstrated
that letrozole achieved a significantly higher clinical re¬
sponse rate than tamoxifen (55% versus 36%; P < 0.001),
enabling more patients treated with letrozole than with ta¬
moxifen to undergo breast-conserving surgery (45% versus
35%; Table 2). Median time to response was 66 days in the
letrozole group and 70 days in the tamoxifen group.
Modified WHO criteria was used to evaluate tumour re¬
sponse in the neoadjuvant setting as follows:
• Partial response (PR): Reduction in tumour size >50%
from pre-treatment size.
Table 2
Primary and secondary efficacy end point results of trial P024 comparing
4 months of neoadjuvant letrozole vs. tamoxifen, in all study patients [12]
Efficacy end points Letrozole (%) Tamoxifen (%) P-value
(n = 154) (n = 170)
Primary end point





Ultrasound response 35 25 0.042
Complete 3 1
Partial 32 24
Mammographic response 34 16 <0.001
Complete 4 0
Partial 30 16
Breast-conserving surgery 45 35 0.022
Agent Marker status Response
rate (%)
P-value
Letrozole ER positive 60 0.005
ER negative 19
PgR positive 63 0.018
PgR negative 41
Tamoxifen ER positive 40 0.031
ER negative 11
PgR positive 43 0.076
PgR negative 28
ER, oestrogen receptor; PgR, progesterone receptor.
• Minor response (MR): Reduction in tumour size >25 and
<50% from pre-treatment size.
• No change (NC): <25% decrease or <25% increase in
tumour size from pre-treatment size.
• Complete response (CR): No measurable tumour.
• Progressive disease (PD): 25% or more increase in tu¬
mour size from pre-treatment size.
There were fewer responses demonstrated by ultrasound
and mammography but responses were significantly more
common with letrozole than tamoxifen whether assessed by
ultrasound ormammography (Table 2). The only other factor
besides treatment which influenced the likelihood ofpatients
being suitable for breast-conserving surgery was tumour size
at presentation with patients with T2 tumours being more
likely to be candidates for breast-conserving surgery than
larger tumours (P = 0.0001). In this randomized study,
letrozole was at least as well tolerated as tamoxifen.
Tumour response in this study was related to ER and PgR
status [5]. There were significantly more responses in pa¬
tients subsequently confirmed to have ER positive tumours
than in patients who on subsequent testing had ER negative
tumours (Table 3). In each of the ER categories, response
rates were higher for letrozole than tamoxifen. There ap¬
peared to be a particular difference in response rates in tu¬
mours that were ER positive and also over expressed erbB 1
and/or erbB2 with an 88% response rate in this group for
letrozole versus a 21% response rate to tamoxifen P =
0.0004 [5],
1.3. Studies with anaslrozole
In Edinburgh, a series of 24 patients have been treated
with neoadjuvant anastrozole [14], These tumours have
recently been stained for erbB2 and a correlation between
the erbB2 status response and change in proliferation in
hormone receptor has been undertaken [15]. Twenty-two
patients had sufficient tumour in all their specimens to al¬
low us to assess erbB2 status prior to treatment and also to
study changes in proliferation as assessed by Ki67 antibody
and PgR as assessed by the DAKO antibody. There were 6
erbB2 3+ tumours with the other 16 tumours being either
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Table 4
Response rates and changes in Ki67 and PgR in 22 patients treated by 3
months of preoperative anastrozole subdivided according to erbB2 status
erbB2 No. Clinical Ultrasound Median Ki67 Fall in
PgR













* Five patients PgR 0 on first biopsy: (a) P — 0.017 and (b) P <
0.0001.
negative or 1+. Comparison has been made between these
two groups. There was no difference in clinical response
between the two groups (Table 4), and initial proliferation
and changes in proliferation and PgR receptor did not dif¬
fer between the different groups. These data demonstrate
anastrozole is clinically and biologically effective in erbB2
positive tumours.
An ongoing multicentre, randomised, double-blind clin¬
ical trial, Immediate Preoperative Arimidex Alone or in
Combination with Tamoxifen (IMPACT) has now com¬
pleted recruiting. It compares anastrozole I mg daily versus
tamoxifen 20 mg daily versus anastrozole plus tamoxifen.
Three hundred and thirty postmenopausal patients with
ER and/or PgR positive breast cancers if large or oper¬
able, or potentially operable but locally advanced, have
been recruited. In this study, treatment was for 3 months
and patients providing they respond continue on the same
endocrine treatment as adjuvant therapy for 5 years. Pri¬
mary endpoints are objective tumour response rates with
secondary endpoints being breast-conserving rate and as¬
sessment of key biological markers including proliferation,
hormone receptors and apoptotic rate.
1.4. Newer Edinburgh studies
In the Edinburgh Breast Unit, we have now treated 83 pa¬
tients with neoadjuvant letrozole [16]. We have correlated
clinical and ultrasound responses and change in tumour vol¬
umes in these patients in relation to the ER ALLRED score.
Sixty of the tumours were ER category 8 and 23 were cat¬
egory 6 or 7 (Table 5). Response rates were similar in ER
categories 8 and 6 + 7 but there was a greater percent¬
age reduction in tumour volume in patients whose tumours
had the highest ER level. This difference was significant
(P < 0.05).
1.5. Selection ofpatients for neoadjuvant therapy
The data outlined indicate that selection for neoadjuvant
endocrine therapy should be based primarily on ER status
and to a lesser extent, PgR status [5], Although P024 sug¬
gested that one of the differences between tamoxifen and
letrozole is that patients with lower levels of ER are more
likely to respond to letrozole than tamoxifen, the numbers
in these categories was small and it remains our policy to
treat patients who are fit for surgery with neoadjuvant en¬
docrine therapy only if their ER ALLRED score is 6 or over
because these are the women who are most likely to respond
and gain a clinical benefit.
1.6. Duration ofneoadjuvant therapy
Standard practice with neoadjuvant chemotherapy is to
administer between three and six cycles prior to surgery,
a time period felt sufficient to delineate responders from
non-responders [17]. The optimal duration of neoadjuvant
therapy has never been investigated in detail. One study at
the Edinburgh Breast Unit gave neoadjuvant tamoxifen to
100 consecutive patients over the age of 70 with ER rich
breast cancers (>20 fmol/mg cytosol protein) [ 18]. It demon¬
strated that after 3 months 72 had responded (based on a
greater than 25% reduction in tumour volume by ultrasound)
and one patient had progressive disease. The remaining 27
continued on tamoxifen for a further 3 months during which
18 patients' disease remained static, four responded but five
progressed. From these data, it can be concluded that if pa¬
tients are not responding by 3 months they are unlikely to
respond and there is the concern that if left on tamoxifen
alone the disease may progress. Three months therefore ap¬
pears sufficient to demonstrate whether the tumour is re¬
sponsive. Maximal response may however take considerably
longer than 3 months and the optimal duration of therapy
depends on initial tumour size and the aim of the neoadju¬
vant therapy. If the aim is to downstage the tumour to allow
breast-conserving surgery, then this can be achieved in the
majority of patients with 3^1 months treatment.
1.7. Response and downstaging in breast cancer
Response rates to preoperative chemotherapy are gen¬
erally around 80% regardless of the regimen used [19].
In appropriately selected patients, neoadjuvant endocrine
Table 5
Response in 83 patients treated with 3 months of neoadjuvant letrozole subdivided according to ALLRED ER score
ALLRED ER score No. of patients No. of responders % Response Median % reduction in tumour volume
Clinical USS
8 60 48 80 76* 67*
6 + 7 23 17 74 63 48
* P< 0.05.
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Tamoxifen 47 13 4 34 0 84
Letrozole 34 10 4 24 1 70
Anastrozole 21 0 0 21 1 51
Exemestane 10 4 1 6 0 42
Totai 112 27 9 85 2 62
a Number of patients who, following 3 months of neoadjuvant therapy, underwent breast-conserving surgery without local radiation therapy (XRT).
b Number of patients who, following neoadjuvant therapy, underwent both breast-conserving surgery and local radiotherapy.
therapy also produces response rates of up to 80%
(Table 5). In the Milan study, 16% of 227 cases having
breast-conserving surgery had evidence ofmultifocality tu¬
mour within the wide excision specimen with the frequency
being highest in larger tumours [20]. Following neoadjuvant
chemotherapy in the Royal Marsden series 28% of patients
who underwent breast-conserving surgery had involved
margins [21], In a series of patients with locally advanced
breast cancer treated with neoadjuvant chemotherapy prior
to surgery, 62.5% of patients had multiple foci of tumour
remaining after wide local excision [22], This contrasts
with our own experience of surgery after neoadjuvant en¬
docrine therapy of 47 patients who initially were treated by
breast-conserving surgery after treatment with neoadjuvant
tamoxifen where in only one case was there an incomplete
excision in a patient with invasive lobular cancer [23].
In a subsequent series treated with neoadjuvant aromatase
inhibitors, 65 patients had breast-conserving surgery and
only two of these had an incomplete excision. When the
residual tumour was evaluated histologically, the nature of
the response to neoadjuvant endocrine therapy was some¬
what different in that the whole tumour appears to shrink
concentrically whereas with chemotherapy the extent ofdis¬
ease was often noted by our pathologist to have remained
unchanged while the cellularity of the tumour was usually
markedly reduced.
1.8. Local recurrence following neoadjuvant endocrine
therapy followed by breast-conserving surgery
Several studies have examined the rates of tumour recur¬
rence following neoadjuvant therapy followed by surgery.
Veronesi et al. reported 12 cases of local recurrence in 203
patients with a median follow-up of 3 years after preoper¬
ative chemotherapy [24]. This was considerably better than
the 22% recurrence rate among the patients who under¬
went mastectomy because after chemotherapy they were un¬
suitable for breast-conserving surgery. In another trial, the
recurrence rates were similar for patients receiving initial
chemoendocrine therapy with recurrence rates of3.5% com¬
pared with patients treated in the standard manner (surgery
followed by systemic therapy) where the recurrence rate was
2.7% [25]. The only data available on local recurrence after
breast-conserving surgery in patients treated with neoadju¬
vant endocrine therapy are presented in Table 6. These are
data from Edinburgh and demonstrate that the overall recur¬
rence rate without radiotherapy was 33% at 5 years [23], If
patients who did not have radiotherapy are excluded, only
two patients from a total of 85 have developed a local re¬
currence at a median follow-up of 5 years. These results
indicate that breast-conserving surgery followed by radio¬
therapy achieves satisfactory local disease control in patients
downstaged by neoadjuvant endocrine therapy.
The population of patients who are treated with neoadju¬
vant endocrine therapy tend to be elderly and these patients
can have significant comorbidity. For many of these patients
despite locally advanced disease they will die from causes
other than breast cancer. For this reason, it is difficult to
compare long term survival of these patients with a series
treated with adjuvant endocrine therapy.
Both disease free survival and overall survival have been
reported to be similar in patients treated with neoadjuvant
chemotherapy preoperatively and in patients treated with
systemic therapy after surgery [26-29]. A recently presented
trial comparing preoperative ER directed neoadjuvant versus
adjuvant therapy was presented and showed no difference in
survival for patients treated with neoadjuvant endocrine or
chemotherapy compared with patients having initial surgery
and follow-up systemic therapy [30],
2. Conclusion
Neoadjuvant endocrine therapy does appear to be effec¬
tive. Reductions in tumour volume using primary endocrine
therapy in ER and/or PgR positive tumours are similar to
those reported with neoadjuvant chemotherapy. In contrast,
toxicity is much lower with neoadjuvant endocrine therapy
and it is extremely well tolerated, with very few patients
having to discontinue therapy because of side effects.
From a surgical perspective, the ability to perform less
extensive surgery is an advantage especially considering
the comorbidity and overall general health of the group
of patients who tend to be treated with neoadjuvant en¬
docrine therapy. The currently available data suggests
that breast-conserving surgery followed by radiotherapy
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produces adequate local disease control in patients down-
staged by neoadjuvant endocrine therapy.
The patients who are most likely to respond to neoadju¬
vant endocrine therapy are those who have higher levels of
ER (ALLRED score 6 and above). Response rates to neoad¬
juvant therapy in postmenopausal women have been shown
to be higher when using aromatase inhibitors than with ta¬
moxifen. This may partly be due to the fact that aromatase
inhibitors are effective in both erbB2 positive and negative
cancers while tamoxifen is less effective in erbB2 positive
tumours and that the aromatase inhibitors produce responses
in tumours with lower levels of ER whereas tamoxifen
does not.
Results of the currently ongoing trails using neoadjuvant
endocrine therapy are awaited with interest.
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The third generation aromatase inhibitors are both remarkably potent and
specific endocrine agents inhibiting aromatase activity and reducing circulat¬
ing oestrogen levels in postmenopausal women to levels never previously
seen. Their therapeutic potential is consequently much greater than the earlier
prototype drugs. Their excellent side-effect profile also allows for potential
wider indications in the treatment of oestrogen-related diseases, including
breast cancer. It still remains to determine whether their potent endocrine
effects translate into increased therapeutic benefit. In advanced breast cancer,
aromatase inhibitors have been shown to have improved efficacy and toxicity
profiles when compared with progestins, aminoglutethimide and tamoxifen.
Aromatase inhibitors have also been used in the neoadjuvant setting, where
they have been shown to achieve higher response rates than tamoxifen and to
be more successful at downstaging tumours. Early results comparing an aro¬
matase inhibitor with tamoxifen in the adjuvant setting in early breast cancer
show anastrozole to be superior to tamoxifen in terms of both disease-free
survival and a lower incidence of new contralateral tumours. There was also a
more favourable side-effect profile, which has implications for potential future
prophylactic treatment. Additionally, since aromatase inhibitors have different
mechanisms of action, unlike antioestrogens, they may be particularly useful
as chemopreventive agents if oestrogens are themselves genotoxic. Aromatase
inhibitors have been used to date almost exclusively in postmenopausal
women. The potential of combining them with luteinising hormone-releasing
hormone analogues allows the possibility of treating premenopausal women
with either oestrogen receptor-positive breast cancer or benign conditions
such as cyclical breast pain, fibroadenomata, recurrent cystic disease or
endometriosis. There is also the potential for their use in men with conditions
such as gynaecomastia or prostate cancer. These new generation aromatase
inhibitors may well have an increasing role in the future management of a
number of conditions in addition to breast cancer.
Keywords: aromatase inhibitors, breast cancer, endocrine, oestrogen, therapeutic
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1. Introduction
Whilst oestrogen is classically regarded as the female sex hormone, being primarily
responsible for sexual development in women (most notably the functional regula¬
tion of the uterus, breast and ovary), its actions stretch beyond this. For example, oes¬
trogen plays a crucial role in normal metabolism of bone and lipids |1|. Furthermore,
it is increasingly recognised to play a role in the natural history of diseases associated
with hormone irregularities including neoplasia of the breast, uterus and ovary [2].
Consequently, the concept of interfering with the synthesis and/or mechanism of
action of oestrogen is an attractive option to control hormone-related disease proc-
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esses. In terms of biosynthesis, oestrogens are the end point in
a sequence of reactions in which other important hormones
such as progestins and androgens are intermediaries. The most
specific method by which to inhibit oestrogen formation (and
thereby avoid the side effects of interfering with the action of
other hormone classes) is to block the last step in the biosyn-
thetic cascade. This is the conversion of androgens, such as
androstenedione and testosterone, into oestrogens, such as
estrone and oestradiol. Since the reaction renders the steroid
molecule aromatic, the enzyme is known as 'aromatase'.
Drugs which inhibit aromatase are not new; indeed the proto¬
type drug aminoglutethimide was first used to treat breast cancer
over 30 years ago [3]. However, the agent was not specific, inhibit¬
ing the biosynthesis of other steroid classes (and required the con¬
comitant administration of corticoid replacement therapy);
neither was aminoglutethimide particularly potent, the standard
dose being 1 g/day (250 mg q.i.d.) 14). However, in the interven¬
ing years, rational drug development has seen the evolution of
agents which inhibit aromatase with remarkable potency and spe¬
cificity. Consequendy, they have a therapeutic potential which far
exceeds that of the prototype drugs. This article will review the
endocrine profile of the latest generation of aromatase inhibitors
(AIs) and consider their potential use in the treatment of oestro¬
gen-related diseases, most particularly breast cancer.
2. Classification of aromatase inhibitors
Inhibitors of aromatase may be subdivided into two main
classes (Figure l). Type I inhibitors interact with the substrate-
binding sites of the enzyme. In structure, most are androgens
(Figure 2); as a consequence they may have hormonal activity
151. However, the inhibition may be mechanism-based in that
the drugs, when bound to the catalytic site of the enzyme, are
metabolised to intermediates which attach irreversibly to the
active site, thereby blocking activity (61. Such inhibitors would
be expected to be particularly specific, only inhibiting mole¬
cules for which they are substrates. Because of the irreversible
nature of the inhibition, the enzyme remains inactive even
after the drug is cleared from the circulation. These inhibitors
have, therefore, been marketed as 'inactivators' [7],
Type II inhibitors interact with the haem moiety of the cyto¬
chrome P450 (CYP450) prosthetic group of the aromatase mole¬
cule (Figure l). These inhibitors are imidazoles and triazoles
(Figure 2). Early Type II drugs had poor specificity because they
interacted with the CYP450 group in other enzymes 18], How¬
ever, the amino acid sequence of CYP450 aromatase is distinct
from other members of the CYP450 family 19) and the latest gen¬
eration of drugs have complete selectivity towards CYP450 aro¬
matase, thus allowing specific inhibition. In contrast to Type I
agents, Type II inhibitors are generally reversible and oestrogen
blockade is dependent upon continued presence of the drug.
The first AIs were used without the knowledge that they had
andaromatase properties 110-12]. These drugs included aminoglu¬
tethimide and testolactone (Table 1). Additionally, the drugs
lacked specificity and produced side effects unconnected with
Table 1. Anti-aromatase agents by generation.










effects on aromatase. Second generation drugs were considerably
more potent but either had poor pharmocokinetics when given
orally (formestane) [13] or affected other steroidogenic enzymes in
addition to aromatase (fadrozole) 114],
As reviewed below, the latest third generation inhibitors
(anastrozole, letrozole and exemestane) are exceptionally
potent and specific, blocking aromatase at nanomolar concen¬
trations [15] and being capable of reducing endogenous oestro¬
gen in postmenopausal women to undetectable levels whilst
having no discernable effects on other hormone classes |16].
3. In vitro studies
Placental microsomes possess high aromatase activity and
have been classically used to assess the ability of drugs to
inhibit oestrogen biosynthesis. Results relating to aminoglu¬
tethimide, anastrozole, letrozole, exemestane and formestane
are presented in Figure 3A. All agents inhibited aromatase
activity in a dose-related manner, but whereas aminogluteth¬
imide needed to be used at micromolar concentrations, the
newer generation of inhibitors were magnitudes of order more
potent, being effective at nanomolar concentrations.
Although placental microsomes are widely used as a screen
for antiaromatase agents, the level of aromatase activity does
not reflect that in peripheral tissues, which is minute in com¬
parison. Since AIs are currently reserved for postmenopausal
patients, it is more appropriate to screen inhibitors against
peripheral tissues, which are the primary site of oestrogen bio¬
synthesis in these patients. About 70% of breast cancers dis¬
play aromatase activity when incubated in vitro as particulate
fractions [17|. Therefore, such tumour homogenates are useful
test systems, as is shown in Figure 3B. Again, the newer gener¬
ation of agents produce dose-related inhibition at nanomolar
concentration, whereas aminoglutethimide requires micromo¬
lar levels. Concentrations which produce 50% inhibition of
activity (IC50) are summarised in Table 2. It can be seen that:
• the Type II inhibitors (anastrozole and letrozole) are
more potent than the Type I inhibitors (formestane and
exemestane)
• letrozole is more powerful than anastrozole, and exemes¬
tane is more powerful than formestane
• the third generation inhibitors are at least 150-fold more
active than aminoglutethimide in this test system
















Figure 2. Differences in structure of anti-aromatase agents.
Whilst disrupted cell preparations are useful model systems,
they do not take into account other factors such as cellular
uptake, intracellular sequestration and metabolism of drugs.
It is therefore advisable to include whole-cell systems, such
as cultured fibroblasts from breast adipose tissue, in any
comparison. Such observations are shown in Figure 4A. The
results are consistent with other whole cell systems [18] in
that letrozole appears to increase differentially in potency as
compared with other Type II inhibitors, such as aminoglu¬
tethimide and anastrozole. Interestingly, exemestane also
appears more active in whole-cell cultures than in disrupted
cell preparations.
Cultured fibroblasts can also be used to demonstrate the dif¬
ference in mechanism of action between irreversible Type I
inhibitors and reversible Type II agents. These fibroblasts can
be preincubated with inhibitors which are then removed before
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Table 2. Inhibition of aromatase activity in whole-cell and disrupted-cell preparation.
Compound Placental microsomes Breast cancer homogenates Mammary fibroblast cultures
IC50 (nM) Relative potency IC50 (nM) Relative potency IC50 (nM) Relative potency
Aminoglutethimide 3000 1 4500 1 8000 1
Anastrozole 12 250 10 450 14 570
Letrozole 12 250 2.5 1800 0.8 10,000
Formestane 50 60 30 150 45 180
Exemestane 50 60 15 300 5 1600
IC50: 50% Inhibitory concentration.
assay for aromatase. If the inhibitor has an irreversible action,
aromatase activity will remain inhibited, but those with reversi¬
ble characteristics will be ineffective. The results in Figure 4B
suggest that the Type II agents - aminoglutethimide, anastro-
zole and letrozole - are reversible, whereas exemestane and
formestane are irreversible. Interestingly, at least at one concen¬
tration, all Type II inhibitors produced a paradoxical increase in
aromatase activity compared with control. Enhanced aromatase
activity is also produced by aminoglutethimide in other systems
|19). This increased activity results from enhanced transcription
of the aromatase gene 120] and stabilisation of the aromatase pro¬
tein 121J. These effects probably account for the increased levels
of ex vivo aromatase activity following aminoglutethimide treat¬
ment of patients with breast cancer [22J. It has been postulated
that increased levels of aromatase protein following chronic
treatment with Type II inhibitors could lead to break-through
of oestrogen synthesis and renewed tumour growth [23].
Finally, in vitro screens on other closely related steroid-
metabolising enzymes have demonstrated the exquisite selec¬
tivity of the newer inhibitors. This specificity is illustrated for
exemestane in Table 3. The drug only affected other steroid
hydroxylases at concentrations that were at least 2800-fold
higher than those influencing aromatase.
4. In vivo studies
Prior to giving drugs to postmenopausal women with breast can¬
cer as treatment, studies have been performed in which the
effects on the agents have been monitored in vivo on whole body
peripheral aromatase and circulating levels of oestrogen [24,251.
To measure peripheral aromatase, radioactive androgen pre¬
cursors were given and the conversion to oestrogens assayed by
measuring the radioactivity in oestrogens purified from either
urine or plasma. Measurements before and after 2-3 months of
treatment with daily milligram amounts of the novel AIs (letro¬
zole, anastrozole and exemestane) indicate that these newer drugs
are able to inhibit peripheral aromatase by > 97% [24], This is a
substantial improvement over aminoglutethimide, which, even
when given in gram doses, inhibits peripheral aromatase by only
90% 124]. (Whilst the difference between 90 and 97% might not
seem large, the improvement is probably better appreciated by
Table 3. Inhibition of hydroxylases by exemestane.
Enzyme IC50 (nM) Relative specificity
Aromatase 25.4 1
21-Hydroxylase > 100,000 > 3937
11 B-Hydroxylase 72,500 2854
18-Hydroxylase 84,500 3327
C2(K22-|yase > 100,000 >3937
The IC50 values of exemestane for aromatase and other steroid hydroxylases.
Unpublished data from di Salle E. personal communication,
IC50: 50% Inhibitory concentration.
considering the residual aromatase which is < 3% with the newer
inhibitors compared with 10% with aminoglutethimide.)
As a consequence of this inhibition, circulating levels of
oestrogen in postmenopausal women fall to levels which are at
the level of detection of current assays [26,271. This degree of
suppression is greater than that produced by earlier generation
inhibitors. For example, incremental reductions in oestrogen
levels can be seen when switching patients relapsing on
aminoglutethimide onto exemestane |28], Effects are achieved
without influences on other circulating hormones [26,27,29] and
can be contrasted with those of aminoglutethimide which,
because of its suppressive effects on corticosteroid synthesis,
require corticoid replacement [30].
Because of this extraordinary potency and specificity for
oestrogen suppression, the third generation AIs produce
endocrine profiles in postmenopausal women that have rarely
been observed previously. An expectation has thereby been
created that these characteristics might be associated with
increased therapeutic benefits, as outlined below.
5. Advanced breast cancer
For most women with advanced metastatic breast cancer, the
outlook is comparatively bleak and the majority will ultimately
die of their disease. Currently, the major realistic objectives of
treatment are therefore to slow progression and to palliate
symptoms rather than effect a cure. What might reasonably be
expected of the newer generation of AIs in this setting? Their
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Figure 3. Effects of anti-aromatase agents on aromatase in breast cancer homogenates.
AG: Aminoglutethimide.
characteristics are the specific reduction of oestrogen concentra¬
tions in postmenopausal women to levels which have never
been consistently achieved previously. The consequence of this,
in the setting of tumour hormone dependence, would be:
• cancers which require oestrogen for their growth would be
more efficiently deprived of hormones
• other tumours which are able to grow with the support of
comparatively small amounts of oestrogen and appear
resistant to less efficient hormone therapy, might respond
to more effective drugs
In comparison to earlier AIs, the clinical expectations are, there¬
fore, that the new generation drugs will produce increased
response rates and second-line responses in patients relapsing
on first-line inhibitors, as well as longer duration of response
(such that some patients may die of non-cancer-related causes,
i.e., a potential increase in cure rates). However, because the
inhibitors are reducing oestrogen levels to extraordinary low
levels, further responses with hormonal agents at relapse will be
less likely. It is also worth making the comparison with
tamoxifen, which until recently was established as first-line
therapy for women with hormone sensitive disease. Although
both tamoxifen and AIs have in common oestrogen deprivation
as their end point, the drugs differ markedly in their mecha¬
nism of action. AIs reduce oestrogen levels, whereas interven¬
tion with tamoxifen blockades oestrogen action whilst leaving
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Figure 4. Inhibition of aromatase activity in fibroblasts.
AG: Aminoglutethimide.
levels of the hormone unchanged (or even raised) [31].
Tamoxifen may also have oestrogen agonist activity which may
reduce its effectiveness and lead to resistance [32], The molecular
changes which occur in tumours following treatment with
tamoxifen are also clearly different from those resulting from
therapy with AIs [33). With these differences in mechanism of
action, it might be expected that AIs may:
• be effective in tamoxifen-resistant tumours
• produce increased response rates (if oestrogen suppression
is more effective than oestrogen antagonism)
• be particularly effective in different cohorts compared with
tamoxifen within groups of hormone-sensitive tumours
• produce responses more quickly (AIs reduce oestrogen levels
rapidly [29,34], whereas the concentrations of tamoxifen for
effective oestrogen blockade accumulate relatively slowly) [35].
Whilst AIs have toxicities, their short-term side effects are com¬
paratively minimal and concerns are largely related to chronic
exposure (see Section 7). It might therefore be predicted that
AIs will be an acceptable form of treatment for advanced dis¬
ease. The evidence in support (or otherwise) of the above theo¬
retical considerations is accumulating from completed and
ongoing clinical trials and these will now be reviewed.
Initially, studies were conducted in the second-line setting in
which AIs were compared with either progestins or early gener¬
ation inhibitors (e.g., aminogluthethimide) in patients resistant
to or relapsing on tamoxifen. A summary of the results from
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Table 4. Second-line therapy with aromatase inhibitors after failure of tamoxifen in advanced breast cancer [36-41].
ANA versus MA LET versus MA EXE versus MA LET versus AG LET versus MA
(1/160 mg) (2.5/160 mg) (25/160 mg) (2.5/50 mg) (2.5/160 mg)
No ofpatients 263/253 174/189 336/403 185/178 199/201
Response rate, complete + partial 12,6/12.2 24/16* 15/12.4 19.5/12.3 16.1/14.9
response (%)
Complete response + partial response 42.2/40.3 35/32 37.4/34,6 36.3/29.3 26.7/23.4
+ stable disease > 24 weeks (%)
Median TTP (months) 5.6/5.5 4.7/3.8* 3.4/3,2* 3/3
Median TTF (months) 5.1/3.9* 3.8/3.7* 3/3* 3/3
Median OS (months) 27/23* 25/22 NR/28.4* 28/20* 29/26
•Significant results.
AG: Aminoglutethimide; ANA: Anastrozole: EXE: Exemesrane: LET: Letrozole; MA: Megestrol acetate: NR: Not reached: OS: Overall survival:
TTF: Time to treatment failure: TTP: Time to tumour progression.
these trials is shown in Table 4. Most trials concluded that in
comparison with other earlier endocrine agents, the third gen¬
eration AIs had superior efficacy and/or toxicity profiles and
none of them were shown to be significantly inferior to the
comparator in any end point of efficacy [36-41]. When many of
these initial studies were performed, the oestrogen receptor
(ER) and progesterone receptor (PgR) status for all patients
enrolled was often not known. For example, between 15 and
20% of patients enrolled into the Letrozole versus Megestrol
Acetate study had unknown ER and PgR status [41]. In the
FEM-INT.01 head-to-head trial of letrozole versus anastrozole,
713 patients who had progressed on antioestrogen therapy
were enrolled. In this study, which involved 112 centres in 19
countries, only 48% of the patient population had confirmed
hormone receptor-positive status [42]. Since it has now been
established that AIs are only effective in patients with hormone
receptor-positive disease, some of the discrepancies that have
been observed between studies may be explained by the hetero¬
geneity of the patient population.
Several small Phase II trials have evaluated the role of AIs,
particularly exemestane, after failure of two previous hormo¬
nal therapies (i.e., tamoxifen plus another agent) 143-45].
Although objective response rates were low (5 - 13%), they
were similar to response rates in Phase III studies of patients
treated with third generation AIs after failure of only one pre¬
vious hormonal therapy 139,46], In advanced disease there
appears to be a lack of cross-resistance between tamoxifen and
AIs and inactivators, which implies that sequential treatment
may also be beneficial.
As a result of these favourable findings, both anastrozole
and letrozole have recently been compared directly with
tamoxifen as first-line treatment for advanced breast cancer. A
study comparing exemestane with tamoxifen has recently
completed recruiting patients, but results are not yet available.
The P025 trial compared letrozole with tamoxifen in 939
patients for the first-line treatment of locally advanced or
metastatic postmenopausal breast cancer [47,48]. Letrozole was
shown to have a superior time to progression (9.4 months
compared with 6 months for tamoxifen (p < 0.0001) and a
significantly greater objective response rate (32% on letrozole,
21% on tamoxifen; p = 0.0002). However, there was no statis¬
tically significant difference in survival between the two
groups. In this study patients were allowed to cross over from
one drug to another and it may be that letrozole is superior in
the second-line setting, especially as survival at early time
points (i.e., up to 2 years) was significantly higher in the letro¬
zole group. The side-effect profile in both groups was similar
in this study.
Two randomised, double-blind, multi-centre Phase III tri¬
als were published in 2000 comparing anastrozole with
tamoxifen as first-line therapy for advanced breast cancer in
postmenopausal women [49-51]. The North American study
showed a clinical benefit in favour of anastrozole with a
median time to progression of 11.1 months for patients
treated with anastrozole compared to 5.6 months for
tamoxifen (p = 0.0098) [49,50]. However, this was not reflected
in the other larger study, conducted in Europe, Australia, New
Zealand, South America and South Africa [51], An important
difference between the trials was that 89% of the patients in
the North American trial were known to be receptor positive
compared with only 45% in the other trial. Again, currently
available data show no difference in survival between patients
treated with anastrozole and tamoxifen.
In summary, third generation AIs are now established as
standard second-line treatment of advanced ER-positive
breast cancer after tamoxifen because of improved efficacy and
reduced adverse effects [52], Trials in metastatic breast cancer
have shown superior efficacy and toxicity profiles when com¬
paring AIs and tamoxifen as first-line endocrine therapy. This
has resulted in the increasing use of AIs as first-line treatment
for metastatic ER-positive breast cancer in postmenopausal
women. It will be necessary to run head-to-head trials of the
available AIs to determine which has the best profile in terms
of efficacy and toxicity.
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6. Neoadjuvant therapy
Neoadjuvant therapy is most frequently given to patients with
large primary tumours with the intent of shrinking the can¬
cers so that inoperable lesions become operable. More con¬
servative surgery may also be performed. Elderly or infirm
patients may avoid surgery altogether. In this respect an effec¬
tive and rapid therapy is particularly attractive since early
tumour shrinkage would reduce time to surgery and provide
psychological reassurance of regressing disease. The character¬
istics considered above for advanced disease suggest that AIs
may have advantages over other endocrine therapies in this
setting and should be associated with better and quicker
response rates and decreased needs for surgery. The clinical
trial evidence for this, together with the associated research
data (neoadjuvant protocols have provided unique opportuni¬
ties for research since the primary tumour is accessible for
biopsy and assessment of response), is summarised below.
Small non-randomised neoadjuvant endocrine studies have
been performed in the Edinburgh Breast Unit using tamoxifen,
anastrozole, exemestane and letrozole. Comparing letrozole with
tamoxifen showed a significant difference in tumour response
rates (letrozole 81%, tamoxifen 48%) over a 3-month period
151]. Comparable results were achieved in a similar study using
anastrozole [53]. Significant tumour volume reductions were
achieved as shown in Table 5. This allowed a large percentage of
patients who would have required a mastectomy pretreatment to
have a wide local excision as their breast surgery (see Table 6).
The optimum duration of neoadjuvant endocrine therapy
has not yet been established [54]. A small series of 94 elderly
patients with ER-positive tumours (> 20 fmol/mg of cytosolic
protein) were treated with neoadjuvant tamoxifen in Edin¬
burgh (Keen J, MD thesis, Edinburgh, 1996). After 3 months
of treatment, 69 patients had responded (> 10% tumour vol¬
ume reduction on ultrasound scan) and seven patients had
progressing disease. At this point, 26 patients elected to con¬
tinue on tamoxifen for a further 3 months (20 responders and
6 non-responders). Of the 20 responders, 14 continued to
show tumour shrinkage, one remained static, but five
tumours which had initially responded showed evidence of
disease progression. Of the six tumours that had shown no
response at 3 months, two increased in size by 5 months and
the remaining four did not change in volume. This data sug¬
gests that continuing patients on neoadjuvant therapy for
> 3 months carries a significant risk of progression in tumours
which initially respond and that if patients have not
responded by 3 months they are unlikely to respond.
These studies have also yielded informative results regard¬
ing the effects of aromatase inhibition on tumour morphol¬
ogy and histology. It is clear that AIs consistently reduce
proliferation in ER-rich tumours and reduce tumour grade
by decreasing mitotic figures. Additionally, immunohisto-
chemical staining for steroid receptors showed that letrozole
and anastrozole, whilst having little effect on ER, produced
marked reduction in the expression of PgR. These observa¬
tions would be consistent with oestrogen deprivation and
contrast with the effect of tamoxifen, which markedly
reduces ER expression but may actually increase that of the
PgR [33,55].
These initial non-randomised studies have provided the
impetus for larger multi-centre randomised trials including
the P024 and Immediate Preoperative Arimidex Compared
to Tamoxifen (IMPACT) trials.
The P024 trial randomised 324 postmenopausal women
with receptor-positive breast cancer to receive 4 months of
neoadjuvant letrozole or tamoxifen [56]. Letrozole achieved a
significantly higher clinical response rate than tamoxifen
(55 versus 36%; p < 0.0001). This allowed more letrozole-
treated patients than tamoxifen-treated patients to undergo
breast-conserving surgery (Table 7). The study also generated
some interesting observations regarding tumour biology. For
example, tumours with low ER responded to letrozole, but
not to tamoxifen, and ER-positive, cerbB-l/2-positive
tumours had an 88% response rate with letrozole but only
21% with tamoxifen (p = 0.0004).
The IMPACT trial has recently completed recruiting
patients. It randomised 330 patients to receive anastrozole,
tamoxifen or a combination of both for 3 months before sur¬
gery and then as adjuvant therapy for 5 years. It is a multi¬
centre, randomised, double-blind trial involving postmeno¬
pausal patients with ER-positive and/or PgR-positive breast
cancer that is large and potentially operable. As its primary
efficacy end points are objective tumour response at
3 months and secondary end points include breast conserva¬
tion rate, biological markers, for example, ER, PgR, Ki67
and safety, it will generate important data on clinical response
and tumour biology.
7. Early breast cancer
In the treatment of early breast cancer, toxicity of therapies
becomes a more important consideration. Many women fol¬
lowing surgery appear free of disease but require long-term
systemic therapy for occult micrometastatic disease. So what
is the potential of AIs in this setting? More effective hormone
suppression might be expected to:
• increase disease-free interval
• reduce relapse rates, particularly in the medium term (in
the short term, most relapses may be expected to come
from the cohort of inherently aggressive, hormone-insensi¬
tive tumours that will not respond to any form of endo¬
crine therapy; in the long term, recurrences may consist of
hormone-insensitive outgrowths from more benign
tumours)
• lessen the chance of recurrent disease responding to other
hormone therapies
• be associated with problems emanating from long-term
oestrogen deprivation, in particular bone loss and unfa¬
vourable changes in lipid profiles
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Table 5. Tumour response in series of patients with locally advanced breast cancer who received neoadjuvant
endocrine therapy in the Edinburgh Breast Unit.*
Agent No. of Patients with > 50% Patients with < 50% reduction Patients with > 25%
patients reduction, n (%) or < 25% increase, n (%) increase, n (%)
Tamoxifen 65 30 (46) 34 (52) 1 (2)
Letrozole 36 32 (89) 3(8) 1 (3)
Anastrozole 23 18(78) 5(13) 0
Exemestane 12 10(83) 2(17) 0
•Tumour volume changes (reduction or increase) were assessed by ultrasound measurements during the 3-month treatment period.
Table 6. Patients with locally advanced breast cancer requiring mastectomy before and after neoadjuvant endocrine
therapy, in studies performed in the Edinburgh Breast Unit.
Agent No. of patients Number initially Number requiring Conversion rate (%)*
requiring mastectomy mastectomy after treatment




Anastrozole 24» 19 2 89
Exemestane 12 10 2 80
•Percentage of patients initially considered only for mastectomy who underwent breast-conserving surgery following treatment. 'Includes one patient who did not
complete full treatment.
These might be expected to be particularly associated with the
most potent of inhibitors and to be greater than with
tamoxifen which has oestrogen agonistic properties. However,
there may be differences between class of inhibitors and the
steroidal agents may be less problematic if, because of their
structure, they have androgenic properties on bone and other
normal target tissues [57,58].
Clinical trials are needed to address these issues and, by the
nature of the questions, these will require to be large and have
an extensive follow up. Such trials are ongoing and are sum¬
marised below.
The only published randomised controlled trial of an AI as
adjuvant therapy compares anastrozole with tamoxifen and is
known as the Arimidex, Tamoxifen Alone or in Combination
(ATAC) trial [59]. It recruited 9366 postmenopausal women
with invasive breast cancer from 381 centres in 21 countries
between July 1996 and March 2000. After completing pri¬
mary therapy (surgery +/- radiotherapy +/- chemotherapy)
patients were randomised to receive anastrozole plus placebo,
tamoxifen plus placebo or anastrozole and tamoxifen together
for 5 years as adjuvant therapy. The groups had similar demo¬
graphics, tumour characteristics and primary treatment.
Approximately 83% of tumours in each group were ER-posi-
tive and 7% ER negative, with the remainder unknown. Pre¬
liminary results of the trial were reported when median
duration of therapy was 33.3 months [59].
The results showed anastrozole to be superior to tamoxifen
in terms of disease-free survival in both the overall population
(hazard ratio 0.83 [95% confidence interval (CI) 0.71 - 0.96],
Table 7. Primary and secondary efficacy end point results
of trial P024 comparing 4 months of neoadjuvant
letrozole versus tamoxifen, in all study patients [54],
Efficacy end points Letrozole
(n = 154) %
Tamoxifen p Value




























p = 0.013) and the ER-positive subgroup. There were also sig¬
nificantly fewer new contralateral primary tumours in the anas-
trozole-treated group (odds ratio 0.42 [0.22 - 0.79],
p = 0.007). Interestingly, the combined arm did not show any
significant improvement over tamoxifen alone. Although phar¬
macokinetics changes may explain the reduced efficacy of the
combination, the suppression of oestrogen concentrations was
similar in the two groups [60]. It is more likely that the differing
effects of the agents on the ER account for the combined arm
having no better efficacy than tamoxifen alone. In postmeno-
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pausal women the effect of tamoxifen is to saturate the ERs and
therefore act predominantly as an oestrogen antagonist. How¬
ever, it has well-documented partial agonist effects. In contrast,
anastrozole has no agonist effects, causing serum oestradiol lev¬
els to become extremely low and obliterating oestrogenic signal¬
ling through the receptor. When the two agents are combined,
tamoxifen may be more likely to have oestrogenic activity
because of the lower level of oestrogen resulting from aromatase
inhibition by anastrozole. Thus anastrozole decreases the oestra¬
diol levels with the same potency, but it has no effect in stop¬
ping tamoxifen binding to the ERs and inducing its partial
agonist effects. This is the most likely explanation for the com¬
bined arm having similar results to the tamoxifen alone arm
[59]. Recurrence and survival data from ATAC was updated and
presented in San Antonio in December 2002. The efficacy
advantages of anastrozole over tamoxifen were maintained with
a 92.2 versus 89.6% 4-year recurrence-free rate in receptor-pos¬
itive patients aged over 50 years.
Whilst the ATAC trial is the only investigation to have
published results, there are other potentially important trials
in progress. These are summarised in Figure 5. These vary in
terms of design but have been particularly interested in the
use of AIs in sequence with tamoxifen in adjuvant postmen¬
opausal breast cancer. Two main trial models have been
established, one giving an AI after 5 years of tamoxifen treat¬
ment or alternatively comparing tamoxifen and AIs alone or
in sequence during the first 5 postoperative years.
These trials will also provide important data regarding the
longer term toxicities of AIs. Results to date suggest that, in
direct comparisons with tamoxifen, AIs appear to have a better
toxicity profile. Fewer patients have to stop therapy because of
drug-related side effects 152). They have a reduced rate of
thromboembolic events compared with tamoxifen. In addi¬
tion, the ATAC data suggests that the rate of endometrial can¬
cer may be reduced to the normal age-matched incidence [59].
This, together with the reduced rate of vaginal bleeding on AI,
could have important economic implications because the cur¬
rent costs of thoroughly investigating women on tamoxifen
who complain of postmenopausal bleeding are expensive.
The ATAC study also demonstrated a lower rate of hot
flushes, vaginal dryness, endometrial cancer, cerebrovascular
events, venous thromboembolism and deep venous thrombo¬
sis (DVT) with anastrozole compared with tamoxifen. There
was an increased rate of musculoskeletal disorders and frac¬
tures with anastrozole. Musculoskeletal problems appear to be
more common with anastrozole than letrozole based on a
study directly comparing the tolerability of these two drugs.
The increase in fracture rate relates to loss of bone density
associated with the decrease in oestrogen levels and it is likely
to also be a problem with letrozole. Exemestane has andro¬
genic effects and could be associated with a lower rate of bone
problems, but as yet there are no clinical data to confirm this.
Ongoing studies are evaluating whether bisphosphonates
given synchronously to women at highest risk of fracture can
reduce the rate of fracture development. The effect of AIs on
lipids is unclear. A small study of patients treated with letro¬
zole indicated that it had adverse effects on lipid profile [61].
The only data for anastrozole are in the metastatic setting and
show no major change in lipids [62].
AIs may currently be considered as first-line therapy in
patients at high risk of DVT and pulmonary embolism [52J.
They may also be recommended as first-line adjuvant therapy
in elderly patients who have a higher rate of adverse effects on
tamoxifen, where quality of life issues may be more pertinent
than survival from breast cancer [52|.
8. Hormone prevention of breast cancer
Risk to breast cancer has a strong hormonal aetiology and
overexposure to oestrogen is thought to promote the disease
[63|. Conversely, endocrine deprivation may prevent breast
cancer [64] and a recent trial of tamoxifen as a preventative
agent has produced promising results [65]. Hence, it may be
that more efficacious endocrine-depriving agents can produce
more beneficial effects. In this respect, the different mecha¬
nisms of action of antioestrogens and AIs may be important.
Most notably, tamoxifen blocks the action of oestrogen at
the level of the ER, which results in blockade of receptor-
mediated signals including proliferation in hormone-depend¬
ent breast cancers. However, tamoxifen (unlike AIs) does not
reduce oestrogen levels. This may be crucial because there is a
suggestion that metabolites of oestrogen are carcinogenic [66|;
AIs which reduce oestrogens may, therefore, be doubly effec¬
tive in both affecting initiation and promotion of cancer.
Against this, AIs have not been used successfully in premeno¬
pausal women, a large population who may be candidates for
hormone prevention. Trials are therefore underway to investi¬
gate the potential ofAIs as preventative agents.
Additionally, ongoing adjuvant trials (Figure 5) will provide
information about the occurrence of new contralateral breast
cancers and side-effect profiles.
Pilot studies of chemoprevention using third generation
AIs are being planned, as reviewed by Goss [67]. They largely
involve women at high risk of breast cancer. The National
Institute of Canada is conducting a pilot double-blind, multi¬
centre trial to evaluate the effect of letrozole or placebo on
breast density of postmenopausal women with high breast
density. After the International Breast Cancer Intervention
Study (IBIS) showed that tamoxifen significantly decreased
the risk of developing breast cancer in high risk women when
compared with placebo, there are plans to compare anastro¬
zole with placebo in IBIS II. In another chemoprevention trial
in progress, an AI is given to women with atypical or epithe¬
lial hyperplasia assessing reduction of hyperplasia or progres¬
sion. Biomarkers of breast cancer risk are being used as end
points in postmenopausal women with ductal carcinoma in
situ (DCIS) and/or low risk invasive cancer [67].
It has been speculated that low doses of very potent AIs,
for example, letrozole, may be able to block in situ oestrogen
synthesis in the breast without interfering with ovarian oes-

































Figure 5. Ongoing trials using tamoxifen and aromatase inhibitors as adjuvant therapy in early breast cancer.
trogen production in premenopausal women [68], This
would potentially allow the agents to be used in chemopre-
vention without having adverse effects on other oestrogen-
dependent tissues.
9. Other indications for aromatase inhibitors
Recently AIs have exclusively been used in postmenopausal
women. This is because experience with prototype drugs
indicate inadequate endocrine suppression and poor clinical
benefit [69]. The problem is that in premenopausal women,
levels of aromatase in the ovary are high and difficult to
block; even if this is achieved, the resultant fall in circulating
oestrogens results in decreased feedback inhibition at the
hypothalamus and pituitary so that levels of gonadotrophins
rise resulting in secondary increases both in androgen sub¬
strate and aromatase in the ovary. It may be that the later
generation of highly potent AIs have sufficient power to over¬
come these secondary effects and use in premenopausal
women may be a future option. However, caution may need
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to be exerted as tropic effects on functioning ovaries may
result in unforeseen pathology. Combining AIs with luteinis-
ing hormone-releasing hormone (LHRH) analogues may
overcome these problems.
Should use in premenopausal women become viable, it
opens the possibility of using AIs to treat benign breast condi¬
tions such as cyclic breast pain, fibroadenomata and recurrent
cystic disease, which occur in women before the menopause.
There are also a variety of hormone-dependent conditions
such as gynaecomastia 1701, uterine fibroids/neoplasia 171),
ovarian cancer [72| and prostate cancers 173], for which endo¬
crine therapy might prove beneficial.
Aromatase has been shown to be of importance in the aeti¬
ology of gynaecomastia, with in vitro studies showing
increased aromatase activity in skin fibroblasts from patients
with gynaecomastia when compared with controls [74]. In
1986, Zachmann and colleagues published a small trial giving
testolactone (150 mg t.i.d. for 2-6 months) to 22 boys with
pubertal gynaecomastia [75]. Zachmann showed a gradual
reduction in breast size over the treatment period with few
unfavourable side effects. It is therefore surprising that no
studies have been published looking at the effects of third
generation AIs in this group. An advantage of these drugs is
that they could be given by a once-daily oral dose. However,
concerns have been raised about the effects on testicular func¬
tion after animal models showed Leydig cell hypertrophy and
hyperplasia and disturbed spermatogenesis [76). It therefore
remains to be established whether the potential benefits out¬
weigh any side effects.
Although androgen deprivation therapy remains the
mainstay of treatment for prostatic cancer, preclinical studies
have suggested that oestrogens may have an important role
in the development and progression of prostatic cancer [75].
Initial studies using the antioestrogen tamoxifen in meta¬
static prostate cancer produced disappointing results with
response rates of between 0 and 23% reported [75). In con¬
trast, a small Phase I/II study using the first generation AI
rogletimide gave more promising results [77). Studies are
being performed to assess the effects of the newer third gen¬
eration AIs on prostate cancer.
It has been established that aromatase is expressed in
endometriotic tissue in contrast to being undetectable in nor¬
mal endometrial tissue [73]. The presence of aromatase results
in local oestrogen and consequently prostaglandin E2 (PGE2;
a potent inducer of aromatase activity in endometriotic stro¬
mal cells) production. This results in a positive feedback loop.
It may, therefore, theoretically be possible to treat endometri¬
osis with AIs. One case where this proved successful was
described by Bulun and colleagues [78). In this case, the biop¬
sied endometriotic tissue showed abnormally high levels of
aromatase mRNA, which might account for the marked suc¬
cess of therapy. Further studies need to be performed to deter¬
mine the role of AIs in treating endometriosis, resistant to
standard regimes.
Although AIs have been used occasionally in the past, it has
usually been with early generation inhibitors and poor results.
The new generation inhibitors offer new opportunities and
the promise of greater success.
10. Expert opinion
The latest generation of AIs, as exemplified by anastrozole,
exemestane and letrozole, are extremely specific and potent
endocrine agents. In postmenopausal women, they reduce cir¬
culating oestrogens to levels not previously seen with other
drugs. It might, therefore, be expected that when used against
breast cancers that require hormones for growth they will pro¬
duce profound antitumour effects. Clinical trials in advanced
disease have now shown that this is the case. All such studies
have proven at least equivalence versus established endocrine
agents and the evidence is gradually accumulating of superior¬
ity over the gold standard hormone treatment, tamoxifen.
Advanced disease with high tumour burden, increased likeli¬
hood of resistance and difficulties in accurately assessing
response is not necessarily the best setting to demonstrate
increased efficacy. Results from neoadjuvant studies in which
effects are monitored on primary tumours are therefore par¬
ticularly interesting; these show clear superiority over
tamoxifen in terms of response rates and decreased need for
major surgery in women presenting with large primary can¬
cers. These data have led to the Inception of large randomised
trials for adjuvant use. Preliminary results for the ATAC trial
are highly promising and have led to the expectation that aro¬
matase inhibition may replace tamoxifen as first-line adjuvant
hormone therapy. However, some degree of caution is war¬
ranted; follow up is short and the effects of long-term use on
normal tissues whose function is dependent upon oestrogen
needs to be assessed fully. The reduction in contralateral can¬
cers in women given adjuvant therapy raises the possibility of
use as a chemopreventative. In this setting, AIs may have
advantages over selective oestrogen receptor modulator
(SERMs), which may abrogate the proliferation effects of oes¬
trogen without blocking genotoxic effects of oestrogen metab¬
olites. AIs which reduce oestrogen levels would be expected to
do both and be more efficient chemoprevention agents in
postmenopausal women. (It is likely that use in premenopau¬
sal women will require combination with an agent to block
feedback responses in the pituitary.) Finally, the therapeutic
potential of AIs stretches beyond postmenopausal breast can¬
cer. There are a variety of benign and malignant diseases
which appear dependent upon oestrogen and might be use¬
fully targeted by aromatase inhibition.
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Published Abstracts
Short- and Long-Term Effects of Letrozole on Tumor Histopathology and
Immunopathology in Patients with Breast Cancer given Neoadjuvant Treatment.
Jackson J, White S, Dixon JM, Anderson TJ, Renshaw L, Miller WR. . Breast Cancer
Research and Treatment vol 77, supp 1, Dec 2003
Neoadjuvant Letrozole : The Edinburgh Experience. Jackson J, Dixon JM, Cameron
DA, Miller WR European Journal of Cancer. Sep 2003 vol 37 supp 5
Is there an optimal duration of neoadjuvant letrozole therapy? Renshaw L, Murray J,
Young O, Cameron DC, Miller WR, Dixon JM. Breast Cancer Reseacrh and Treatment
vol 78 supp 1, Dec 2004
Microarray analysis of sequential tumour biopsies from patients receiving neoadjuvant
therapy is able to distinguish sub-populations of breast cancers with differential response
to the aromatase inhibitor, letrozole. Miller WR, Renshaw L, Murray J, Larionov A,
Anderson TJ, White S, Hampton G, Walker JR, Ho S, Krause A, Evans DB, Dixon JM.
Breast Cancer Reseacrh and Treatment vol 78 supp 1, Dec 2004
Early changes in tumour Ki67 expression differentiate for pathological (but not clinical)
response in breast cancers treated neo-adjuvantly with letrozole. Anderson TJ, Dixon
JM, Murray J, Renshaw L, White S, Miller WR. Breast Cancer Reseacrh and
Treatment vol 78 supp 1, Dec 2004
Prediction of hormone response in breast cancer by microarray analysis of sequential
tumour biopsies from patients receiving neoadjuvant therapy with letrozole. Miller WR,
Renshaw L, Murray J, Larionov A, Anderson TJ, White S, Hampton G, Walker JR, Ho
S, Krause A, Evans DB, Dixon JM. European Journal ofCancer. Sep 2005 vol 3 supp 1
Neoadjuvant letrozole is equally effective in Her 2 positive and negative breast cancers.
Young O, Murray J, Renshaw L, Evans DB, Cameron D, Dowsett M, Miller WR,
Dixon JM. European Journal of Cancer. Sep 2005 vol 3 supp 1
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C). End point assessments include clinical and pathologic responses,
changes in cholesterol and lipid profiles and tolerability. For those
patients with clinical response, assigned treatment continued adjuvantly
post-surgery.
Results: From Feb 2002 to April 2003, a total of 41 patients were
recruited. Twenty-nine patients have completed 3 months of treatment
and were operated. The tumor size shrunk to 3 cm or less for 65% of
the patients, who were then suitable for conservative surgery. However,
only one patient decided for lesser surgery. All except one of the
patients tolerated the treatment well. One patient (group A) developed
allergic skin rashes and withdrew from treatment. The clinical response
rates were 61.5%, 60% and 54.5% respectively for Groups A, B and C.
The cholesterol levels (figure 1) for group A patients dropped
progressively and statistical difference was observed between 5,h week
after operation and preoperative level (P=0.026). No difference was
observed for the other groups.
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Data on COX expression, and aromatase expression are being analyzed
and the correlation with clinical response will be reported.
Discussion: The treatment with celecoxib and exemestane is well
tolerated. This combination regimen poses an advantage over the anti-
aromatase therapies in reducing the serum cholesterol profiles of
postmenopausal patients with breast cancer.
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Type 1 insulin-like growth factor receptor expression and
activation in clinical breast cancer.
Gee JM, Rubini M, Robertson JF, Ellis IO, Gutteridge E, Nicholson RI.
Cardiff University, Cardiff United Kingdom; University of Ferrara,
Ferrara, Italy; Nottingham City Hospital, Nottingham, United Kingdom
Background: Insulin-like growth factors (IGFs) bind to and activate
the type 1 insulin-like growth factor receptor (IGF-1R). IGF-1R
signalling is a dominant pathway for endocrine responsive breast cancer
in vitro, including MCF-7. In such cells, IGF-1R expression, activation
and its signalling are prominent and IGFs are growth promoting.
However, associations between IGF-1R expression, endocrine response
and prognostic features are only poorly documented in clinical disease,
and receptor activation has not to date been investigated in vivo.
Materials and Methods: In the present study, IGF-1R expression and
activation has been immunocytochemically-assessed in an archival
clinical breast cancer series (n=65). IGF-1 Roc antibody and a phospho-
specific IGF-1R antibody (detecting Y1316 phosphorylation in the
kinase domain) were used to monitor receptor expression and activation
respectively, employing peroxidase-labelled polymer detection.
Antibody validity was confirmed in MCF-7 with/without IGF-1
treatment.
Results: IGF-1R expression and activation were heterogeneously
detected in the tumour epithelial cells of most breast cancers.
Immunostaining was principally at the plasma membrane and diffusely
in the cytoplasm. Staining in these compartments positively associated
(p<0.001). Plasma membrane IGF-1R expression directly associated
with oestrogen receptor (ERa; p=0.028) and progesterone receptor
(p=0.041), and indirectly with epidermal growth factor receptor (EGFR;
p=0.02) and grade (p=0.067). Increased IGF-1 R expression also
associated with responsive disease at 6 months (p=0.03) and an extended
time to progression on endocrine therapy (p=0.009). Associations were
lost on ERa subdivision. Plasma membrane IGF-1R activation directly
correlated with IGF-1R expression (p<0.001). Subdivision by IGF-1R
expression and activation revealed response at 6 months (p=0.049)
and increased time to progression on endocrine therapy (p=0.0174)
when both expression and activation were elevated. Some association
was also observed in ERa positive disease, although this proved non¬
significant. There were no associations with patient survival.
Discussion: IGF-1R is enriched in ERa positive/well-differentiated/
EGFR negative and endocrine responsive clinical breast cancer. Endocrine
responsive disease also has elevated IGF-1R activation (as in MCF-7)
suggesting IGF-1 R signalling is important to these tumours in vivo. The
impact of endocrine treatments on IGF-1R signalling and the role of
IGF-1R at relapse should now be examined in vivo using these new
assays for receptor expression and activation.
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Short and long term effects of letrozole on tumour histo- and
immuno-pathology in breast cancer patients given neoadjuvant
treatment.
Jackson J, White S, Dixon JM, Anderson TJ, Renshaw L, Miller WR.
Western General Hospital, Edinburgh, United Kingdom
Background: Letrozole is an effective endocrine treatment in
postmenopausal women with ER-rich cancers. Neoadjuvant therapy
combined with sequential biopsy allows accurate monitoring of tumour
changes with treatment. The objective of this study is to monitor the
effects of letrozole on tumour grading features, ER, PgR (a marker of
oestrogenic activity) and Ki67 (a marker of proliferation).
Materials and Methods: 50 postmenopausal women with large primary
breast cancers were treated with neoadjuvant letrozole 2.5mg daily for
3 months. Tumour samples were taken at diagnosis, after 10-14 days
and after 3 months of treatment. ER, PgR and Ki67 were assessed by
immunohistochemistry; these and grading features were scored as
described by Miller et al [Euro J Cancer 39 (2003) 462-468].
Results: At initial biopsy all cancers were scored ER 5+2 or 5+3 (by
Alfred score); 45 of 50 (90%) were PgR positive (range 1+2 to 5+3);
Ki67 scores ranged from 5-60%. Changes with treatment from initial
biopsy at diagnosis are summarised in the table.
10-14 Days 3 Months
Increase No Change Decrease Increase No Change Decrease
ER 0 50 0 0 50 0
PgR 0 14 36* 1 9 40*
Ki67 1 1 48* 0 1 49*
*p<0.00001 compared with initial biopsy, by paired Wilcoxon rank test
ER: the score was unaffected by treatment with letrozole.
PgR: By 10-14 days, 25 of the PgR positive cases reduced to 0, 11
other cases decreased by both proportion and intensity but not to 0.
Fourteen cases were unchanged, including the five that were negative.
By 3 months, a further 5 PgR positive patients dropped to 0 and one of
the PgR negative cancers became focally positive.
Ki67: Scores had decreased to 1% or less in 23 cases after 10-14 days of
treatment; 32 cases had a score of 1% or less at 3 months. Ki67 scores
subsequently increased between 10-14 days and 3 months in 5 cases.
Histological grading: By 10-14 days, 8 cases showed an increase in
gland features, 13 cases showed a decrease, and 3 an increase in nuclear
grading. 8 cases showed a decrease in mitosis.
Conclusion: Letrozole has been shown to have marked anti-oestrogenic
and anti-proliferative effects in tumours within 10-14 days. These
changes precede any clinically apparent indication of response.
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Multi-center clinical trials of trilostane (modrenal) for advanced
breast cancer in post-menopausal women.
Leonard RCF, Bundred N, Buzdar A, Canney P, Rea D, Spittle MF,
Stewart AL, Verrill M. Singleton Hospital, Swansea, United Kingdom;
South Manchester University Hospital, Manchester, United Kingdom;
MD Anderson Cancer Center, Texas; Western Infirmary, Glasgow, United
Kingdom; Queen Elizabeth Hospital, Birmingham, United Kingdom;
Middlesex Hospital, London, United Kingdom; Christie Hospital,
Manchester, United Kingdom; Newcastle General Hospital, Newcastle
upon Tyne, United Kingdom
Background: Trilostane (Modrenal) has been shown recently to
modulate binding of estrogen to both ERa and ER(3 and block cell
proliferation in breast cancer cells mediated through both ERE and
API-dependent pathways. In multi-center, international clinical trials
a total of 783 post-menopausal women with advanced, progressing
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261 Pharmacokinetic (PK) study to evaluate the combination
of exemestane (E) and tamoxifen (T) in the treatment of
metastatic breast cancer: preliminary results.
Rivera E, Valero V, Francis D, Hortobagyi G. Universiy of
Texas M.D. Anderson Cancer Center, Houston, TX
E is a new Type I, steroidal aromatase inactivator that irreversibly binds to
the aromatase enzyme. T has antiestrogenic and estrogenic properties and is
probably the best known hormonal therapy for patients with breast cancer.
The antitumor activity of E, given alone or in combination with T, was
investigated in rats by Zaccheo ct al (J Steroid Biochcm Mol Biol 1993). The
combined treatment resulted in higher antitumor activity compared to either
agent alone. The increase in efficacy with this combination led us to design
a pilot study in which toxicity and PK could be evaluated. Response was
considered a secondary cndpoint. Patients were eligible if they were
postmenopausal, had either measurable or evaluablc disease, or if they had
prior tamoxifen and/or aromatase inhibitors either in the adjuvant or metastatic
setting. Patients were not eligible if they had prior history of thromboembolic
events, were on HRT, or were taking over-the-counter estrogenic supplements.
Patients were given E 25 mg daily for 2 weeks. After the second week, patients
continued on E and started on T 20 mg daily. Blood samples for E levels,
estradiol, estrone, and estrone sulfate were collected on day 14 of the 2-week
single agent E period and approximately 4 weeks after starting the
combination treatment. Eighteen patients were registered in the study but
only 17 underwent treatment and PK sampling. One patient withdrew
consent and discontinued treatment. Median age was 62 years (range, 46-
84) and all patients had a performance status of 1. Sixteen patients had received
prior hormonal therapy, most of which had received more than one prior
hormonal agent . Thirteen patients had received prior tamoxifen, 6 had
received aromatase inhibitors (Als), 2 toremifene, 2 progestins, and 2 had
received androgens. Of the patients who had received prior Als, 2 had
previously received exemestane. All patients had estrogen and/or
progesterone receptor-positive tumors.We have seen 1 PR, 1MR, 3SD, 7PD,
and 4 are too early to evaluate. The most common toxicity observed include:
grade 1 fatigue, grade 1 / 2 hot flashes, grade 1 nausea, grade 1 vaginal
bleeding, and grade 2 bone pain. PK analysis is currently being performed.
Updated information, including PK analysis and estrogen levels, will be
provided at a later time. The results of this study will help decide the need
for further evaluation of this combination.
262 Anastrozole therapy does not compromise lipid
metabolism in breast cancer patients previously treated
with tamoxifen.
Wojtacki J, Lesniewski-Kmak K, Kruszewski WJ. PCK Maritime
Hospital, Gdynia; Military School of Medicine, Warsaw; Medical
University of Gdansk, Poland
Background: Tamoxifen (TAM) exerts beneficial influence on lipid profile as
a result of its estrogen-like properties. A number of new-generation aromatase
inhibitors used sequentially to the initial adjuvant TAM are being currently
investigaed in clinical trials, including anastrozole (ANS). There are
concerns, however, that ANS, as a potent supressor of estrogen, may reverse
beneficial effects ofTAM on the scrum lipids profile. The current study updates
at prolonged observation our previous results on effects of ANS used in
sequence to TAM in breast cancer patients.
Materials and Methods: Analysis included 43 postmenopausal breast
cancer women, converted to ANS (lmg/d.) after 14-234 weeks (median: 67)
of TAM (20mg/d.) treatment used for advanced disease (N=25) or in adjuvant
setting (N=18). Concentrations of basic blood lipids and body mass index
values (BMI) were measured before treatment, and at minimum 24 (median:
26, range: 24 - 33) and 60 (median: 63, range: 60 - 70) weeks of ANS
administration afterwards.
Results: there was no statistically significant change over time in basic
lipid paramctres, that included total (TCH)- (p=0.23), LDL- (p=0.26), and
HDL-cholestcrol (p=0.37), triglycerides (p=0.32), the number of patients
with TCH>200mg/dl (p=0.55), the atherogenic risk ratios: TCH/HDL
(p=0.45) and LDL/HDL-cholcsterol (p=0.39) as well as in mean BMI values
(p=0.54).
Conclusion: administration of ANS for > 60 months in sequence to TAM
does not affect lipid profile of breast cancer patients.
263 Anastrozole demonstrates clinical and biological
effectiveness in erbB2 ER positive breast cancers.
Dixon JM, Jackson J, Hills M, Renshaw L, Cameron DA,
Anderson TJ, Miller WR, Dowsett M. Western General Hospital,
Edinburgh & Royal Marsden Hospital, London, United Kingdon
22 postmenopausal women with large operable or locally advanced with
oestrogen receptor (ER) rich breast cancers were randomised to receive lmg
or lOmg of anastrozole for 3 months following which they had surgery. The
age range of women was from 56 to 92 ER levels were Allrcd score 5 (1
patient), 6 (3 patients), 7(10 patients), 8 (8 patients). Rcsponders continued
on anastrozole post surgery for 5 years. Median follow up: 44 months.
All patients had erbB2 assessed in their initial biopsy using the HercepTest.
Response was assessed by clinical examination (pre) and ultrasound
according to standard criteria (CR/PR complete or partial response, SD stable
disease). Proliferation before and after 3 months (post) was assessed by Ki67.
Progesterone receptor (PgR) was assessed before and after treatment.
Clinical Ultrasound Median Ki67 Fall in
ErbB2 No CR/PR SD CR/PR SD Pre Post PgR
0/1+ 16 15 1 10 6 23.5 5+ 13/13*
3+ 6 6 0 5 1 22.5 7.5- 3/4*
*5 patients PgR 0 on first biopsy, ~p=0.017, +p<0.0001
Response did not differ in relation to erbB2 status All 0/1+ and all 3+ patients
had a reduction in proliferation. In the 16 patients with 0/1+ crbB2 tumours
there have been 3 events (1 death, 1 local recurrence, 1 lung metastasis). In
the 6 erbB2 3+ patients there have been 2 events (1 local recurrence —» lung
metastasis and 1 liver metastasis) both patients are still alive. These are the
first data demonstrating the clinical and biological effectiveness of
anastrozole in crbB2 positive ER positive breast cancers.
264 Neoadjuvant letrozole: the Edinburgh experience.
Dixon JM, Jackson J, Renshaw L, Cameron DA, Miller WR.
Western General Hospital, Scotland, United Kingdon
The randomised neoadjuvant trial of letrozole versus tamoxifen reported a
clinical response rate of 55% (85/154) for patients randomised to letrozole
and a relationship between response and ER level.
83 postmenopausal patients with large operable or locally advanced ER
rich breast cancers have been treated with 3 months of letrozole and response
assessed clinically and volume changes over the 3 month study assessed by
clinical measurement and ultrasound - 65 patients responded - overall
response rate 78%, a significantly better response rate than in the 024 study,
p=0.0004. Response rate did not differ significantly between ER categories
but percentage reduction in volume did (Table).
ER Score No of No of % Median % Reduction in Tumour Volume
Allrcd Pts Rcsponders Response Clin USS
8 60 48 80 76+ 67+
6 + 7 23 17 74 63 48
+p<0.05
Letrozole is confirmed as being a highly effective agent at producing tumour
shrinkage in postmenopausal women with ER rich breast cancers.
Is there an optimal duration of neoadjuvant letrozole therapy?
Renshaw L, Murray J, Young O, Cameron D, Miller WR, J M Dixon. Edinburgh
Breast Unit, Western General Hospital, Edinburgh, UK
Background: Randomised studies of neoadjuvant aromatase inhibitors have treated
patients for 3 - 4 months. The aim of this review was to assess whether tumours continue
to respond to neoadjuvant letrozole for periods longer than 3-4 months.
Patients and Methods: 142 postmenopausal women with large operable or locally
advanced ER rich (ER Allred score 6 or more) breast cancer were enrolled into a
prospective audit assessing response to neoadjuvant letrozole 2.5mg per day. Clincal
response was assessed at 3 months; non responders and patients whose tumours had
become operable or had responded sufficiently to allow breast conserving surgery
proceeded to surgery. The remaining 42 patients who were either unfit for surgery,
refused surgery, had responded but still required mastectomy or were inoperable,
continued letrozole for a further 3 months. 22 patients continued letrozole for a total of
12 months. Reductions in tumour volume over the first 3 months were compared with 3-
6 and a period of between 6-12 months were calculated.
Results: Median % reduction in the tumour volumes from 0-3 months, 3-6 months and
6-12 months are shown in the table.
Number of Patients Median 95% CI
% reduction from 0-3 months 42 52 37-62
% reduction from 3-6 months 42 57 26-100
% reduction from 6-12 months 22 66 22-100
Tumours continued to reduce in volume during the 12 months study period.
Complete responses: At 3 months there were 4/42 (9.5%) complete responses, by 6
months there were 12/42 (29%) and by 12 months 8/22 (36%). One patient who was
responding at 3 months had disease progression at 12 months.
Conclusion: Neoadjuvant letrozole produces ongoing tumour shrinkage in
postmenopausal women over 12 months in large operable or locally advanced ER+
breast cancers. Patients whose tumours are responding to letrozole at 3 months can
expect further reduction in tumour volume with continued treatment. There is no
optimum duration for use of neoadjuvant letrozole; it can be used safely for up to 12
months.
Microarray analysis of sequential tumour biopsies from patients
receiving neoadjuvant therapy is able to distinguish sub-
populations of breast cancers with differential response to the
aromatase inhibitor, letrozole.
William R Miller, PhD.DSc 1, Lorna Renshaw, RGN \ Juliette Murray, MB,ChB \
Alexey Larionov, MD 1, Thomas J Anderson, PhD, FRCPath \ Sharon White,
BSc 1, Garret Hampton, PhD 3, John R Walker, PhD 3, Steven Ho, PhD 3,
Andreas Krause, PhD 2, Dean B Evans, PhD 2 and Michael J Dixon, MD \ 1
Breast Unit Research Group, University of Edinburgh, Edinburgh, Scotland,
United Kingdom, EH4 2XU ;2 Novartis Institutes for BioMedical Research,
Novartis Pharma AG, Basel, Switzerland, CH-4002 and 3 Novartis Genomic
Institute, San Diego, United States .
Introduction: Microarray analysis of sequential tumour biopsies taken during
neoadjuvant therapy permits identification of genes whose changes in expression
correlate with response and resistance to treatment. The present study has analysed the
molecular changes in individual breast cancers which occur within 14 days of starting
therapy with letrozole.
Materials and methods: 81 postmenopausal women with large operable or locally
advanced breast cancers treated with a 3 months of neoadjuvant letrozole (2.5mg daily)
had tissue sampled at diagnosis, 14 days and 3 months. Tumours were monitored and
response was based on clinical, ultrasound and mammographic changes. RNA was
extracted and doubly amplified before hybridization on Affymetrix chips (HG U133A).
Results: Sufficient good quality RNA for microarray was obtained from all 3 tumour
samples in 69 patients. Analysis is complete on 56 cases. Based on differing clustering
techniques including either the 100 or 1% (223) genes showing the greatest change or
the 1000 highest average expressed levels, it was possible to identify highly consistent
patterns of changes in expression level with treatment. Furthermore, tumours could be
subdivided into groups showing distinct patterns of molecular changes. The genes
involved included known markers of hormone sensitivity (trefoil factors, PgR, LIV-1),
tumour progression (cyclin B2, CDC28, BRCA1 associated RING domain 1, antigen
identified by monoclonal antibody Ki67) as well as novel candidate genes. Tumour from
remaining 13 cases are currently being analysed before microarray changes are
correlated to clinical and pathological response data.
Conclusions: Changes in tumour gene expression in biopsies taken before and after 14
days treatment with neoadjuvant letrozole may define of tumour cohorts with differing
response to letrozole. This should permit early recognition of response/resistance to the
drug and add to our understanding of its mode of action.
Early changes in tumour Ki67 expression differentiate for
pathological (but not clinical) response in breast cancers
treated neo-adjuvantly with letrozole.
Thomas J Anderson, PhD FRCPath \ Michael J Dixon, MD 1, Juliette Murray,
MB ChB 1, Lorna Renshaw, RGN 1, Sharon White, B.Sc 1 and William R Miller,
PhD DSc 1. 1 Edinburgh Breast Unit Group, Western General Hospital,
Edinburgh, UK.
Background: We have previously shown that neo-adjuvant treatment with the
aromatase inhibitor, letrozole, produce marked anti-oestrogenic and anti-proliferative
effects in tumours within 10-14 days. The objective of this study was to determine
whether these changes were related to clinical and pathological responses as assessed
after 3 months of treatment
Materials and Methods: 63 postmenopausal women with large primary breast cancers
were treated with neoadjuvant letrozole 2.5mg daily for 3 months. Tumour samples were
taken at diagnosis, after 10-14 days and after 3 months of treatment.
Oestrogen receptor(ER),progesterone receptor(PgR), Ki67 and morphology were
assessed as described by Miller et al [Eur J Cancer 39 (2003) 462-468].
Results: 49(78%) patients had a clinical response( >50% reduction in tumour volume at
3month by serial ultrasound) and 44(75%) of 59 assessable tumours displayed evidence
of a pathological response (decreased cellularity/increased fibrosis). Pre-treatment scores
for Ki67 were similar in responders(R) and non-responders(NR) whether assessed
clinically or by tumour pathology. Treatment was associated with highly significant
Ki67 decreases in all tumour sub-groups (all at least p< 0.005 by paired Wilcoxon rank
test) at 14days. Values (mean%±SEM) for pre-treatment vs 14days were 14.04± 1.13 vs
5.04i0.96 for clinical responders, 15.81 ±2.12 vs 7.08±2.15 for clinical non-responders,
13.95± 1.07 vs 4.28±0.88 for pathology responders and 15.97±2.22 v 9.35+ 2.22 for
pathology non-responders. However, levels of Ki67 at 14days into treatment were not
significantly different in clinical responders and NR, but scores were significantly higher
in tumours which subsequently did not change pathology at 3months compared with
those showing a pathological response. Parallel measurements of ER and PgR failed to
detect differences in these parameters between clinical/pathological responding and non-
responding tumours although significant decreases in expression of PgR were observed
at 14days in all patient groups.
Conclusion: Letrozole is capable of producing profound decreases in expression of Ki67
and PgR although these do not always translate into clinical response. However, the
expression of Ki67 at 14days is significantly higher in tumours which subsequently fail
to show morphological evidence of response. It remains to determine whether these
changes are associated with differences in tumour behaviour in the long-term.
PREDICTION OF HORMONE RESPONSE IN BREAST CANCER
BY MICROARRAY ANALYSIS OF SEQUENTIAL TUMOUR
BIOPSIES FROM PATIENTS RECEIVING NEOADJUVANT
THERAPY WITH LETROZOLE.
Miller WR 1, Renshaw L 1, Larionov A 1, Anderson TJ 1, White S 1, Hampton G 2,
Walker JR 2, Ho S 2, Krause A 3, Evans DB 3, Dixon JM 1.1 Breast Research
Group, Edinburgh Breast Unit, Western General Hospital, Edinburgh, UK;2
Genomics Institute of the Novartis Research Foundation, San Diego, USA;3
Novartis Pharma AG, Basel.
Background: Changes in tumour RNA expression may be monitored in sequential
biopsies of individual tumours taken during neoadjuvant therapy and analysed by
microarray analysis. In the present study, changes occurring within 10-14 days have
been related to clinical response status assessed after 3 months of treatment.
Methods: 58 postmenopausal women with large operable ER-rich breast cancers were
treated for 3 months with neoadjuvant letrozole. Clinical response was based on clinical
and ultrasound changes. Cancers were sampled at diagnosis, 10-14 days and 3 months;
RNA was extracted and hybridized on Affymetrix HG_U 133A GeneChips.
Results: 52 cases were assessable for response; 37 (71%) responded (>50% reduction in
tumour volume) and 15 were classified as minimal or no response. Changes in
expression of 125 gene probes were informative in distinguishing between tumours
subsequently displaying clinical response and those not. The gene onthology of the
probe sets included protein metabolism (26%), transcription/translation (18%), signal
transduction (14%), cell proliferation/apoptosis (14%). Clustering of these gene changes
produced profiles highly predictive of response/resistance to letrozole.
Conclusions: Changes in pattern of gene expression can be detected in biopsies taken
before and after 14 days treatment with neoadjuvant letrozole. These may elucidate the
mechanisms of tumour response and allow early recognition of response/resistance.
Patterns of expression changes can be used to predict subsequent tumour response to
treatment.
Neoadjuvant letrozole is equally effective in Her 2 positive and
negative breast cancers
0 Young \ J Murray 1, L Renshaw \ D B Evans 2, D Cameron 1, M Dowsett3, W
R Miller1 and J M Dixon 1. 1 Edinburgh Breast Unit, Western General Hospital,
Edinburgh, United Kingdom, EH4 2XU ; 2 Oncology, Novartis AG, Basel,
Switzerland, CH-4002 and 3 Royal Marsden Hospital, London, United Kingdom,
SW3 6JJ .
Her 2 status does not influence response to neoadjuvant letrozole.
Background: 69% of ER+ and Her 2 positive breast cancers responded to neoadjuvant
letrozole, whereas only 17% of such tumours responded to tamoxifen in the study
reported by Ellis et al (J Clin Oncol 2001:19:3808-3816). In ER+, Her 2 negative
cancers the response rate to letrozole was 53%. This study used an antibody which is not
currently in routine use for Her 2 testing and considered all 2+ and 3+ staining as
overexpression. The current study set out to further investigate the interaction between
Her 2 status and response to neoadjuvant letrozole.
Patients and Methods: 172 postmenopausal women with large operable or locally
advanced ER rich (ER Allred score 6 or more) breast cancers were enrolled into a
prospective audit assessing response to 3 months of neoadjuvant letrozole 2.5mg per
day. Her 2 status was assessed using the Hercept test with FISH for 2+ samples.
Response was assessed clinically and by ultrasound. Response rate and % reduction in
tumour area and volume in Her 2 positive (3+ or 2+ and FISH positive) tumours have
been compared with cancers classified as Her 2 negative (0,+ or 2+ and FISH negative).
Results: Of the 172 patients, 18 tumours were classified as Her 2 positive ( either 3+ or
2+ and FISH +ve) and 154 were Her 2 negative.
Clinical Responses: At 3 months by WHO criteria 106/154 (69%) Her 2 negative and
11/18 (61%) Her 2 positive tumours had a clinical response p=0.506, Fisher's exact test.
Details of tumour response are given in the table.
Reductions in tumour area and volume during letrozole treatment (volume calculated
using the formula d3/6).
Her 2 Negative Her 2 Positive
Median 95% CI Median 95% CI
Clinical area 64% 57-68 64% 45-91
Clinical volume 78% 73-84 68 52-92
Ultrasound area 52% 48-60 47% 41-70
Ultrasound volume 67% 62-72 66% 37-83
None of the differences between Her 2 negative and Her 2 positive cancers were
significant.
Conclusion: Neoadjuvant letrozole in this series of ER + breast cancers was equally
effective in both Her 2 positive and negative tumours. It reduced tumour volume at 3
months by at least 66% in both groups. The efficacy of letrozole does not appear to be
influenced by Her 2 status.
